2015N267693_04 CONFIDENTIA L
The GlaxoSmithKline group of companies 205665
1TITLE PA GE
Division: World wide Development
Information Type: Protocol Amendment
Title: A randomized, open label study  to evaluate the effect of 
daprodustat on blood pressure in subjects with anemia associated 
with chronic kidney  disease on hemodial ysis swi tched from a 
stable dose of an ery thropoiesis -stimulating agent
Short Title: Anemia Studies in CKD: Erythropoiesis via a Novel PHI  
Daprodustat –Blood Pressure ( ASCEND -BP)
Compound Number: [COMPANY_004]1278863
Development Phase: IIB
Effective Date: 23-OCT -2019
Protocol Amendment Number:  04
Sponsor Name [CONTACT_29560]:
GlaxoSmithKline Research & Development Limited
[ADDRESS_351656] Information can be found in the Study  Reference
Manual (SRM).
Regulatory Agency Identifying Number(s): IND Number : 101,291
Copy right 2019theGlaxoSmithKline group of companies.  All rights reserved.  
Unauthorised cop ying or use of this information is prohibited.
2015N267693_04 CONFIDENTIA L
The GlaxoSmithKline group of companies 205665
2Revision Chronology
GlaxoSmith Kline
Document NumberDate Version
2015N267693_00 2016 -AUG -02 Original
2015N267693_01 2016 -NOV -21 Amendment No. 01
This protocol amendment was written to clarify  specific biomarkers being drawn, modify  
time points of biomarkers, clarify  safet y laboratory studi es, and clarify  day/time of 
assessments.  An additional potential study  visit is added.
2015N267693_02 2017 -JUL-31 Amendment No. 2
This protocol amendment was written to clarify  the descriptive statistics and include them 
in the objectives and endpoints table(s) as well as remove one blood pressure 
measurement. Additional minor changes were made for clarity  of study  procedures.
2015N267693_03 [ADDRESS_351657] -23 Amendment No. 4
This protocol amendment was written to remove the interim anal ysis from the statistical 
section due to more rapid recruitment than anticipated.   During the update, the objectives 
and endpoints were streamlined , the stratification variable of previous ESA dose was 
added to the models as it was inadvertently  left out, the daprodustat dosing algorithm was 
updated , and exploratory  endpoints were added to further clarify  results.
During this time the safety  language was updated as well as clar ification of 
inclusion/exclusion criteria in response to an internal audit.
[COMPANY_003]
[COMPANY_003]
2015N267693_04 CONFIDENTIA L
[ADDRESS_351658] to ensure that site
staff receives the appropriate information throughout the study . 
Investigator Name:
[CONTACT_132026]:
Investigator Phone Number:
Investigator Signature [CONTACT_1782]
2015N267693_04 CONFIDENTIA L
205665
5TABLE OF CONTENTS
PAGE
1.PROTOCOL SYNOPSIS FO R STUDY 205665 ................................ ........................ 8
2.INTRODUCTION ................................ ................................ ................................ ....13
2.1. Study Rationale ................................ ................................ .......................... 14
2.2. Brief Background ................................ ................................ ........................ 15
3.OBJEC TIVE(S) AND ENDPOINT (S)................................ ................................ ......15
4.STUDY DESIGN ................................ ................................ ................................ ....16
4.1. Overall Design ................................ ................................ ............................ 16
4.2. Treatment Arms and Duration ................................ ................................ .....18
4.3. Type and Number of Subjects ................................ ................................ .....19
4.4. Design Justification ................................ ................................ ..................... 19
4.5. Dose Justification ................................ ................................ ........................ 21
4.6. Benefit:Risk Assessment ................................ ................................ ............ 22
4.6.1. Risk Assessment ................................ ................................ ......... 22
4.6.2. Benefit Assessment ................................ ................................ .....22
4.6.3. Overall Benefit:Risk Conclusion ................................ ................... [ADDRESS_351659] AWAL CRITERIA ............. 22
5.1. Hemoglobin Stability Criteria ................................ ................................ .......23
5.2. Inclusion Criteria ................................ ................................ ......................... 23
5.3. Exclusion Criteria ................................ ................................ ........................ 24
5.4. Screening/Baseline/Run -in Failures ................................ ............................ 26
5.5. Withdrawal/Stoppi[INVESTIGATOR_2121] ................................ ................................ .......26
5.5.1. Criteria for Permanent Discontinuation from Study 
Treatment and Early Withdrawal ................................ .................. 26
[IP_ADDRESS]. Hemoglobin Stoppi[INVESTIGATOR_2121] ................................ .....27
5.5.2. Missed Clinic Visits/Lost to Fol low-up................................ .......... 28
5.5.3. Liver Chemistry Stoppi[INVESTIGATOR_2121] ................................ ................ 29
[IP_ADDRESS]. Study Treatment Restart or Rechallenge .................... [ADDRESS_351660] and Other Study Treatment ................................ ....30
6.2. Treatment Assignment ................................ ................................ ................ 30
6.3. Blinding ................................ ................................ ................................ .......31
6.4. Startin g Dose and Dose Adjustment Algorithm ................................ ........... 31
6.4.1. Subjects Randomized to Daprodustat ................................ .......... 31
6.4.2. Subjects Randomized to Epoetin Alfa ................................ .......... 32
6.5. Packaging and Labeling ................................ ................................ .............. 32
6.6. Preparation/Handling/Storage/Accountability ................................ .............. 32
6.7. Compliance with Study Treatment Administration ................................ .......33
6.8. Treatment of Study Treatment Overdose ................................ .................... 33
6.9. Treatment after the End of the Study ................................ .......................... 33
6.10. Lifestyle and/or Dietary Restrictions ................................ ............................ [ADDRESS_351661] of Care ................................ ................................ ......... 34
6.11.5. Iron Protocol ................................ ................................ ................ 34
7.STUDY ASSESSMENTS AN D PROCEDURES ................................ ..................... 35
7.1. Time and Event s Table ................................ ................................ ............... 36
7.2. Screening and Critical Baseline Assessments ................................ ............ 38
7.3. Safety ................................ ................................ ................................ ......... 38
7.3.1. Adverse Events (AE) and Serious Adverse Events (SAEs) .......... 38
[IP_ADDRESS]. Time Period and Frequency for Collecting AE 
and SAE Information ................................ .................. 38
[IP_ADDRESS]. Method of Detecting AEs and SAEs ........................... 39
[IP_ADDRESS]. Follow -up of AEs and SAEs ................................ ........ 39
[IP_ADDRESS]. Adverse Events of Special Interest ............................. 39
[IP_ADDRESS]. Cardiovascular and Death Events .............................. 39
[IP_ADDRESS]. Regulatory Reporting Requirements for SAEs ............ 40
[IP_ADDRESS]. Possible Suicidality R elated Adverse Events .............. 40
7.3.2. Pregnancy ................................ ................................ ................... 40
7.3.3. Physical Exams ................................ ................................ ........... 40
7.3.4. Vital Signs and W eight................................ ................................ .41
7.3.5. Electrocardiogram (ECG) ................................ ............................. 41
7.3.6. Clinical Safety Laboratory Assessments ................................ ......41
7.4. Pharmacokinetics ................................ ................................ ....................... 42
7.4.1. Blood Sample Collection ................................ .............................. 42
7.4.2. Sample Analysis ................................ ................................ .......... 43
7.5. Biomarker(s)/Pharmacodynamic Markers ................................ ................... 43
7.5.1. Ambulatory Blood Pressure Monitoring (ABPM) ........................... 43
[IP_ADDRESS]. ABPM Delay Due to High Hgb ................................ ....44
7.5.2. Blood Pressure Regulation Biomarkers ................................ .......44
7.6. Genetics ................................ ................................ ................................ .....44
8.DATA MANAGEMENT ................................ ................................ ........................... 44
9.STATISTICAL CONSIDER ATIONS AND DATA ANAL YSES ................................ .45
9.1. Hypothese s................................ ................................ ................................ .45
9.2. Sample Size Considerations ................................ ................................ .......45
9.2.1. Sample Size Assumptions ................................ ........................... 45
9.2.2. Sample Size Sensitivity ................................ ................................ 46
9.2.3. Sample Size Re -estimation or Adjustment ................................ ...46
9.3. Data Analysis Considerations ................................ ................................ .....46
9.3.1. Analysis Populations ................................ ................................ ....46
9.3.2. Interim Analysis ................................ ................................ ........... 47
9.4. Key Elements of Analys is Plan ................................ ................................ ...47
9.4.1. Primary Analyses ................................ ................................ ......... 47
9.4.2. Secondary Analyses ................................ ................................ ....47
9.4.3. Other Analyses ................................ ................................ ............ 47
10.STUDY GOVERNANCE CON SIDERATIONS ................................ ........................ 48
10.1. Posting of Information on Publicly Available Clinical Trial Registers ............ 48
2015N267693_04 CONFIDENTIA L
205665
710.2. Regulatory and Ethical Considerations, Including the Informed 
Consent Process ................................ ................................ ........................ 48
10.3. Qualit y Control (Study Monitoring) ................................ .............................. 49
10.4. Quality Assurance ................................ ................................ ....................... 49
10.5. Study and Site Closure ................................ ................................ ............... 49
10.6. Records Retention ................................ ................................ ...................... 50
10.7. Provision of Stu dy Results to Investigators, Posting of Information 
on Publicly Available Clinical Trials Registers and Publication .................... 51
11.REFERENCES ................................ ................................ ................................ .......52
12.APPENDICES ................................ ................................ ................................ ........ 55
12.1. Appendix 1 –Abbreviations and Trademarks ................................ .............. 55
12.2. Appendix 2: Liver Safety Required Actions and Follow up 
Assessments ................................ ................................ .............................. 58
12.3. Appendix 3: Daprodustat Risk Assessment ................................ ................ 64
12.4. Appendix 4: Definition of and Procedures for Recording, Evaluating, 
Follow -Up and Reporting of Adverse Events ................................ ............... [ADDRESS_351662] of Highly Effective Methods for Avoiding 
Pregnancy in Females of Reproductive Potential (FRP) .............. 80
12.4.8. Collection of Pregnancy Information ................................ ............ 81
12.5. Appendix 5 -Country Specific Requirements ................................ .............. 82
12.6. Appendix 6 –Ambulatory Blood Pressure Monitoring Device ...................... 83
12.7. Appendix 7 –Protocol Changes ................................ ................................ ..85
12.7.1. Amendment 1 ................................ ................................ .............. 85
12.7.2. Amendment 2 ................................ ................................ ............ 108
12.7.3. Amendment 3 ................................ ................................ ............ 135
12.7.4. Amendment 4 ................................ ................................ ............ 164
2015N267693_04 CONFIDENTIA L
205665
81. PROTOCOL SYNOPSIS FO R STUDY 205665
Ratio nale
The purpose of this stud y is to compare the effects on blood pressure of daprodustat to 
epoetin alfa in hemodial ysis-dependent (HD) subjects with anemia associated with 
chronic kidney  disease ( CKD ).  The stud y will also assess various biomarkers assoc iated 
with blood pressure ph ysiology  that may  provide insight into the mechanism(s) of the 
hypertensive effects associated with erythropoiesis stimulating agent(s) ( ESAs ).
Objective(s)/Endpoint(s)
Objectives Endpoints
Primary
To compare the effect of dap rodustat to epoetin 
alfa on blood pressure (BP) after Acute 
Challenge 2 (8 weeks of hemoglobin [Hgb ]
maintenance therapy)Average of systolic blood pressure (SBP) as 
measured by [CONTACT_288617] (ABPM) over [ADDRESS_351663] -dosing after 
8 week s of Hgb maintenance therapy
Secondary
To compare the initial effect of daprodustat to 
epoetin alfa on BP after Acute Challenge 1 ( 2 
weeks of erythropoiesis -stimulating agent [ESA]
washout)Average of SBP , diastolic blood pressure 
(DBP), mean arterial bl ood pressure (MAP), 
and heart rate (HR) as measured by [CONTACT_288618] [ADDRESS_351664] -dosing at Day 1
Area under the effect curve (AUEC )of SBP , 
DBP, MAP, and HR as measured by [CONTACT_288618] [ADDRESS_351665] -dosing at Day 1
To compare the effect of daprodustat to epoetin 
alfaon BP after Acute Challenge 2Average of DBP , MAP, and HR as measured 
by [CONTACT_288619] [ADDRESS_351666] -dosing at Day 57.
AUEC of SBP , DBP, MAP, and HR as 
measured by [CONTACT_288619] [ADDRESS_351667] -dosing at 
Day 57.
To estimate the initial effect of daprodustat on 
SBP, DBP, HRandMAP after Acute Challenge 
1Change from pre -dose in SBP, DBP, HR,and 
MAP at each timepoint at Day 1
To characterize the pharmacokinetics of 
daprodustatPlasma concentrations of daprodustat and 
metabolites and derived pharmacokinetic 
parameters inc luding maximum observed 
concentration (Cmax ), time of occurrence of 
Cmax (tmax ), terminal phase half -life (t½)and 
area under concentration -time curve from time 
zero to 24 hours (AUC [0-24])as appropriate
Safety
To assess the safety and tolerability of 
daprodustatIncidence and severity of adverse events ( AEs)
and serious adverse events ( SAEs )
2015N267693_04 CONFIDENTIA L
205665
9Objectives Endpoints
Reasons for discontinuation of study treatment
Absolute values and changes from baseline 
over time in laboratory parameters, 
electrocardiograms ( ECGs )and vital sig ns
Exploratory
To investigate the effect of daprodustat and 
epoetin alfa on vasoactive mediators of blood 
pressurePlasma concentrations and derived 
parameters including Cmax, tmax, t½ and 
AUC(0 -24) as appropriate (to include 
erythropoietin, endothelin -1, nitric oxide, 
asymmetric dimethylarginine, renin, 
angiotensin -IIand metabolites , and 
noradrenalin) 
To summarize the effect of daprodustat and 
epoetin alfa on SBP after Acute Challenge 1 
and Acute Challenge 2AUEC of SBP as measured by [CONTACT_288619] [ADDRESS_351668]-dosing
To compare the effect of daprodustat to epoetin 
alfa on SBP after 8 weeks of Hgb maintenance 
therapy Change from Day 1 pre -dose SBP to Day 57
pre-dose
To compare the effect of daprodustat to epoetin 
alfa on SBP at Cmax of each study treatment , 
as measured by [CONTACT_44117].  Change in SBP from pre -dose on Day 1 to 
Cmax of the study treatment onDay 1
Change in SBP from pre -dose on Day 1 to
Cmax of the study treatment on Day 57
Change in SBP from pre -dose on Day 57 to 
Cmax of the study treatment on Day 57
To compare the effect of daprodustat to epoetin 
alfa on SBP at respective Cmax of the 
erythropoietin level,as measured by [CONTACT_44117]. Change in SBP from pre -dose on Day 1 to 
Cmax of erythropoietin onDay 1
Change in SBP from pre -dose on Day 1 to 
Cmax of er ythropoietin on Day 57
Change in SBP from pre -dose on Day 57 to 
Cmax of erythropoietin on Day 57
Overall Design
This study  will be an open -label, randomized, parallel -group design in HD subjects with 
anemia associated with CKD.  There will be a screeni ng period, a 2-week ESA washout 
period, an initial 24 -hour acute challenge, an 8-week Hgb -maintenance period, a second
24-hr acute challenge and a follow -up visit 14±3 day s after completing treatment.  The 
study  design is outlined below:
2015N267693_04 CONFIDENTIA L
205665
10Stud y Design
Subjects will be screened for eligibility  within 7 -30 day sprior to the start of theESA 
washout period .
Subjects that qualify  for enro lment will be washed out of their ESA for 2weeks; the start 
of the ESA washout should be timed to coincide as close ly as possible with their next 
planned ESA dose.   Subjects are enrolled once they  enter the ESA washout period.
Following the 2-week ESA washout, subjects will be randomized 1:1 and stratified b y 
prior ESA dose, based on the average weekl y (for epoetins or darbepoetin) or monthly  
(for methoxy  polyethylene gl ycol (PEG) -epoetin beta) dosing during the 12 weeks prior 
to ESA washout as follows:
Low ESA dose: <100 U/kg /week epoetin alfa OR <0.5 µg/kg/week darbepoetin 
OR <0.6 µg/kg/week methoxy  PEG -epoetin beta
High ESA dose: ≥100 U/kg /week epoetin alfa OR ≥0.5 µg/kg/week darbepoetin 
OR 0.6 µg/kg/week methoxy  PEG -epoetin beta
On Day  1, subjects will be randomized and undergo Acute Challenge 1, a single dose 
challenge to compare the acute effects on BP of the high est planned once -daily  
maintenance dose of daprodustat (24 mg) to the highest starting dose of epoetin alfa 
(100 U/kg ).  Subjects will have BP monitored for [ADDRESS_351669] serial 
blood sampling to assess the pharmacokinetics of daprodustat and the time -course of 
various biomarkers.  Acute Challenge 1 will be started promptly following completion of 
a mid -week dial ysis session.
After completing Acute Challenge 1, all subjects will enter the 8 -week Hgb maintenance 
period where doses of either daprodustat or epoetin alfa will be administered and 
adjusted, as needed.
On Day  57, following the 8 -week Hgb maintenance period, subjects will undergo Acute 
Challenge 2; this challenge will, similar to Acute Challenge 1, involve assessing the 
effect of d aprodustat and epoetin alfa on BPas assessed b y 24-hr ABPM measurement.  
The subjects will be administered the same dose of either daprodustat or epoetin alfa that 
was given in Acute Challenge 1, and serial blood sampling will be performed to assess Week -2: ESA 
Washout
Day 1: Randomize & 
Acute Challenge 1Day 15, 29 & 43: Dose 
Adjustment (as needed)
Day 57: Acute Challenge 2Hgb Maintenance Period 
Week 10: Follow -up
Screening: Between [ADDRESS_351670] Requirement Specification (PRS).  If the ABPM fails the 
QC criteria following Acute Challenge 2, one additional Acute Challenge may  be made 
aftera subsequent, mid -week dial ysis visit [ADDRESS_351671]’s Hgb ≥11.5.  
Treatment A rms and Duration
The total maximum duration of subject involvement is up to 16weeks (Screening to 
Follow -up) as described below:
Screening : Screening will occur at le ast one week prior to but not more than 30 
days prior to washout. 
ESA Washout : Subjects that meet eligibility  criteria will begin the 2-week ESA 
washout .
oThis should be timed such that this day  occurs on the date that would have 
been the next scheduled do se of ESA (or as close as practicable).
oFor subjects with a three -times weekly  dialy sis schedule, this day  must not 
occur on the first dialy sis session of the week (e.g., if Monday -Wednesday -
Friday  schedule, the study  visit cannot be on Monday ).
oFor subjec ts with a four -to five -times weekl y dialysis schedule, this day can 
be on an y hemodial ysis session of the week.
Randomization & Acute Challenge 1 (Day  1): Subjects will be randomized 1:[ADDRESS_351672]’s dialy sis session.
Hgb Maintenance Period : Subjects randomized to daprodustat will start an 8 -week 
Hgb maintenance peri od based on a starting dose and dose adjustment algorithm.    
Subjects randomized to epoetin alfa will begin an 8 -week Hgb maintenance 
period where Hgb will be managed in accordance with local labelling.
2015N267693_04 CONFIDENTIA L
205665
12Acute Challenge 2 (Day  57): At the end of the [ADDRESS_351673]’s dialy sis session.
Follow -up: A Follow -up visit will be scheduled to occur 14 3 day s after 
completing treatment.
Treatment A rm Descriptions
Treatment Arm Acute Challenge 1 Hgb Maintenance Phase Acute Challenge 2
A100 U/kg IV epoetin 
alfaIVepoetin alfa according to label100 U/kg IV epoetin
alfa
B 24 mg daprodustatQDdaprodustat according to dose 
adjustment algorithm24 mg daprodustat
Type and Number of Subjects
The study  will enroll hemodialy sis-dependent subjects with anemia associated with 
CKD currently  treated with an ESA.  Subjects with Hgb values of 8.5-11.5 g/dL, 
inclusive at both Screening and Day  1, are eligible, and the subjects must currentl y be 
on an ESA product.
Approximately  124 subjects will be screened to achieve approximately  62 
randomized and 50 evaluable subjects for a total of 25 evaluable subjects per 
treatment group.
If subjects prematurel y discontinue the study, additional replacement subjects may be 
randomized and assigned to the same treatment arm at the discretion of the Sponsor in 
consultation with the investig ator.
Analysis
The primary  endpoint for this study  is average s ystolic blood pressure (SBP) over [ADDRESS_351674] is 
daprodustat versus epoetin alfa for this challenge.
The primary  anal ysis of average SBP over [ADDRESS_351675] -dose during Acute Challenge 2 
will be an anal ysis of covariance (ANCOVA) with terms for treatment, prior ESA 
dose (low/high), post-HD/pre -Acute Chall enge [ADDRESS_351676] -
HD/pre -Acute Challenge [ADDRESS_351677] -HD/pre -Acute Challenge 1 SBP, and 
treatment b y (difference in post -HD SBP between Acute Challenge 1 and 2) 
interaction.  Note that the pre -challenge SBP may  change over time between Acute 
Challenge [ADDRESS_351678] of treatment phase on the covariate. Therefore, if the interaction term in 
this model is significant at the 0.10 level, then the primary  model will be ANCOVA 
with terms for treatment , prior ESA dose (low/high), and post -HD/pre -Acute 
2015N267693_04 CONFIDENTIA L
205665
13Chal lenge 1 SBP.  The primary  model will provide a point estimate and two -sided 
95% CI  for the treatment effect and a p -value for the superiorit y assessment.  
Superiority  will be established if the p -value is <0.05.
The comparison of daprodustat versus epoetin alfa on [ADDRESS_351679] -dose in Acute 
Challenge 1 will be anal yzed using ANCOVA with terms for treatment , prior ESA 
dose (low/high), and post -HD/pre -Acute Challenge 1 SBP.  Sim ilar analy ses will be 
performed for DBP, MAP, and HR.
ANCOVA using the primary  model will be used for the analy sis of average DBP, 
MAP, and HRover [ADDRESS_351680] -dose in Acute Challenge 2 replacing the baseline SBP 
term with the analogous baseline measurement for DBP, MAP, and HR, respectively .
AUECs of SBP, DBP, MAP , and HR post Acute Challenge 2 and 1 will be anal yzed 
using ANCOVA with terms for treatment andprior ESA dose (low/high) with 95% 
CIs and p -values provided for the treatment effect.
Null Hy pothesi s: The difference between 24 mg daprodustat versus 100 IU/kg
epoetin alfa on 6 hr average SBP under a background of treatment (i.e., during Acute 
Challenge 2) is zero.
Alternative Hy pothesis: The difference between 24 mg daprodustat versus 100 IU/kg
epoeti n alfa on 6 hr average SBP under a background of treatment (i.e. during Acute 
Challenge 2) is not zero.
2. INTRODUCTION
Anemia is a common complication of chronic kidney  disease (CKD).  The cause of 
anemia in this population is multi -factorial, including rela tive or absolute deficiency  of 
erythropoietin (EPO), reduced iron availability  related to chronic inflammation, and 
gastrointestinal blood loss.  Current treatments for anemia associated with CKD include 
erythropoiesis -stimulating agents (ESAs) such as rec ombinant human (rh) EPO, 
supplemental iron therapy (intravenous and/or oral), and blood transfusions.  However, 
each of these treatments has significant limitations:
ESAs : In order to achieve target hemoglobin (Hgb) levels (which are lower than 
normal Hgb levels), treatment with ESAs markedly  increases plasma EPO 
concentrations to supra -physiologic levels.  Treatment with ESAs has also been 
associated with increased cancer -related morbidit y and mortality and increased 
risk of major cardiovascular (CV) event s (e.g., stroke, my ocardial infarction and 
all-cause mortality ) [FDA , 2011 ], as well as ESA -induced h ypertension.
Iron : Poor compliance is seen with oral iron therapy  due to gastrointestinal 
intolerance while intravenous (IV) iron may  have an increased risk of infection 
and/or iron overload as well as an increased risk for congestive heart failure 
[Agarwal , 2015 ].
Blood transfusions : These are avoided when possible because of potential allo -
immunization, which can pre clude the possibility  of receiving a kidney  transplant 
in addition to a risk of infection.
Hypoxia -inducible factor (HIF) prol yl hydroxylase inhibitors (PHI s) are an emerging new 
class of agents under investigation for the treatment of anemia associated wi th CKD.  
2015N267693_04 CONFIDENTIA L
205665
14These molecules stimulate ery thropoiesis through inhibition of HI F-prolyl hydroxylase 
domain enzy mes (PHD1, PHD2, PHD3).  This activity  results in the accumulation of 
HIFα transcription factors which leads to increased transcription of HIF -responsive 
genes, stimulating components of the natural response to hy poxia.  During hy poxia, PHD 
enzy mes are inhibited, resulting in the accumulation of unhy droxy lated HIFα subunits, 
which dimerize with HIFβ subunits to affect the transcription of HIF -responsive genes, 
including EPO and others involved in increasing oxy gen availability  and utilization.  
Other functions regulated by  [CONTACT_278808], angiogenesis, 
extracellular matrix metabolism, apoptosis, energy and glucose metabolism, vascular 
tone, cell adhesion, and motility  [Haase , 2013].
Daprodustat ([COMPANY_004]1278863) is a small molecule, oral inhibiter of t he HIF -PHD enzy mes 
which may  present several important advantages over other ESAs.  It is an oral 
medication and does not require cold-chain storage as do some ESAs, thus increasing 
ease of use for patients.  Moreover, data indicate that daprodustat can ef fectively  raise 
Hgb concentrations with lower EPO levels than those observed after administration of 
ESAs [ Provenzano, 2011 ].  Because of the increased CV risk associated with raising Hgb 
concentrations through large increases in EPO levels [ Pfeffer , 2009 ], daprodustat has the 
potential to raise Hgb with less CV risk than other ESAs.   
.
2.1. Study  Rationale
Current labelling for all ESAs includes a contraindication in patients with uncontrolled 
hypertension, and increases in blood pressure (BP) and/or antihy pertensive medication 
use has been observed in several clinical trials with ESAs.  While t he mechanism for this 
hypertensive effect is not known, hy pertension has been consistentl y observed in 
approximately  25 to 30% of CKD patients initiating ESA therapy , and varies between an 
average of approximately 5 to 8 mmHg in sy stolic blood pressure (SBP), and 4 to 6 
mmHg in diastolic blood pressure (DBP) reviewed in [ Krapf , 2009 ].  Additionally , 
increases in BP are a well -recognized risk factor for CV events, in particular heart failure, 
ischemic stroke and m yocardial infarction [ Rodriguez , 2014 ].  Finally , treatment with 
ESAs has been associated with increased risk of major CV events including m yocardial 
infarction, stroke and death.
Daprodustat has been shown to effectivel y raise and manage Hgb levels in subjects with 
CKD with lower levels of EPO than the ESAs.  As the hy pertensive effects of ESAs 
appear dose -related [ Abraham , 1991 ], there is the potential that daprodustat can treat 
anemia in CKD patients without the hy pertensive ef fects observed with the ESAs.  This 
study  will use two 24- hr Acute Challenges to compare the effect of daprodustat to rhEPO 
on BP as measured by [CONTACT_46674] (ABPM) following both a 
2-week ESA washout period (Acute Challenge 1) and an 8-week Hgb -maintenance 
period (Acute Challenge 2).
Therefore, the purpose of this study  is to compare the effects on blood pressure of 
daprodustat to epoetin alfa in hemodialy sis-dependent (HD) subjects with anemia 
associated with CKD.  The study  will a lso assess various biomarkers associated with 
CCI
CCI
CCI
2015N267693_04 CONFIDENTIA L
205665
15blood pressure ph ysiology  that may  provide insight into the mechanism(s) of the 
hypertensive effects associated with ESAs.
2.2. Brief Background
Daprodustat is a HIF -PHI currently  being investigated as a treatment f or anemia 
associated with CKD in both hemodialy sis dependent (HD)and non -dialysis dependent 
(ND) subjects, with adequate safety  and efficacy  demonstrated in clinical trials of up to 
24 weeks’ duration.  Both pre -clinical and clinical data show that daprod ustat stimulates 
EPO production resulting in increased ery thropoiesis and elevation in Hgb 
concentrations.  These increases in Hgb are achieved with peak EPO levels substantially  
lower than those observed with ESAs [Holdstock , 201 6].  Data from completed clinical 
and pre -clinical studies are provided in the Daprodustat I nvestigator Brochure (IB) and 
IB Supplement 01 and 02 [GlaxoSmithKline Document Number RM2008/[ZIP_CODE]/07 , 
GlaxoSmithKline Document Number 2015N266524_00 , GlaxoSmithKline Document 
Number 2015N266524_01 ].
3. OBJECTIVE(S) A ND END POINT(S)
Objectives Endpoints
Primary
To compare the effect of daprodustat to epoetin 
alfa on blood pressure (BP) after Acute 
Challenge 2 (8 weeks of hemoglobin [Hgb ]
maintenance therapy)Average of systolic blood pressure (SBP) as 
measured by [CONTACT_288617] (ABPM) over [ADDRESS_351681] -dosing after 
8 weeks of Hgb maintenance therapy
Secondary
To compare the initial effect of daprodustat to 
epoetin alfa on BP after Acute Challenge 1 ( 2
weeks of erythropoiesis -stimulating agent [ESA]
washout)Average of SBP ,diastolic blood pressure 
(DBP), mean arterial blood pressure (MAP), 
and heart rat e (HR) as measured by [CONTACT_288618] [ADDRESS_351682] -dosing at Day 1
Area under the effect curve (AUEC )of SBP ,
DBP, MAP, and HR as measured by [CONTACT_288618] [ADDRESS_351683] -dosing at Day 1
To compare the effect of daprodustat to epoetin 
alfa on BP after Acute Challenge 2Average of DBP , MAP, and HR as measured 
by [CONTACT_288619] [ADDRESS_351684] -dosing at Day 57.
AUEC of SBP , DBP, MAP, and HR as 
measured by [CONTACT_288619] [ADDRESS_351685] -dosing at 
Day 57.
To estimate the initial effect of daprodustat on 
SBP, DBP, HR and MAP after Acute Challeng e 
1 Change from pre -dose in SBP, DBP, HR and 
MAP at each timepoint at Day 1
To characterize the pharmacokinetics of 
daprodustatPlasma concentrations of daprodustat and 
metabolites and derived pharmacokinetic 
parameters including maximum observed 
concentr ation (Cmax ), time of occurrence of 
2015N267693_04 CONFIDENTIA L
205665
16Objectives Endpoints
Cmax (tmax ), terminal phase half -life (t½)and 
area under concentration -time curve from time 
zero to 24 hours (AUC [0-24]) as appropriate
Safety
To assess the safety and tolerability of 
daprodustatIncidence and severit y of adverse events ( AEs)
and serious adverse events ( SAEs )
Reasons for discontinuation of study treatment
Absolute values and changes from baseline 
over time in laboratory parameters, 
electrocardiograms ( ECGs )and vital signs
Exploratory
To investigate the effect of daprodustat and 
epoetin alfa on vasoactive mediators of blood 
pressurePlasma concentrations and derived 
parameters including Cmax, tmax, t½ and 
AUC(0 -24) as appropriate (to include 
erythropoietin, endothelin -1, nitric oxide, 
asymmetric dimet hylarginine, renin, 
angiotensin -IIand metabolites , and 
noradrenalin) 
To summarize the effect of daprodustat and 
epoetin alfa on SBP after Acute Challenge 1 
and Acute Challenge 2AUEC of SBP as measured by [CONTACT_288619] [ADDRESS_351686] -dosing
To compare the effe ct of daprodustat to epoetin 
alfa on SBP after 8 weeks of Hgb maintenance 
therapy Change from Day 1 pre -dose SBP to Day 57
pre-dose
To compare the effect of daprodustat to epoetin 
alfa on SBP at Cmax of each study treatment , 
as measured by [CONTACT_44117] Change in SBP from pre -dose on Day 1 to 
Cmax of the study treatment on Day 1
Change in SBP from pre -dose on Day 1 to 
Cmax of the study treatment on Day 57
Change in SBP from pre -dose on Day 57 to 
Cmax of the study treatment on Day 57
To compare the effect of daprod ustat to epoetin 
alfa on SBP at Cmax of the erythropoietin level , 
as measured by [CONTACT_44117] Change in SBP from pre -dose on Day 1 to 
Cmax of erythropoietin on Day 1
Change in SBP from pre -dose on Day 1 to 
Cmax of erythropoietin on Day 57
Change in SBP from pre -dose on Day 57 to 
Cmax of erythropoietin on Day 57
4. STUDY DESIGN
4.1. Overall Design
This study  will be an open -label, randomized, parallel -group design in HD subjects with 
anemia associated with CKD.  There will be a screening period, a 2-week ESA washout 
2015N267693_04 CONFIDENTIA L
205665
17perio d, an initial 24 -hr Acute Challenge, an 8-week Hgb -maintenance period, a second
24-hr Acute Challenge and a follow -up visit 14±3 day s after completing treatment.  The 
study  design is outlined in Figure 1.
Figure 1 Study  Design
Subjects will be screened for eligibility  within 7 -30 day sprior to the start of an ESA 
washo ut period .
Subjects that qualify  for enrolment will be washed out of their ESA for 2weeks; the start 
of the ESA wash out should be timed to coincide as closely  as possible with their next 
planned ESA dose.   Subjects are enrolled once they  enter the ESA washout period.
Following the 2-week ESA washout, subjects will be randomized 1:1 and stratified b y 
prior ESA dose, base d on the average weekl y (for epoetins or darbepoetin) or monthly  
(for methoxy  polyethylene gl ycol (PEG) -epoetin beta) dosing during the 12 weeks prior
to ESA washout as follows:
Low ESA dose: <100 U/kg /week epoetin alfa OR <0.5 µg/kg/week darbepoetin 
OR <0 .6 µg/kg/week methoxy  PEG -epoetin beta
High ESA dose : ≥100 U/kg /week epoetin alfa OR ≥0.5 µg/kg/week darbepoetin 
OR 0.6 µg/kg/week methoxy  PEG -epoetin beta
On Day  1, subjects will be randomized and undergo Acute Challenge 1, a single dose 
challenge to compare the acute effects on BP of the highest planned once -daily  
maintenance dose of daprodustat (24 mg) to the highest starting dose of epoetin alfa 
(100 U/kg).   Subjects will have BP monitored for [ADDRESS_351687] serial 
blood sampling to assess the pharmacokinetics of daprodustat and the tim e-course of 
various biomarkers.  Acute Challenge 1 will be started promptly following completion of 
a mid -week dial ysis session.
After completing Acute Challenge 1, all subjects will enter the 8 -week Hgb maintenance 
period where doses of either daprodustat or epoetin alfa will be administered and 
adjusted, as needed, based on dosing guidance as described in Section 6.4.Week -2: ESA 
Washout
Day 1: Randomize & 
Acute Challenge 1Day 15, 29 & 43: Dose 
Adjustment (as needed)
Day 57: Acute Challenge 2Hgb Maintenance Period
Week 10: Follow -up
Screening: Between 7 and 30 
days prior to ESA W ashout

2015N267693_04 CONFIDENTIA L
205665
18On Day  57, following the 8 -week Hgb maintenance period, subjects will undergo Acute 
Challenge 2; this challenge will, similar to Acute Challenge 1, involve assessing the 
effect of daprodustat and epoetin alfa on BPas assessed b y 24-hr ABPM measurement.  
The subjects will be administered the same dose of either daprodustat or epoetin alfa that 
was given in Acute Challenge 1, and serial blood sampling will be performed to assess 
daprodustat pharmacokinetics, and to characterize the time course of various biomarkers.  
Acute Challenge [ADDRESS_351688] Requirement Specification (PRS).  If the ABPM fails the 
QC criteria following Acute Challenge 2, one additional Acute Challenge may  be made 
after a subsequent, mid -week dial ysis visit [ADDRESS_351689]’s Hgb ≥11.5.  See Section 
[IP_ADDRESS] for guidance.
4.2. Treatment A rms and Duration
The total duration of subject involvement is up to 16weeks (Screening to Follow -up) as 
described below:
Screening : Screening will occur at least one week prior to but not more than 30 
days prior to washou t.
ESA Washout : Subjects that meet eligibility  criteria will begin the 2-week ESA 
washout at Week -2.
oThis should be timed such that this day  occurs on the date that would have 
been the next scheduled dose of ESA (or as close as practicable).
oFor subjects with a three -times weekly  dialy sis schedule, this day  must not 
occur on the first dialy sis session of the week (e.g., if Monday -Wednesday -
Friday  schedule, the study  visit cannot be on Monday ).
oFor subjects with a four -to five -times weekl y dialysis schedul e, this day  can 
be on an y hemodial ysis session of the week.
Randomization & Acute Challenge 1 (Day  1): Subjects will be randomized 1:[ADDRESS_351690]’s 
dialy sis session.
Hgb Maintenance Period : Subjects randomized to daprodustat will start an 8 -week 
Hgb mai ntenance period based on a starting dose and dose adjustment algorithm 
as described in Section 6.4.1 .  Subjects randomized to epoetin alfa will begin an 
8-week Hgb maintenance period where Hgb will be managed in accordance with 
local labelling.
Acute Challenge 2 : At the end of the [ADDRESS_351691]’s dialy sis session.
Follow -up: A Follow -up visit will be scheduled to occur 14 3 day s after 
completing treatment.
Table 1 Treatment A rm Descriptions
Treatment Arm Acute Challenge 1 Hgb Maintenance Phase Acute Challenge 2
A100 U/kg IV epoetin 
alfaIV epoetin alfa according to label100 U/kg IV epoetin 
alfa
B 24 mg daprodustatQD daprodustat according to dose 
adjustment algorithm ( Section 6.4.1 )24 mg da produstat
4.3. Type and Number of Subjects
The study  will enroll hemodialy sis-dependent subjects with anemia associated with CKD 
currentl y treated with an ESA.  Subjects with Hgb values of 8.5to11.5 g/dL, inclusive at 
both Screening and Day  1, are eligible, and the subjects must currentl y be on an ESA 
product.
Approximately  124 subjects will be screened to achieve approximately  62 randomized 
and 50 evaluable subjects for a total of 25 evaluable subjects per treatment group.
If subjects prematurel y discontinu e the study , additional replacement subjects may  be 
randomized and assigned to the same treatment arm at the discretion of the Sponsor in 
consultation with the investigator.
4.4. Design Justification
This study  will be an open -label, multi -center, randomized, p arallel -group design in HD 
subjects with anemia associated with CKD.  There will be a screening period, a 2-week 
ESA washout period, an initial 24 -hour Acute Challenge, an 8-week Hgb -maintenance 
period ,a second 24-hr Acute Challenge ,and a follow -up visit 14 ± 3 day s after 
completing treatment.
2015N267693_04 CONFIDENTIA L
205665
20This will be an open -label study  since the primary  endpoint (SBP by  [CONTACT_44117]) is an 
objective measure and unlikely  to be influenced b y knowledge of the treatment 
received.  Additionally ,blinding of an injectable compar ator and oral study drug 
is impractical in this case.
A screening period will be used to assess Hgb stability  in order to minimize the 
potential for enrolling patients with highly  variable Hgb despi[INVESTIGATOR_288587].
In ourprevious daprodustat study  experi ence in Phase 2b , HD -dependent subjects 
with anemia associated with CKD were administered placebo for 4 weeks, with a 
mean decrease between 0.61 and 0.72 g/dL in Hgb.  No subject met either the 
Hgb stoppi[INVESTIGATOR_288588].  Theref ore, the risk of a 
subject meeting Hgb withdrawal criteria is considered low during this phase.
The Acute Challenge days have been designed to be consistent with the 
methodology  used in a published study  [Kang , 1998 ](See Figure 2).  Although 
the goal of the current study  is to attempt to replicate the blood pressure results 
from the IV administration of epoetin alfa in thatpublication ,SBP will be the 
primary  endpoint rather than MAP since SBP is the overall best predictor of 
future cardiovascular risk in a hy pertensive population, and MAP is biased toward 
DBP [Agarwal , 201 5].
Acute Challenge 1 will assess whether there are any  immediate effects of 
daprodustat or epo etin alfa on blood p ressure.  This assessment will also 
determine the abilit y to replicate the findings in the published study and will 
provide information for an interim analy sis (See Section 9.3.2 ).
The 8 -week Hgb Maintenance Pha se will replicate the management procedures 
planned for the Phase 3 studies as described in Section 6.4.  The duration was 
chosen to be consistent with the timeframe in which the hy pertensive effects of 
ESAs hav e been observed (i.e., 4 to 8 weeks) [ Samtleben ,1988 ].
Acute Challenge 2 will again assess the effects of daprodustat or epoetin alfa on 
BP following 8 weeks of anemia treatment utilizing the same assessment as Acute 
Challenge 1. The purpose of Acute Challenge 2 is to assess any  BP effects of 
ESA administration that may  be potentiated (or possibly  diminished) following 
long-term administration of an ESA.
2015N267693_04 CONFIDENTIA L
205665
21Figure 2 Changes in MA P after administration of rhEP O (rHuEPO) and control
Values are mean ± SD; *P<0.[ADDRESS_351692] -HD [ Kang , 1998]
4.5. Dose Justification
Daprodustat Treatment Group
Acute Challenge 1 & 2 : The dose to be used for this group will be the highest planned 
mainte nance dose for a once -daily regimen (i.e., 24 mg) for treatment of anemia 
associated with CKD.  In a previous GlaxoSmithKline ([COMPANY_004] )study  (PHI112843 ), a 
single, oral dose of [ADDRESS_351693] been defined at Day 57to minimize marked increases in Hgb.
Hgb Maintenance Phase : Starting doses of daprodustat will be based on Hgb levels, 
as described in Section 6.4.[ADDRESS_351694] dose adjustment, and are based on modelling and simulation of the 
dose-Hgb response results from Phase 2 studies.  
Epoetin alfa Treatment Group
Acute Challenge 1 & 2 : The dose to be used for this group will be the highest labelled 
starting dose for epoetin alfa (100 U/kg, IV) which is consistent with the epoetin alfa 
dose used in the published study  where an acute increase in MAP with rhEPO was 
observed [ Kang , 1998 ].  As subjects in this group will have been washed off ESA for 
2weeks prior to Acute Challenge [ADDRESS_351695] been defined at Day 57to 
minimize marked increases in Hgb (See Table 2).
Hgb Maintenance Phase : The dosage of epoetin alfa during the 8 -week Hgb 
2015N267693_04 CONFIDENTIA L
205665
22maintenance phase will be adjusted (if necessary ) according to the local labelling in 
order to manage the subject’s Hgb within the target range (10.0 -11.0 g/dL). In a 
previous study  ([COMPANY_004] Study  PHI113633 ), HD subjects that had a 4 -week ESA 
washout were initiated on a mean dose of rhEPO of 89 IU/kg /week (n=39), with the 
dose increased to a mean of 102 IU/kg/ week 4 weeks later.
4.6. Benefit:Risk A ssessment
Summaries of fi ndings from both clinical and non -clinical studies conducted with 
daprodustat can be found in the Daprodustat Investigator’s Brochure (IB) and IB 
Supplements , if applicable .
4.6.1. Risk A ssessment
The potential risks of clinical significance including AEs of spec ial interest ( Section 
[IP_ADDRESS] ), and the mitigation strategies for this protocol taking into account the results of 
clinical and non -clinical studies with daprodustat, are outlined in Section 12.3.
4.6.2. Benefit A ssessment
In clinical trials of up to [ADDRESS_351696] that the increases in Hgb are achieved with EPO exposure lower 
than those observed with rhEPO.
4.6.3. Overall Benefit:Risk Conclusion
Daprodustat demonstrates a positive benefit vs. risk based on the evidence as follows.  In 
clinical trials up to 24 weeks in duration , daprodustat maintained Hgb to target range in 
subjects with anemia associated with CKD (both ND and HD) with a safety  profile 
consistent with the patient population.
This protocol employ s precautions to mitigate known and potential risks to enrolled 
subjects (See Section 12.3).  Given these precautions, as well as the potential benefit that 
daprodustat holds for the treatment of anemia associated with CKD compared to the 
current standard, the overall benefit ri sk balance is considered to be positive.
5. SELECTION OF STUDY P OPULA TION A ND 
WITHDRA WAL CRITERIA
Specific information regarding warnings, precautions, contraindications, adverse events, 
and other pertinent information on daprodustat that may  impact subject e ligibility  is 
provided in the Daprodustat I nvestigator’s Brochure and IB Supplements , if applicable .
Deviations from inclusion and exclusion criteria are not allowed because they can 
potentially  jeopardize subject safet y, the scientific integrit y of the st udy, or regulatory  
acceptability .  Adherence to the criteria as specified in the protocol is essential.
2015N267693_04 CONFIDENTIA L
205665
235.1. Hemoglobin Stability  Criteria
Entry  into the study  requires a stable Hgb between 8.5and 11.5 g/dL, inclusive .  This is 
confirmed from twoHgb values ob tained atthe Screening Visit and Washout Visit, with 
both values between 8.5 and 11.5 g/dL.   These will be taken via a validated point -of-care 
device to measure Hgb (i.e., HemoCue) prior to the dialy sis session of the day .  The value 
at the Washout Visit must not have decreased b ymore than 1.0 g/dL from the Screening 
Visit value . For subjects with a three -times weekly  dialysis schedule, Hgb values must 
not be obtained on the first dialy sis session of the week (e.g., if Monday -Wednesday -
Friday  schedule, t he study  visit cannot be on Monday ).  For subjects with a four -to five -
times weekly  dialy sis schedule, Hgb values can be obtained on any  hemodialy sis session 
of the week.
5.2. Inclusion Criteria
A subject will be eligible for inclusion in this study onl y if al l of the following criteria 
apply :
AGE
1.≥[ADDRESS_351697] AND DIAGNOSIS INCLUDING DISEASE SEVERITY
2.Hemoglobin: Stable Hgb 8.5to 11.5 g/dL inclusive (See Section 5.1).
3.Dialysis frequency: On hemodialy sis (HD, hemofiltration or hemodiafiltration) 
three -to five -times weekly  for at least 4 weeks prior to screening.
4.Dialysis adequacy : A single pool Kt/V urea 1.2 based on a historical value obtained 
within the 3 months prior to screening in order to ensure the adequacy  of dialy sis.  If 
Kt/V urea is not available, then an average of the last 2 values of urea reduction ratio 
(URR) is at least 65%.  NOTE : Only  needs confirming at screening.
5.ESA treatment :Treat ed with anESA (epoetins or their biosimilars, darbepoetin, or 
methoxy  PEG -epoetin beta ) for at least 4 weeks prior to screening.
6.Iron replacement therapy : Subjects may  be on stable (≤50% change in overall dose 
and compliance of 80% of prescribed doses in the 4 weeks prior to and including the 
screening period) maintenance oral or IV ( ≤100 mg/week) iron supplementation.  If 
subjects are on oral or IV iron, then doses must be stable for the 4 weeks prior to 
Washout .
7.Weight:   Mid-week weight change between di alysis treatments <5% as assessed 
post-dialy sis at the Screening and Washout visits .
8.Antihypertensive Medication: Meets the following criteria:
On at least 1antihy pertensive medication [excluding diuretics]
AND
On that same medication and the same dose fo r at least [ADDRESS_351698] will not be eligible for inclusion in this study  if an y of the following criteria 
apply :
CKD -RELATED CRITERIA
1.Dialysis modality : Planned change from HD to peritoneal dialy sis within the study  
time period, or on home dialy sis.
2.Renal transplant : Planned kidney  transplant within the 16weeks following the 
Screening visit.
3.High ESA dose : An epoetin alfa dose of ≥360 U/kg/week IV or ≥250 U/kg/week 
subcutaneous (SC), or darbepoetin dose of ≥1.8 µg/kg/week IV or SC, or methoxy  
PEG -epoetin beta dose of 2.2 µg/kg/week within the 8 weeks prior to screening 
through Week -4.
4.Mircera : Planned o r recorded a dministration of Mircera ( methoxy  PEG -epoetin beta ) 
within the 4 weeks prior to theWashout visit.
CARDIOVASCULAR DISEA SE-RELATED CRITERIA
5.Myocardial infarction or acute coronary syndrome: Within the 3 months prior to 
Washout .
6.Stroke or trans ient ischemic attack: Within the 3 months prior to Washout .
7.Heart failure: Chronic Class I V heart failure ( HF), as defined b y the [LOCATION_001] 
Heart Association (NYHA) functional classification sy stem diagnosed prior to 
Washout .
8.QT interval corrected for heart rateusing Bazett’s formula (QTcB ):QTcB >500 
msec, or QTcB >530 msec in subjects with Bundle Branch Block.  There is no QTc 
exclusion for subjects with a predominantly  paced rhy thm.
9.Current uncontrolled hypertension: Resting post dialy sissystolic blood pressure 
>160 mmHg; or diastolic blood pressure >100 m mHg at screening or uncontrolled 
hypertension as determined by [CONTACT_093] .
10.Atrial Fibrillation: Presence of atrial fibrillation.
OTHER DISEASE -RELATE D CRITERIA
11.Inflammatory disease: Active chron ic inflammatory  disease that could impact 
erythropoiesis (e.g., scleroderma, s ystemic lupus ery thematos us, rheumatoid arthritis, 
celiac disease) diagnosed prior to Washout .
12.Aplasias: History  of bone marrow aplasia or pure red cell aplasia.
13.Other causes of anemia: Pernicious anemia, thalassemia major, sickle cell disease or 
2015N267693_04 CONFIDENTIA L
205665
25myelodysplastic s yndrome.
14.Liver disease (any one of the following):
Alanine transaminase (ALT) >2x upper limit of normal (ULN) (screening only )
Bilirubin >1.5xUL N (screening only )
NOTE: Isolated bilirubin >1.5xUL N is acceptable to keep in the stud yif bilirubin 
is fractionated and direct bilirubin <35%.
Current unstable liver or biliary  disease per investigator assessment, generally  
defined b y the presence of ascites, encephalopathy, coagu lopathy , 
hypoalbuminaemia, esophageal or gastric varices, persistent jaundice, or cirrhosis.
NOTE: Stable chronic liver disease (including asymptomatic gallstones, chronic 
hepatitis B or C, or Gilbert’s sy ndrome) are acceptable if subject otherwise meets 
entry criteria.
15.Major surgery: Major surgery  (excluding vascular access surgery ) within the 3
months prior to Washout or planned during the study .
16.Transfusion: Blood transfusion within the 8 weeks prior to Washout , or an 
anticipated need for blood transfusi on during the study .
17.Gastrointestinal (GI) bleeding: Evidence of actively  bleeding gastric, duodenal, or 
esophageal ulcer disease ORclinically  significant GI bleeding within the 8weeks
prior to Washout .
18.Acute Infection: Clinical evidence of acute infecti on or history  of infection requiring 
intravenous (IV) antibiotic therap y within the 8weeks prior to Washout .
NOTE: IV antibiotics as prophy laxis are allowed.
19.Malignancy: History  of malignancy  within the two y ears prior to screening through 
Day [ADDRESS_351699] (e.g., Bosniak Category  IIF, III or IV) 3 cm.
NOTE: ONL Y exception is localized squamous cell or basal cell carcinoma of the 
skin that has been definitively  treated more than 4 weeks p rior to screening.
20.Blood Pressure Measurement: Subjects with an upper arm diameter which cannot 
be measured b y oscillometer/ sph ygmomanometer cuff ORfor whom blood pressure 
cannot be measured in the opposite arm of current vascular access.
CONCOMITANT ME DICATIONS
21.Severe allergic reactions: History  of severe allergic or anaphy lactic reactions or 
hypersensitivity  to excipi[INVESTIGATOR_38852] .
22.Drugs and supplements: Use of an y prescription or non -prescription drugs or 
dietary  supplements tha t are prohibited (See Section 6.11.3 ), from screening until 
Washout .
23.Prior investigational product exposure : The subject has participated in a clinical 
trial and has received an experimental investigational prod uct within the [ADDRESS_351700] prior to screening , 
whichever is longer .
2015N267693_04 CONFIDENTIA L
205665
26GENERAL HEALTH RELATED CRITERIA
24.Other conditions: Any other condition, clinical or laboratory  abnormality , or 
examination finding that the investigator considers would put the subject at 
unacceptable risk, which may  affect study  compliance or prevent understanding of the 
aims or investigational procedures or possible consequences of the stud y.
25.Females ONLY: Subject is pregna nt [as confirmed by  a positive serum human 
chorionic gonadotrophin (hCG) test for females of reproductive potential (FRP) 
only], subject is breastfeeding, or subject is of reproductive potential and does not 
agree to follow one of the contraceptive options listed in the L ist of Highl y Effective 
Methods for Avoiding Pregnancy  in Section 12.4.7 .
DIAGNOSTIC ASSESSMENTS AND OTHER CRITERIA
26.Vitamin B 12:At or below the lower limit of the reference range (may  rescreen in a 
minimum of 8 weeks , following treatment ).
27.Folate: <2.0 ng/mL (4.5 nmol/L) (may  rescreen in a minimum of 4 weeks , following 
treatment ).
28.Ferritin: <100 ng/mL
29.Transferrin saturation (TSAT): <20%.
5.4. Screening/Baseline/Run -in Failures
Screen failures are d efined as subjects who consent to participate in the clinical trial but 
who never enter the washout period .  In order to ensure transparent reporting of screen 
failure subjects, meet the Consolidated Standards of Reporting Trials (CONSORT) 
publishing requi rements, and respond to queries from Regulatory  authorities, a minimal 
set of screen failure information is required including Demograph y, Screen Failure 
details, Eligibility  Criteria, and Serious Adverse Events (see Section [IP_ADDRESS] ).
5.5. Withdrawal/Stoppi[INVESTIGATOR_2121]
A subject may  withdraw from the study  at any  time at his/her own request, or may  be 
withdrawn at an y time at the discretion of the investigator for safety, behavioral or 
administrative reasons.  If a sub ject withdraws from the study , he/she may  request 
destruction of an y samples taken, and the investigator must document this in the site 
study  records .
If a decision is made to withdraw a subject, he/she should return to the clinic as soon as 
possible to co mplete the Earl y Withdrawal assessments .  The Follow -up visit should be 
performed 14 ± 3days after last dose (see Time and Events Table Section 7.1).
In all cases, the reason for withdrawal from the study  and d ate of the last dose of study  
treatment will be recorded in the eCRF.
5.5.1. Criteria for Permanent Discontinuation from Study  Treatment and 
Early Withdrawal
Subjects must permanently discontinue study treatment and be withdrawn from the 
study  for the following r easons:
2015N267693_04 CONFIDENTIA L
205665
27Meets Hgb stoppi[INVESTIGATOR_3418] (See Section [IP_ADDRESS] )
Receives a blood transfusion
Receives a kidney  transplant
Becomes pregnant or intends to become pregnant during the stud y
Active GI bleeding
Diagnosis of cancer, with the exception of squamous cell or basal cell carcinoma
Liver chemistry  abnormalities exceeding the threshold criteria (See Section 5.5.3 )
Misses 2 consecutive dialy sis sessions
Useof prohibited me dication (See Section 6.11.3 )
Myocardial infarction or acute coronary  syndrome
Stroke or transient ischemic attack
New diagnosis of Class IV heart failure, as defined by  [CONTACT_247555] (NYHA) fun ctional classification s ystem
Active chronic inflammatory  disease that could impact ery thropoiesis
Any new diagnosis of hematological disease including those affecting platelets, 
white or red blood cells, coagulation disorders, or any other cause of anemia of
chronic disease other than renal disease
[IP_ADDRESS]. Hemoglobin Stoppi[INVESTIGATOR_278784]  a point -of-care Hgb anal yzer (HemoCue) to each site for rapid and 
convenient monitoring of Hgb levels and to ensure consistency  of Hgb measurements 
across sites parti cipating in the study .
Blood samples for measurement of Hgb concentrations via HemoCue will be collected 
(Table 2) and recorded in the eCRF.  The table below summarizes the Hgb values and 
corresponding action to be taken at each v isit. If the subject meets the below condition(s), 
then I P must be permanently  stopped.
2015N267693_04 CONFIDENTIA L
205665
28Table 2 Hgb Stoppi[INVESTIGATOR_288589] 1 (Prior to Acute Challenge 1)
Hgb at Visit Action
<7.5Repeat HemoCue assessment on the same sample at same study visit to confirm; take average of [ADDRESS_351701] from the study.
7.5-<11.5decrease of 2.0 in Hgb 
over 2 weeksRepeat HemoCue assessment on the same sample at same study visit 
to confirm; take average of [ADDRESS_351702] from the study.
11.5Repeat HemoCue assessment on the same sample at same study visit to confirm; take average of 2 
values.  If confirmed, avoid dosing and continue washout for one additional week.  Progress with 
Acute Challenge 1 one week later ifHgb has decreased below 11.5; if not then withdraw subject from 
study.
Days 15, 29, & 43
Hgb at Visit Action
<7.5Repeat HemoCue assessment on the same sample at same study visit to confirm; take average of [ADDRESS_351703] from the study.
7.5-<12.0decrease of 2.0 in Hgb 
over 2 weeksRepeat HemoCue assessment on the same sample at same study visit 
to confirm; take average of [ADDRESS_351704] from the study.
Day 57 (Prior to Acute Challenge 2)
Hgb at Visit Action
<7.5Repeat HemoCue assessment on the same sample at same study visit to confirm; take average of [ADDRESS_351705] from the study.
7.5-<11.5decrease of 2.0 in Hgb 
over 2 weeksRepeat HemoCue assessment on the same sample at same study visit 
to confirm; take average of [ADDRESS_351706] from the study.
11.5Repeat HemoCue assessment on the same sample at same study visit to confirm; take average of [ADDRESS_351707] from the study.
5.5.2. Missed Clinic Visits/Lost to Follow -up
The following actions must be taken when a subject fails to attend the clinic for a 
required stud y visit:
The site must att empt to contact [CONTACT_131993] -schedule the missed visit as 
soon as possible.
The site must counsel the subject on the importance of maintaining the assigned 
visit schedule and ascertain whether or not the subject wishes to and/or should 
continue in th e study .
In cases where the subject is deemed ‘lost to follow up’, the investigator or 
designee must make every effort to regain contact [CONTACT_1155] (where 
possible, [ADDRESS_351708]’s last 
known mai ling address or local equivalent methods).  These contact [CONTACT_131994]’s medical record.
2015N267693_04 CONFIDENTIA L
205665
29Should the subject continue to be unreachable, only then will he/she be considered 
to have withdrawn from the study  with a primary  reason of “Lost to Follow -up”.
5.5.3. Liver Chemistry Stoppi[INVESTIGATOR_131957] y and evaluate liver event etiology (in alignment with the Food and 
Drug Administration [FDA ]premarketing clinical liver safet y guidance). 
Discontinuation of study  intervention for abnormal liver tests is required when:
a participant meets one of the conditions outlined in the algorithm below.
when in the presence of abnormal liver chemistries no t meeting protocol -specified 
stoppi[INVESTIGATOR_004], the investigator believes study  intervention discontinuation is in 
the best interest of the participant. 
Phase II Liver Chemistry Stoppi[INVESTIGATOR_288590] t 
Discontinue  Study  Treatmen t Plus
Bilirubin≥2x
ULN (>35% 
direct) 
or plus
INR>1.5 , if 
measur ed*
Possi ble
Hy’s LawALT≥3xULNALT≥5xULNALT≥3xULN
Plus
Sympt oms of 
liver injury
or 
hyper sensitivityALT≥3xULN
but able to 
monitor 
week ly for 
4 week sNo
Yes
YesYes YesNo No No
NoYes
ALT≥3xULN
persist for
4 week s or 
stoppi[INVESTIGATOR_278786]
*INR value not applicable to subjects on  anticoagu lantsYesIf subj ect to be moni tored weekl y must refer to Liver Safety Requi red  Actions and  Follow  up 
Assessme nts  section  in  the  Appendi x
Must refer to Liver Safety Requi red Actions and Follow  up Assess ments section in the Appendi x
Repor t as an SAE if possible Hy’s Law case:  ALT≥3xUL N and  Bilirubin≥2xULN (>35% direct)  or 
INR>1.5 , if measur ed*
Liver Safet y Required Actions and Follow up Assessments Section can be found in 
Section 12.2.
[IP_ADDRESS]. Study  Treatment Restart or Rechallenge
Study  treatment restart or rechallenge after liver chemistry  stoppi[INVESTIGATOR_288591].
2015N267693_04 CONFIDENTIA L
[ADDRESS_351709]’s last visit.
6. STUDY TREA TMENT
6.1. Investigati onal Product and Other Study  Treatment
The term ‘stud y treatment’ is used throughout the protocol to describe an y combination 
of products received b y the subject as per the protocol design.  Stud y treatment may 
therefore refer to the individual study  treat ments or the combination of those study  
treatments.
Product name: [CONTACT_288659]: Tablet
Unit dose strength(s)/Dosage level(s): 1 mg, 2 mg, 4 mg, 6 mg, 8 mg, 10 mg tablet strengths/ 1 mg, 2 mg, 4 mg, 
6 mg, 10 mg , 12 mg & 24 mg dosage levels
Rout e of Administration Oral
Physical description: 1 mg, 2 mg & 4 mg tablets: 7.0 mm round, compound radius, white film 
coated tablets
6 mg, 8 mg & 10 mg tablets: 9.0 mm round, compound radius, white film 
coated tablets
Method for individualizing dosage: See Section 6.4.[ADDRESS_351710] dialy sis session of the 
week (e.g., if Monday -Wednesday -Friday schedule, the study  visit cannot be on 
Monday ).  For subjects with a four to five times weekl y dial ysis schedule, randomization 
can be on an y hemodial ysis session of the week.
Subjects can take their tablets without regard to food.  For all study  visits, it is 
recommended for subjects not to eat a heav y meal before coming to the clinic in order to 
avoid lipemia of the blood sample collected for the anal ysis of transferrin, iron and total 
iron binding capacit y (TIBC).
6.2. Treatment A ssignment
Subjects will be stratified by [CONTACT_278823] (as outlined in Section 4.1) and randomized 
1:[ADDRESS_351711] potential 
selection bias due to the open -label design.  Once a randomization number has been 
assigned b y an Interactive Voice/Web Response System (IVWRS )at time of 
Randomization , it must not be re -assigned.
2015N267693_04 CONFIDENTIA L
[ADDRESS_351712] doses adjusted, as required, to target Hgb 
within the range of 10.0-11.0 g/dL.  Dose adjustments will be assigned automatically via 
the IVWRS based on the subject’s Hgb value via onsite HemoCue assessment according 
to the following algorithms:
Day 1 (HemoCue Prior to Acute Challenge 1)
Hgb (g/dL) Action or Dose
<7.5Repeat HemoCue assessment on the same sample at same study visit to confirm; take 
average of [ADDRESS_351713] from the study.
7.5and <10.0 6 mg daprodustat
10.0 and <11.5 4 mg daprodustat
11.5Repeat HemoCue assessment on th e same sample at same study visit to confirm; take 
average of [ADDRESS_351714] from study.
The 8 week Hgb maintenance dosing will begin on Day 2, following Acute Challenge 1.
Acute Challenge dosing is the same for all subjects on the daprodustat arm: 24 mg.
Days 15, 29, 43, &57
The available dose steps for daprodustat are outlined below (highlighted boxes indicate 
starting doses).  Dose adju stments will result in the daprodustat dose being increased or 
decreased b y one dose step .
Hgb (g/dL)Hgb change since
previous study visitDose Adjustment
<7.5 Any changeRepeat HemoCue assessment on the same sample at same study 
visit to confirm; ta ke average of [ADDRESS_351715] from the study.
7.5 to <9.5 Decreasing or No change 1Increase to the next higher dose step
7.5 to <9.5 Increasing 2Maintain dose
2015N267693_04 CONFIDENTIA L
205665
329.5 to ≤11.5 Any change Maintain dose
>11.5 to <12.0Increasing or No change Decrease to the next lower dose step
Decreasing Maintain dose
≥12.0 Any changeRepeat HemoCue assessment on the same sample at same study 
visit to confirm; take average of 2 v alues.  If confirmed, HOLD dosing 
for 2 weeks until next study visit.3
7.5 to <12.0increase of 1.3in Hgb 
over 2 weeks 4Repeat HemoCue assessment on the same sample at same study 
visit to confirm; take average of 2 values. If confirmed, decrease to 
next lower dose step ,
7.5 to <12.0Increase of > 2 .0in Hgb 
over previous 4 weeks 
(Days 29 , 43, 574only)Repeat HemoCue assessment on the same sample at same study 
visit to confirm; take average of 2 values. If confirmed, decrease to 
next lower dose step ,
1No change is defined as an increase < 0.5 g/dL
2Increase is defined as an increase ≥ 0.5 g/dL
3If Hgb remains ≥12.[ADDRESS_351716] dose.
4 Only applies at Day 57 if a repeat AC2 is necessary.  The dose should be decreased for the 1 week between AC2 
and Additional AC2.
6.4.2. Subjects Randomized to Epoetin A lfa
Subjects randomized to epoetin alfa will be administered according to loc al labelling and 
clinical practice guidelines to keep Hgb in the target range (10.0 -11.0 g/dL).  For 
additional guidance on Hgb -based stoppi[INVESTIGATOR_288592] [IP_ADDRESS] .
6.5. Packaging and Labeling
Daprodustat tablets are packed in white, opaque high densit y polyeth ylene (HDPE) 
bottles with child -resistant closures.  The contents of the label will be in accordance with 
all applicable regulatory  requirements.
6.6. Preparation/Handling/Storage/A ccountability
No special preparation of study  treatment is required.
Only  subjects enrolled in the study  may  receive study  treatment and onl y 
authorized site staff may  supply  or administer study  treatment.  All study  
treatments must be stored in a secure environmentally  controlled and monitored 
(manual or automated) area in accordance with the labelled storage conditions 
with access limited to the investigator and authorized site staff.
The investigator, institution, or the head of the medical institution (where 
applicabl e) is responsible for study  treatment accountability , reconciliation, and 
record maintenance (i.e., receipt, reconciliation and final disposition records).
Further guidance and information for final disposition of unused study  treatment 
are provided in the Study Reference Manual ( SRM ).
2015N267693_04 CONFIDENTIA L
205665
33Under normal conditions of handling and administration, study  treatment is not 
expected to pose significant safet y risks to site staff .
A Material Safety  Data Sheet (MSDS)/equivalent document describing 
occupational hazards a nd recommended handling precautions either will be 
provided to the investigator, where this is required by  [CONTACT_1207], or is available 
upon request from [COMPANY_004].
6.7. Compliance with Study  Treatment A dministration
For subjects r andomized to daprodustat, treatment d osing details including dates for dose 
increases/reductions, will be recorded in RAMOS NG .
For subjects randomized to daprodustat, for Acute Challenge 1 and 2, stud y site 
personnel will confirm compliance.  When daprodustat is administered at home (Hgb 
maintenance period), subjects will be instructed to return all unused randomized 
treatment at each clinic visit.  A record of the number of daprodustat tablets dispensed to 
and taken b y each subject will be maintained and reconciled with randomized treatment 
and compliance records.
For subjects randomized to epoetin alfa, they  will receive all study  treatment directly  
from the investigator or designee, under medical supervision.  The date and time of each 
dose administered in the clinic will be recorded in the source documents.  The dose of 
study  treatment and study  subject identification will be confirmed at the time of dosing 
by a member of the study site staff other than the person administering the study  
treatment.
6.8. Treatment of Study  Treatment Overdose
Ther e is no specific antidote for overdose with daprodustat.  The expected manifestations 
of daprodustat overdosage include signs and s ymptoms associated with an excessive 
and/or rapid increase in Hgb concentration.  Daprodustat is highly protein bound; thus, 
clearance of daprodustat by  [CONTACT_288620].  Daprodustat metabolites are, in part, cleared via 
hemodialy sis.  In the event of a suspected overdose, it is recommended that the 
appropriate supportive clinical care be instituted, as dictated b y the subject’s clinical 
status.  Additionally , subjects should be monitored closely  for CV events, increased heart 
rate and hematologic abnormalities.
Consult the approved product label for inf ormation on overdose for epoetin alfa.
6.9. Treatment after the End of the Study
Subjects will not receive any  additional treatment from [COMPANY_004] after completion of the 
study  because the indication being studied is not life threatening or seriously  debilitating 
andother treatment options are available.
The investigator is responsible for ensuring that consideration has been given to the post -
study  care of the subject’s medical condition.
2015N267693_04 CONFIDENTIA L
[ADDRESS_351717] yle and/or Dietary  Restrictions
6.10.1. Meals and Dietary  Restrictions
Daprodust at can be taken without regard to meals.
All subjects will be instructed to limit caffeine -or xanthine -containing products (e.g., 
coffee, tea, cola drinks, chocolate) for 24h prior to both Acute Challenge 1 and Acute 
Challenge 2.  
6.11. Concomitant Medication s and Non -Drug Therapi[INVESTIGATOR_278788], including over -the-counter medications and supplements, 
taken during the stud y will be recorded in the eCRF.  Start/stop dates and route of 
administration will be recorded for g eneral concomitant medication s.
6.11.1. Weight and A ntihy pertensive Medication Changes
It is preferred that changes to subject weight and antihy pertensive medication(s) are not 
made while the subject is part of this study , however ,subjects should remain in the study  
regardless of an y changes .  All medication and dose changes should be recorded in the 
eCRF.
6.11.2. Permitted Medications and Non -Drug Therapi[INVESTIGATOR_288593] a prohibited medication in Section 6.11.[ADDRESS_351718] 
dose of randomized tr eatment is prohibited and will constitute a protocol violation .
Strong inhibitor sof CYP2C8 (e.g., gemfibrozil , high dose clopi[INVESTIGATOR_7745] [300 mg ])
Strong inducer sof CYP2C8 (e.g., rifampin/rifampi[INVESTIGATOR_2513] )
6.11.4. Standard of Care
During the study , investigators are expec ted to monitor the subject’s overall clinical 
status to ensure standards of care are met to enable consistency  of practice with Kidney  
Disease Improving Global Outcomes (KDIGO) guidelines or local equivalent.
6.11.5. Iron Protocol
Subjects must remain iron replete throughout the study .  If ferritin and TSAT are 
collected per local clinical practice while enrolled , the following is recommended .
Iron therap y will be administered if ferritin is ≤100 ng/mL and/or TSAT is ≤20%.  The 
investigator should choose the route of administration and dose of iron based on subject’s 
iron status and local clinical practice.  
All iron (excluding multivitamins) must be stopped and cannot be administered if:
Ferritin >800 ng/mL AND TSAT >20% OR
2015N267693_04 CONFIDENTIA L
205665
35TSAT >40%
7. STUDY A SSESSMENTS A ND PROCEDUR ES
Protocol waivers or exemptions are not allowed with the exception of immediate safety  
concerns.  Therefore, adherence to the stud y design requirements, including those 
specified in the Time and Events Table (Section 7.1), are essential and required for stud y 
conduct.
If assessments are scheduled for the same nominal time, then the assessments 
should occur in the following order:
1.12-lead ECG
2.vital signs
3.blood draws
Note: The timing of the assessments should all ow the blood draw to occur at the 
exact nominal time.
The change in timing or addition of time points for any  planned stud y 
assessments must be documented in a Note to File which is approved b y the 
relevant [COMPANY_004] stud y team member and then archived in the st udy sponsor and 
site study  files, but this will not constitute a protocol amendment.
The Institutional Review Board (IRB)/Independent Ethics Committee (IEC)
will be informed of an y safety issues that require alteration of the safet y 
monitoring scheme or a mendment of the Informed Consent Form.
No more than [ADDRESS_351719] safety .
2015N267693_04 CONFIDENTIA L
205665
367.1. Time and Events Table
Table 3 Study  Procedures and A ssessments
Procedure 1Screening WashoutTreatment Period 2Follow -up2
Day 1 Day 15 Day 29 Day 43 Day 57 Early WD Week 10
Informed Consent X
Entry Criteria X
Physical, Medical History, Demography X
HemoCue Hgb X X X4X X X X4X X
Enrolment X
IVWRS X X X X
Randomization X
Acute Challenge X4X4
ABPM Assessment X4X4
Dose Adjustment X X X
Females Only: Serum Pregnancy Test X X X X X
Females Only: Estradiol & FSH (if required)3X
ECG X X4X4X
Vital signs & weight (Pre -& Post -dialysis) X X X4X X4X
Clinical Chemistry X X X X X
Hematology X X X X X
Folate and Vitamin B12 X
Ferritin, transferrin, total iron , TSAT, UIBC X
Pharmacokinetic/Biomarker Assessments X4X4
Hgb Maintenance Period 5========================== =============
Adverse Events Assessment X6X X4X X X X4X
Review Concomitant Medications X X X4X X X X4X
1 All assessments should be done predialysis/predose except as noted.
2 Allowable time window 2 days EXCEPT Follow -up Visit whi ch is 3 days.
3 As detailed in Inclusion Criteria.
4 Detailed timings for assessments on Acute Challenge Days are given in Table 4.
5 From the end of Acute Challenge 1 to the beginning of Acute Challenge 2.
6 Only SAEs assessed as related to study participation are collected at this visit. See Section 12.4 for additional details.
2015N267693_04 CONFIDENTIA L
205665
37Table 4 Study  Procedures and A ssessments on A cute Challenge Day s (Tr eatment Period Day  1 and Day 57)
ProcedurePre-
DialysisPost -
DialysisPredoseTime (in hours relative to dosing)
0 0.5 1 2 3 4 6 8 12 16 24
HemoCue Hgb 1X X
IVWRS X
ABPM Assessment1, 3=================================== ======================================================== 
Administer Study Treatment 1X
Serum Pregnancy Test1X
ECG1X X
Vital Signs and Weight1X X X X X
Clinical Chemistry X
Hematology X
Pharmacokinetic s4X X X X X X X X X X X
Erythropoietin X X X X X X X X X X X
Endothelin -1 X X X X X X X
Nitric Oxide X X X X X X X
Asymmetric dimethylarginine X X X X X X X
Renin X X X X X X X
Angiotensi n-II X X X X X X X
Noradrenalin X X X X X X X
Adverse Events Assessment1X X X X X X X X X X X
Review Concomitant Medications1X X
Initiate Hgb maintenance dosing2X
1 Procedures to be repeated if Acute Challe nge 2 fails quality control criteria (For more detail refer to Section 7.5.1 )
2 Applies to Acute Challenge 1 only
3Timing of ABPM measurements does not correlate with specified time points in Table 4.
4 PK to be drawn from daprodustat subjects only.
2015N267693_04 CONFIDENTIA L
205665
387.2. Screening and Critical Baseline A ssessments
Medical history , including cardiovascular disease and associated risk factors, (as detailed 
in the eCRF) will be assessed at scr eening.
The following demographic parameters will be captured: y ear of birth, sex, race and 
ethnicity .
Medical/medication/family  history  will be assessed as related to the inclusion/exclusion 
criteria listed in Section 5.
7.3. Safet y
7.3.1. Adverse Events (A E) and Serious A dverse Events (S AEs)
The definitions of an AE or SAE can be found in Section 12.4.
The investigator and their designees are responsible for detecting, documenti ng and 
reporting events that meet the definition of an AE or SAE.
[IP_ADDRESS]. Time Period and Frequency  for Collecting A E and SA E Information
Any SAEs assessed as related to study  participation (e.g., protocol -mandated 
procedures, invasive tests, or change in existing therap y) or related to a [COMPANY_004] 
product will be recorded from the time a subject consents to participate in the 
study  up to and including any  follow -up contact.
AEs will be collected from the start of washout until the follow -up contact (see 
Section [IP_ADDRESS] ), at the timepoints specified in the Time and Events Table (Section 
7.1).
Medical occurrences that begin prior to the start of washout but after obtaining 
informed co nsent may  be recorded on the Medical History /Current Medical 
Conditions section of the CRF.
All SAEs will be recorded and reported to [COMPANY_004] within 24 hours, as indicated in 
Section 12.4.  The investigator will sub mit any  updated SAE data to the sponsor 
within 24 hours of it being available.
Investigators are not obligated to activel y seek AEs or SAEs in former study 
subjects.  However, if the investigator learns of any  SAE, including a death, at any  
time after a su bject has been discharged from the study , and he/she considers the 
event reasonabl y related to the study  treatment or study  participation, the 
investigator must promptly  notify  [COMPANY_004].
NOTE: The method of recording, evaluating and assessing causalit y of AEs a nd SAEs 
plus procedures for completing and transmitting SAE reports to [COMPANY_004] are provided in 
Section 12.4.
2015N267693_04 CONFIDENTIA L
205665
[IP_ADDRESS]. Method of Detecting AEs and SA Es
Care must be taken not to introduce bias when detecting AEs and/or SAEs. Open -ended 
and non -leading verbal questioning of the subject is the preferred method to inquire about 
AE occurrence.  Appropriate questions include:
“How are you feeling?”
“Have you had an y (other) medical problems since y our last visit/contact?”
“Have you taken any  new medicines, other than those provided in this study , since 
your last visit/contact?”
[IP_ADDRESS]. Follo w-up of A Es and SA Es
After the initial AE/SAE report, the investigator is required to proactivel y follow each 
subject at subsequent visits/contacts.  A ll SAEs, and AEs of Special Interest (as defined 
in Section [IP_ADDRESS] ) will be followed until resolution, until the condition stabilizes, until 
the event is otherwise explained, or until the subject is lost to follow -up (as defin ed in 
Section 5.5).  Further information on follow -up procedures is given in Section 12.4.5 .
[IP_ADDRESS]. Adverse Events of Special Interest
The investigator or site staff will be responsible for detecting, documenting and reporting 
any AEs of special interest or any  event that may  potentially  be one of the categories 
listed below (using preferred terms):
Death, myocardial infarction ( MI), stroke , heart failure, thromboembolic even ts,
thrombosis of vascular access
Thrombosis and/or tissue ischemia secondary  to excessive ery thropoiesis
Cardiomy opath y
Pulmonary  artery  hypertension (see also Section [IP_ADDRESS] )
Cancer -related mortality  and tumo r progression and recurrence
Esophageal and gastric erosions
Proliferative retinopathy , macular edema, choroidal neovascularization
Exacerbation of rheumatoid arthritis
Worsening of h ypertension
The results of an y investigation should be recorded in the re levant sections of the 
subject’s eCRF.
[IP_ADDRESS]. Cardiovascular and Death Events
[COMPANY_004] has identified CV and death events of special interest for all clinical studies.  
Investigators will be required to fill out the specific CV event page of the eCRF for the 
CV AEs an d SAEs or any  event that may  potentially  be one of the categories listed in 
Section 12.4.3 .
2015N267693_04 CONFIDENTIA L
205665
[IP_ADDRESS]. Regulatory  Reporting Requirements for SA Es
Prompt notification by  [CONTACT_288621] y of a product under clinical investigation are met.
[COMPANY_004] has a legal responsibility  to notify  both the local regulatory  authorit y and othe r 
regulatory  agencies about the safet y of a product under clinical investigation.  [COMPANY_004] will 
comply  with country  specific regulatory  requirements relating to safet y reporting to the 
regulatory  authorit y, Institutional Review Board (IRB)/Independent Ethics C ommittee 
(IEC) and investigators.
Investigator safety  reports are prepared for suspected unexpected serious adverse 
reactions according to local regulatory  requirements and [COMPANY_004] policy  and are forwarded 
to investigators as necessary .
An investigator who rec eives an investigator safety  report describing a SAE(s) or other 
specific safet y information (e.g., summary or listing of SAEs) from [COMPANY_004] will file it with 
the IB and will notify  the I RB/IEC, if appropriate according to local requirements.
[IP_ADDRESS]. Possible Suicidal ity Related A dverse Events
If during the stud y there is an occurrence of an AE or SAE which in the investigator’s 
opi[INVESTIGATOR_1649], is possibly  related to suicidality , the Possible Suicidality  Related Adverse Events 
(PSRAE) eCRF form should be completed (in additio n to the AE and SAE pages, as 
appropriate).
This event may  include, but is not limited to, one that involves suicidal ideation, a 
preparatory  act toward imminent suicidal behavior, a suicide attempt, or a completed 
suicide.  The investigator will exercise his or her medical and scientific judgment in 
deciding whether an event is possibly  related to suicidality .
7.3.2. Pregnancy
Details of all pregnancies in female subjects and the outcome for the neonate, if 
applicable, will be collected after the start of dosing and until 14days post -last dose.   If a 
pregnancy  is reported ,then the investigator should inform [COMPANY_004] within 2 weeks of 
learning of the pregnancy  and should follow the procedures outlined in Section 12.4.8.
7.3.3. Physical Exams
A complete ph ysical examination will include, at a minimum, assessment of the 
cardiovascular, respi[INVESTIGATOR_696], gastrointestinal and neurological sy stems.
Investigators should pay  special attention to clinical signs related to previous 
serious illne sses.
For height and weight measurements, the subject is recommended to wear indoor, 
daytime clothing with no shoes.
2015N267693_04 CONFIDENTIA L
[ADDRESS_351720] -dialysisand recorded as specified in the 
Time and Events Table (Section 7.1).
7.3.5. Electrocardiogram (ECG)
ECG measurements will be taken at the time points specified in the Time and Events 
Table (Section 7.1).  Full [ADDRESS_351721] in a sup ine 
position.  Heart rate ( HR), PR interval, QRS duration, and QT (uncorrected) interval will 
be measured.  QTcB will be calculated (machine -read or manually ).
At the Screening visit two additional ECGs are required if the initial ECG indicates 
prolonged Q Tc (see Section 5.3) using the automated or manuall y calculated QTcB 
value.  The average QTcB value of all three ECGs will be used to determine eligibility .  
Additional details are provided in the SRM.
ECG data will be read locally .
All ECGs will be performed before measurement of vital signs and collection of blood 
samples for laboratory  testing.
7.3.6. Clinical Safety  Laboratory  Assessments
All protocol required laboratory  assessments, as defined in Table 5must be conducted in 
accordance with the Laboratory  Manual, and Protocol Time and Events Schedule.  
Laboratory  requisition forms must be completed and samples must be clearly  labelled 
with the subject number, protocol number , site/center number, and visit date.  Details for 
the preparation and shipment of samples will be provided b y the laboratory and are 
detailed in the SRM.  Reference ranges for all safety  parameters will be provided to the 
site by  [CONTACT_288622] e for the assessments.
If additional non -protocol specified laboratory  assessments are performed at the 
institution’s local laboratory  and result in a change in subject management or are 
considered clinically  significant by  [CONTACT_093] (e.g., SAE or A E or dose 
modification) the results must be recorded in the eCRF.
Refer to the SRM for appropriate processing and handling of samples to avoid duplicate 
and/or additional blood draws.
All study -required laboratory  assessments will be performed b y a central laboratory , apart 
from HemoCue Hgb .The results of each HemoCue test must be entered into the eCRF.
NOTE:  Local laboratory results are onl y required in the event that the central laboratory  
results are not available in time for either a treatment and/or response evaluation to be 
performed.  If a local sample is required ,it is important that the sample for central 
2015N267693_04 CONFIDENTIA L
[ADDRESS_351722] be entered into the 
eCRF.
Hematology , clinical chemistry , and additional parameters to be tested are listed in Table 
5.
Table 5 Protocol Required Safety  Laboratory  Assessm ents
Laboratory 
AssessmentsParameters
HematologyPlatelet Count RBC Indices: WBC Count with 
Differential:
RBC Count MCV Neutrophils
Hemoglobin MCH Lymphocytes
Hematocrit MCHC Monocytes
WBC Count (absolute) RDW Eosinophils
Reticulocyte Count CHr Basophils
Clinical 
ChemistryPotassium AST (SGOT) Total and direct/indirect 
bilirubin
Sodium ALT (SGPT) Total Protein
Glucose Calcium (Albumin adjusted) Alkaline Phosphatase
Albumin Phosphate
Other Screening 
TestsSerum hCG pregnancy test Serum f erritin Folate
Estradiol 1Serum iron Vitamin B12
FSH1Serum transferrin UIBC
TSAT
NOTE: Details of Liver Chemistry Stoppi[INVESTIGATOR_131963] -Up Assessments after liver 
stoppi[INVESTIGATOR_31777] 12.2.
1As needed in women of non -child bearing potential only.
Abbreviations: ALT= Alanine transaminase; AST= Aspartate transaminase; CHr=Reticulocyte hemoglobin content; 
FSH=follicle stimulating hormone; MCH= Mean corpuscular hemoglobin; MCHC= Mean corpuscular hemoglobin 
concentration; MCV= Mean corpuscular volume; RBC= Red blood cell; RDW= Red blood cell distribution width; 
SGOT=Serum glutamic oxaloacetic transaminase; SGPT=Serum glutamic -pyruvic transaminase; TSAT = transferrin 
saturation; UIBC= unsaturated iron binding capacity; WBC= White blood cells;
All laboratory  tests with values that are considered clinically  significantl y abnormal 
during participation in the study  or within 14 ( 3) day s after the last dose of study  
treatment should be repeated until the values return to normal or baseline.  If such values 
do not return to normal within a period judged reasonable b y the investigator, the
etiology should be identified and the sponsor notified.
7.4. Pharmacokinetic s
7.4.1. Blood Sample Collection
Blood samples for pharmacokinetic (PK) anal ysis of daprodustat and its metabolites 
([COMPANY_004]2391220 [M2], [COMPANY_004]2531403 [M3], [COMPANY_004]2487818 [M4], [COMPANY_004]2506102 [M5], 
[COMPANY_004]2531398 [M6], and [COMPANY_004]2531401 [M13]) will be collected at the time points 
indicated in Section 7.1, Time and Events Table.  The actual date and time of each blood 
2015N267693_04 CONFIDENTIA L
205665
43sample collection will be recorded.  The timing of PK samples may  be altered and/or PK 
samples may  be obtained at additional time points to ensure thorough PK monitoring.
Details of PK blood sample collection (including volume to be collected), processing, 
storage and shippi[INVESTIGATOR_42232].
If the subject is unable to provide a sufficient blood quantity  per time point or there is 
significant concern for this by  [CONTACT_288623], these serial blood draws may  be 
omitted.
7.4.2. Sample A nalysis
Plasma analy sis will be performed under the control of Bioanal ysis, Immunogenicity , and 
Biomarkers -In Vitro/In Vivo Translation Platform/Scinovo, GlaxoSmithKline , the 
details of which will be included in the SRM.  Concentrations of daprodustat and its 
metabolites ([COMPANY_004]2391220 [M2], [COMPANY_004]2531403 [M3], [COMPANY_004]2487818 [M4], [COMPANY_004]2506102 
[M5], [COMPANY_004]2531398 [M6], and [COMPANY_004]2531401 [M13]) will be det ermined in plasma 
samples using the currently  approved bioanal ytical methodology .  Raw data will be 
archived at the bioanal ytical site (detailed in the SRM).
7.5. Biomarker(s)/Pharmacody namic Markers
7.5.1. Ambulator y Blood Pressure Monitoring (ABPM)
Blood pressure an d pulse will be measured during Acute Challenge 1 and 2 through the 
use of an ambulatory  blood pressure monitoring device.  Subjects will wear the ABPM 
device for two sessions during the stud y (i.e., Acute Challenge 1 and 2), occurring at Day  
1 (randomizat ion) and at Day 57.  The ABPM device will be placed prior to Acute 
Challenge dosing , and will remain on the subject’s arm until [ADDRESS_351723] -dosing.  The ABPM device will automatically  
calculate MAP.
The device planned for use in this study  is the Mortara Ambulo 2400 ; a specification 
sheet for this device can be found in Section 12.6.
After both Acute Challenge [ADDRESS_351724] Requirement Specification (PRS).  If the ABPM fails the 
QC criteria following Acute Challenge 2, one additional Acute Challenge may  be made 
in a subsequent, mid -week dialy sis visit [ADDRESS_351725] will receive the same stud y treatment for the repeat Acute Cha llenge 2 as was 
administered on Day  57 as a single additional dose. No additional clinical chemistry , 
hematology , pharmacokinetic or biomarker sampling will be done, however all other 
procedures will be performed as detailed in Table 4.
2015N267693_04 CONFIDENTIA L
205665
[IP_ADDRESS]. ABPM Delay  Due to High Hgb
Day 1:  If the HemoCue Hgb is confirmed to be ≥11.5 g/dL , then avoid dosing and 
continue washout for one additional week.  No other assessments should be performed 
for that subject during the visit.  When the subject ret urns 7 day s later, re -draw the Hgb 
for HemoCue and assess.  If confirmed to be <11.5 g/d Lthen p rogress with the 
remainder of assessments and perform Acute Challenge [ADDRESS_351726] be withdrawn.
Day 57:   If the HemoCue Hgb is confirmed to be ≥11.5 g/dL , then hold the dose(s) of I P
for [ADDRESS_351727] returns 7 day s later, re -draw the Hgb for HemoCue and assess.  If 
confirmed to be <11.5 g/d Lthen p rogress w ith the remainder of assessments and 
perform Acute Challenge 2.  If the Hgb remains high, the subject must be withdrawn.
7.5.2. Blood Pressure Regulation Biomarkers
Blood samples will be collected during this study  to investigate the mechanism of the 
effect of d aprodustat on blood pressure.  Biomarkers selected will explore the renin -
angiotensin -aldosterone axis, the nitric oxide and endothelin axes, sodium retention and 
HIF signalling.
Biomarkers may  include erythropoietin, nitric oxide (NO), as ymmetric dimethy arginine 
(ADMA), renin, angiotensin -II(1-8) and metabolites (1 -7and 1 -5), endothelin -1 (ET -1), 
and noradrenalin. Samples will be collected as specified in the Time and Events Table 
(Section 7.1).  The timing of the collections may  be adjusted on the basis of emerging 
pharmacokinetic or pharmacod ynamic (PD) data from this study or other new 
information in order to ensure optimal evaluation of the PD endpoints.
If the subject is unable to provide a sufficient bloo d quantity  per time point or there is 
significant concern for this by  [CONTACT_288623], these serial blood draws may  be 
omitted.
7.6. Genetics
Genetics are not evaluated in this study .
8. DATA MANAGEMENT
For this study ,subject data will be entered into [COMPANY_004] defined electronic case report 
forms (eCRFs), transmitted electronicall y to [COMPANY_004] or designee and combined with 
data provided from other sources in a validated data sy stem.
Management of clinical data will be performed in accordance with applicable 
[COMPANY_004] standards and data cleaning procedures to ensure the integrit y of the data, 
e.g., removing errors and inconsistencies in the data.
Adverse events and concomitant medications terms will be coded using MedDRA 
(Medical Dictionary  for Regulatory  Activities) and an internal validated 
medication dictionary , [COMPANY_004]Drug.
2015N267693_04 CONFIDENTIA L
205665
45CRFs (including queries and audit trails) will be retained b y [COMPANY_004], and copi[INVESTIGATOR_131964] y.  Subject initials 
will not be collected or transmit ted to [COMPANY_004] according to [COMPANY_004] policy .
9. STATISTICA L CONSIDER ATIONS AND DA TA 
ANALYSES
The primary  endpoint for this study  is average s ystolic blood pressure (SBP) over [ADDRESS_351728] is daprodustat versus 
epoetin alfa for this challenge.
The comparison of daprodustat versus epoetin alfa on 6 hr average SBP during Acute 
Challenge 1 is a secondary  endpoint.
9.1. Hypotheses
Null Hy pothesis: The difference between 24 mg daprodustat versus 100 IU/kg epoetin 
alfa on 6 hr average SBP under a background of treatment (i.e., during Acute Challenge 
2) is zero.
Alternative Hy pothesis: The difference between 24 mg daprodustat versus 100 IU/kg 
epoetin alfa on 6 hr average SBP under a background of treatment (i.e. during Acute 
Challenge 2) is not zero.
9.2. Sample Size Considerations
9.2.1. Sample Size A ssumptions
It is expected that 31 subjects will be randomized into each treatment arm.  Assuming a 
20% withdrawal rate during the Hgb Maintenance Period, there will be 25 subjects per 
treatment arm that will undertake Acute Challenge 2.  The study  will continue to recruit 
subjects until it is projected that 25 subjects per treatment arm complete and pass QC for
Acute Challenge 2.
Assuming a 5% significance level and a true standard deviation (SD) of 16 mmHg for 
average SBP over 6 hours, a sample size of 25 subjects per treatment group will provide 
greater than 90% power to detect a -15 mmHg difference bet ween treatment groups.  
Under these assumptions, statistical significance will be obtained if there is more than a 
9.1 mmHg mean difference observed in favor of daprodustat.
2015N267693_04 CONFIDENTIA L
205665
46Table 6 Power and Half -width of 95% CI for pair -wise compa risons, 
assuming a [ADDRESS_351729] 
15 mm Hg differenceHalf-Width of 95% CI 2
Acute Challenge 1 31 95% 8.1 mmHg
Acute Challenge 2 125 90% 9.[ADDRESS_351730]
9.2.2. Sample Size Sensitivity
Changes to power and the half -width of the 95% confidence interval for Acute Challenge 
2 due to vary ing assumptions on the SD for average SBP over 6 hr are explored in Table 
7below.
Table 7 Half-width of 95% CI for pair -wise comparisons, assuming [ADDRESS_351731]
15 mm Hg differenceHalf-Width of 95% CI
14 96% 8.0 mmHg
16†90% 9.1 mmHg
18 82% 10.2 mmHg
20 74% 11.4 mmHg
†Primary Comparison
9.2.3. Sample Size Re -estimation or A djustment
Subjects that withdraw prior to the Acute Challenge [ADDRESS_351732] is the intent to treat (ITT) population defined as all 
randomized subjects that received at least one dose of study  treatment.
In addition ,a per -protocol population may  be investigated.  Details will be provided in 
the Reporting and Anal ysis Plan (RAP) for the study.
2015N267693_04 CONFIDENTIA L
[ADDRESS_351733] -dose during Acute Challenge 2 will 
be an analy sis of covariance (ANCOVA) with terms for treatment, prior ESA dose
(low/high), and post -HD/pre -Acute Challenge [ADDRESS_351734] -HD/pre -
Acute Challenge [ADDRESS_351735] -HD/pre -Acute Challenge 1 SBP, and treatment by  
(difference in post -HD SBP between Acute Challenge 1 and 2) interaction.  Note that the 
pre-challenge SBP may  change over time between Acute Challenge [ADDRESS_351736] of treatment phase 
on the covariate. Therefore, if the interaction term in this model is significant at the 0.10 
level, then the primary  model will be ANCOVA with terms for treatment , prior ESA dose
(low/high), and post -HD/pre -Acute Challenge 1 SBP.  The primary  model will provide a 
point estimate and two-sided 95% CI for the treatment effect and a p -value for the 
superiority  assessment.  Superiority  will be established if the p -value is <0.05.
9.4.2. Secondary  Analyses
Average SBP over [ADDRESS_351737] -dose in Acute Challenge 1 will be anal yzed using ANCOVA 
with ter ms for treatment , prior ESA dose (low/high), and post -HD/pre -Acute Challenge [ADDRESS_351738] Acute Challenge 2 and 1 will be anal yzed 
using ANCOVA with terms for treatment and prior ESA dose (low/high) with 95% CI s 
and p -values provided for the treatment effect.
9.4.3. Other A nalyses
The difference in SBP between pre -dose in Acute Challenge 1 and pre -dose in Acute 
Challenge 2 will be summarized by  [CONTACT_1570].  Similar summaries of DBP ,MAP , 
andHRwill be performed.
For each acute challenge, change from pre -challenge in SBP, DBP, MAP, and HRwill be
summarized by  [CONTACT_288624].  I n addition, for each acute challenge ,
SBP, DBP, MAP, and HRwill be summarized by  [CONTACT_288624].  
Line graphs of this information will be provided by  [CONTACT_288625].
2015N267693_04 CONFIDENTIA L
205665
48For each acute challenge, the concentration of erythropoietin, endothelin -1, nitric oxide, 
asymmetric dimethy larginine, renin, angiotensin -IIand metabolites ,and noradrenalin
will be summarized by  [CONTACT_288624].  L ine graphs of this 
information will be provided by  [CONTACT_288626].
Further statistical considerations will be addressed in the RAP.
10. STUD Y GOVERNANCE CONSIDE RATIONS
10.1. Posting of Information on Publicly  Available Clinical Trial 
Registers
Study  information from this protocol will be posted on publicly  available clinical trial 
registers before enrollment of subjects begins.
10.2. Regulatory  and Ethica l Considerations, Including the 
Informed Consent Process
Prior to initiation of a site, [COMPANY_004] will obtain favorable opi[INVESTIGATOR_1649]/approval from the 
appropriate regulatory  agency  to conduct the stud y in accordance with International 
Conference on Harmonization (ICH)Good Clinical Practice (GCP) and applicable 
country -specific regulatory  requirements.
The study  will be conducted in accordance with all applicable regulatory  requirements, 
and with [COMPANY_004] policy .
The study  will also be conducted in accordance with I CH Good Clinical Practice (GCP), 
all applicable subject privacy  requirements, and the guiding principles of the current 
version of the Declaration of Helsinki.  This includes, but is not limited to, the following:
IRB/IEC review and favorable opi[INVESTIGATOR_1649]/approval of the study  protocol and 
amendments as applicable
Obtaining signed informed consent
Investigator reporting requirements (e.g., reporting of AEs/SAEs/protocol 
deviations to I RB/IEC)
[COMPANY_004] will provide full details of the above procedures, either verball y, in wr iting, 
or both
Signed informed consent must be obtained for each subject prior to participation 
in the study
The IEC/I RB, and where applicable the regulatory authority , approve the clinical 
protocol and all optional assessments, including genetic research.
Optional assessments (including those in a separate protocol and/or under separate 
informed consent) and the clinical protocol should be concurrentl y submitted for 
approval unless regulation requires separate submission.
2015N267693_04 CONFIDENTIA L
205665
49Approval of the optional assessmen ts may  occur after approval is granted for the 
clinical protocol where required b y regulatory  authorities.  I n this situation, 
written approval of the clinical protocol should state that approval of optional 
assessments is being deferred and the study , with the exception of the optional 
assessments, can be initiated.
10.3. Qualit y Control (Study  Monitoring)
In accordance with applicable regulations including GCP, and [COMPANY_004] procedures, 
[COMPANY_004] monitors will contact [CONTACT_288627], study  requirements, and their responsibilities to satisfy  
regulatory , ethical, and [COMPANY_004] requirements.
When reviewing data collection procedures, the discussion will also include 
identification, agreement and documentation of da ta items for which the eCRF
will serve as the source document.
[COMPANY_004] will monitor the study  and site activity  to verify  that the:
Data are authentic, accurate, and complete.
Safety  and rights of subjects are being protected.
Study  is conducted in accordance with the currently  approved protocol and any  
other study  agreements, GCP, and all applicable regulatory  requirements.
The investigator and the head of the medical institution (where applicable) agrees to 
allow the monitor direct access to all relevant docu ments
10.4. Qualit y Assurance
To ensure compliance with GCP and all applicable regulatory  requirements, [COMPANY_004] 
may conduct a quality  assurance assessment and/or audit of the site records, and 
the regulatory  agencies may  conduct a regulatory inspection at any  time d uring or 
after completion of the study .
In the event of an assessment, audit or inspection, the investigator (and institution) 
must agree to grant the advisor(s), auditor(s) and inspector(s) direct access to all 
relevant documents and to allocate their tim e and the time of their staff to discuss 
the conduct of the stud y, any findings/relevant issues and to implement any 
corrective and/or preventative actions to address any  findings/issues identified.
10.5. Stud y and Site Closure
Upon completion or premature disco ntinuation of the study , the [COMPANY_004] monitor will 
conduct site closure activities with the investigator or site staff, as appropriate, in 
accordance with applicable regulations including GCP, and [COMPANY_004] Standard 
Operating Procedures.
[COMPANY_004] reserves the right to tem poraril y suspend or prematurel y discontinue this 
study  at an y time for reasons including, but not limited to, safety  or ethical issues 
or severe non -compliance. For multicenter studies, this can occur at one or more 
or at all sites.
2015N267693_04 CONFIDENTIA L
205665
50If [COMPANY_004] determines such action is needed, [COMPANY_004] will discuss the reasons for taking 
such action with the investigator or the head of the medical institution (where 
applicable).  When feasible, [COMPANY_004] will provide advance notification to the 
investigator or the head of the medical inst itution, where applicable, of the 
impending action.
If the stud y is suspended or prematurely discontinued for safet y reasons, [COMPANY_004] will 
promptly  inform all investigators, heads of the medical institutions (where 
applicable) and/or institution(s) conducting the study . [COMPANY_004] will also promptly  
inform the relevant regulatory  authorities of the suspension or premature 
discontinuation of the study  and the reason(s) for the action.
If required b y applicable regulations, the investigator or the head of the medical 
institution (where applicable) must inform the I RB/I EC promptl y and provide the 
reason for the suspension or premature discontinuation.
10.6. Records Retention
Following closure of the study , the investigator or the head of the medical 
institution (where applicabl e) must maintain all site study  records (except for 
those required b y local regulations to be maintained elsewhere), in a safe and 
secure location.
The records must be maintained to allow eas y and timely  retrieval, when needed 
(e.g., for a [COMPANY_004] audit or reg ulatory  inspection) and must be available for review 
in conjunction with assessment of the facilit y, supporting s ystems, and relevant 
site staff.
Where permitted b y local laws/regulations or institutional policy, some or all of 
these records can be maintai ned in a format other than hard cop y (e.g., microfiche, 
scanned, electronic); however, caution needs to be exercised before such action is 
taken.
The investigator must ensure that all reproductions are legible and are a true and 
accurate cop y of the origin al and meet accessibility and retrieval standards, 
including re -generating a hard cop y, if required.  Furthermore, the investigator 
must ensure there is an acceptable back -up of these reproductions and that an 
acceptable qualit y control process exists for making these reproductions.
[COMPANY_004] will inform the investigator of the time period for retaining these records to 
comply  with all applicable regulatory  requirements.  The minimum retention time 
will meet the strictest standard applicable to that site for the study , as dictated by  
[CONTACT_65406], [COMPANY_004] 
standards/procedures, and/or institutional requirements.
The investigator must notify  [COMPANY_004] of any  changes in the archival arrangements, 
including, but not limited to, arc hival at an off -site facility  or transfer of 
ownership of the records in the event the investigator is no longer associated with 
the site.
2015N267693_04 CONFIDENTIA L
[PHONE_5982].7. Provision of Study  Results to Investigators, Posting of 
Information on Publicly Available Clinical Trials Registers 
and Publication
Where required b y applicable regulatory  requirements, an investigator signatory  will be 
identified for the approval of the clinical study  report.  The investigator will be provided 
reasonable access to statistical tables, figures, and releva nt reports and will have the 
opportunity  to review the complete study  results at a [COMPANY_004] site or other mutually -
agreeable location.
[COMPANY_004] will also provide the investigator with the full summary  of the stud y results.  The 
investigator is encouraged to share th e summary  results with the study  subjects, as 
appropriate.
[COMPANY_004] will provide the investigator with the randomization codes for their site only  after 
completion of the full statistical analy sis.
The procedures and timing for public disclosure of the results summary  and for 
development of a manuscript for publication will be in accordance with [COMPANY_004] Policy .
A manuscript will be progressed for publication in the scientific literature if the results 
provide important scientific or medical knowledge.
2015N267693_04 CONFIDENTIA L
[PHONE_5983]. REFERENCES
Abraham PA, Macres MG. Blood pressure in hemodialy sis patients during amelioration 
of anemia with ery thropoietin. J Am Soc Nephrol 1991; 2: 927 -936.
Agarwal R, Kusek JW, Pappas MK. A randomized trial of intravenous and oral iron in 
chronic kidney  disease. Kidney Int 2015; 88: 905 -914.
Brodie MJ, Mintzer S, Pack AM, Gidal Gary  E, Vecht CJ, Schmidt D. Enzy me induction 
with antiepi[INVESTIGATOR_006]: Cause for concern? Epi[INVESTIGATOR_8330] 2013: 54:11 –27.
Campochiaro PA and the first ARVO/[COMPANY_007] I nstitute Working Group et al. Ocular versus 
extraocular neovascularization: Mirror images or vague resemblances. Invest Ophthalmol 
& Vis Sci. 2006; 47:462 -474.
Chen H, Yu KD, Xu GZ. Association between Variant Y402H in Age -Related Macular 
Degeneration (AMD) Susceptibility  Gene CFH and T reatment Response of AMD: A 
Meta -Anal ysis. PloS ONE 2012; 7: e42464 
FDA Drug Safet y Communication: Modified dosing recommendations to improve the 
safe use of ery thropoiesis -stimulating agents (ESAs) in chronic kidney  disease. Safet y 
Announcement issued Ju ne 24, 2011.  L ink: 
http://www.fda.gov/Drugs/DrugSafet y/ucm259639.htm#sa
Formenti F, Beer PA, Croft QPP, Dorrington KL, Gale DP, Lappin TRJ, Lucas GS, 
Maher ER, Maxwell PH, McMullin MF, O’Connor DF, Percy  MJ, Pugh CW, Ratcliffe 
PJ, Smith TG, Talbot NP, Rob bins PA. Cardiopulmonary function in two human 
disorders of t he hypoxia -inducible factor (HIF) pathway : von Hippel -Lindau disease and 
HIF-2α gain -of-function mutation. FASEB J 2011; 25: 2001 -2011.
Genetic insights into age -related macular degeneration: Controversies addressing risk, 
causality , and therapeutics. Mol. Asp. Med. 2012; 33: 467 -486.
GlaxoSmithKline Document Number 2015N266524_00 Supplement to [COMPANY_004]1278863 
Investigator’s Brochure, 17 -DEC -2015.
GlaxoSmithKline Document Number 2015N266524_01 Supplement to [COMPANY_004]1278863 
Investigator’s Brochure, 08 -APR -2016.
GlaxoS mithKline Document Number RM2008/[ZIP_CODE]/07 I nvestigator’s Brochure, [ADDRESS_351739] -2015.
Haase VH. Mechanisms of Hy poxia Responses in Renal Tissue. JASN 2013; 24: [ADDRESS_351740] growth in advanced stages of autosomal dominant 
polycystic kidney  disease ; Kidney International (2018) 94, 849 –851.
2015N267693_04 CONFIDENTIA L
205665
53Holdstock L , Meadowcroft AM, Maier R, Johnson BM, Jones D, Rastogi A, Zeig S, 
Lepore JJ, Cobitz AR. Four -week studies of oral hy poxia -inducible factor -proly l 
hydroxylase inhibitor [COMPANY_004]1278863 for treatment of anemia. JASN 2016; 27:1234 -1244
James L P, Letzig L, Simpson PM, Capparelli E, Roberts DW, Hinson JA Davern TJ Lee 
WM. Pharmacokinetics of acetaminophen -protein adducts i n adults with acetaminophen 
overdose and acute liver failure. Drug Metab Dispos 2009; 37: 1779 -1784.
Kang D -H, Yoon K -I, Han, D -S. Acute effects of recombinant human ery thropoietin on 
plasma levels of proendothelin -1 and endothelin -1 in haemodialy sis patie nts. Nephrol 
Dial Transplant 1998; 13:2877 -2883.
Krapf, R, Hulter, HN. Arterial hy pertension by  [CONTACT_288628] -
stimulating agents (ESA). Clin J Am Soc Nephrol 2009; 4: [ADDRESS_351741] progression in a mous e model of autosomal 
dominant poly cystic kidney  disease; Kidney International, 2018.
Muz B, Khan MN, Kiriakidis S, Paleolog EM. The role of h ypoxia and HIF -dependent 
signalling events in rheumatoid arthritis. Arthritis Research & Therapy 2009; 11: 201 -
209.
Navaneethan SD, for CRIC investigators: Prevalence, Predictors, and Outcomes of 
Pulmonary  Hypertension in CKD. J Am Soc Nephrol 2016, 27:877 –886.
Ohnhaus EE, Breckenridge AM, Park BK. Urinary  excretion of 6β -Hydroxy cortisol and 
the Time Course Measurement of Enzy me Induction in Man.  Eur J Clin Pharmacol
1989:36:39 -46.
Pfeffer MA, Burdmann EA, Chen C et al. for the TREAT I nvestigators. A Trial of 
Darbepoetin Alfa in Ty pe 2 Diabetes and Chronic Kidney  Disease. N Engl J Med 2009; 
361: 2019 -2032.
Provenzano R, Tumlin J, Zabaneh R, et al. Pharmacokinetics of oral FG -4592 to treat 
anemia in hemodial ysis patients. National Kidney  Foundation Conference, 201 1 
(Abstract #189).
Rodriguez CJ, Swett K, Agarwal SK, Folsom AR, Fox ER, L oehr LR, Ni H, Rosamond 
WD, Chang PP. Sy stolic blood pressure levels among adults with h ypertension and 
incident cardiovascular events. The Atherosclerosis Risk in Communities Study .JAMA 
Intern Med 2014; 174: [ADDRESS_351742] -Daniel B, Gurland HJ. 
Blood pressure changes during treatment with recombinant human ery thropoietin. Contr 
Nephrol 1988; 66:114 -122.
Smith TG, Brooks JT, Balan os GM, Lappin TR, Lay ton DM, Leedham DL, L iu C, 
Maxwell PH, McMullin MF , McNamara CJ, Percy  MJ, Pugh CW, Ratcliffe PJ, Talbot 
2015N267693_04 CONFIDENTIA L
205665
54NP, Treacy  M, Robbins PA. Mutation of von Hippel -Lindau tumour suppressor and 
human cardiopulmonary  physiology . PLoS Med 2006;3: e 290
Westra J, Molema G, Kallenberg CG. Hy poxia -inducible factor -1 as regulator of 
angiogenesis in rheumatoid arthritis -therapeutic implications. Curr Med Chem 2010; 17: 
254-63.
2015N267693_04 CONFIDENTIA L
[PHONE_5984]. APPENDICES
12.1. Appendix 1 –Abbreviations and Trademarks
Abbrev iations
ABPM Ambul atory  blood pressure monitoring
ADMA Asymmetric dimethy arginine
AE Adverse event
ALT Alanine transaminase
AMD Age-Related Macular Deg eneration
ANCOVA Analy sis of Covariance
AST Aspartate transaminase
AUEC Area under the effect curve
AUC (0 -24) Area under concentration -time curve from time zero to 24 hours
BP Blood pressure
CHr Reticulocy te hemoglobin content
CI Confidence interval
CKD Chronic kidney  disease
Cmax Maximum observed concentration
CPK Creatine phosphokinase
CV Cardiovascular
DBP Diastolic blood pressure
dL Deci liter
DNA Deox yribonucleic acid
ECG Electrocardiogram
ECHO Echocardiogram
eCRF Electronic Case Report Form
EDW Estimated Dry  Weight
EPO Erythropoietin
ESA Erythropoiesis -stimulating agent
ET-1 Endothelin -1
FDA Food and Drug Administration
FRP Females of Reproductive Potential
FSH Follicle Stimulating Hormone
GCP Good Clinical Practice
G Gram
GI Gastrointestinal
[COMPANY_004] GlaxoSmithKline
hCG Human chorionic gonadotrophin
HD Hemodialy sis dependent
HDPE High Density Polyethylene
HF Heart Failure
Hgb Hemoglobin
HIF Hypoxia -inducible factor
HR Hour/heart rate
2015N267693_04 CONFIDENTIA L
205665
56IB Investigator’s Brochure
ICH International Conference on Harmonization
IEC Independent Ethics Committee
INR International Normalized Ratio
IRB Institut ional Review Board
ITT Intent -to-treat
IU International Unit
IV Intravenous
IVWRS Interactive Voice/Web Response Sy stem
KDIGO Kidney  Disease Improving Global Outcomes
KG Kilogram
LDH Lactate deh ydrogenase 
MAP Mean Arterial Blood Pressure
MCH Mean corpuscular hemoglobin
MCHC Mean corpuscular hemoglobin concentration
MCV Mean corpuscular volume
MedDRA Medical Dictionary  for Regulatory  Activities
MG Milligram
MI Myocardial infarction
ML Milliliter 
mmHG Millimeter of mercury
MSDS Material Saf ety Data Sheet
ND Non-dialysis dependent
NO Nitric Oxide
NOAEL No Observed Adverse Effect Level
NYHA [LOCATION_001] Heart Association
PASP Pulmonary  Artery  Systolic Pressure
PCI Percutaneous Coronary  Intervention
PD Pharmacod ynamic
PEG Polyethylene gl ycol
PGI2 Prostaglandin I [ADDRESS_351743] Requirement Specification
PRVP Peak Right Ventricular Pressure
PSRAE Possible suicidality  related adverse event
QC Quality  Control
QTc QT interval corrected for heart rate
QTcB QT interval corrected for heart rate using Bazett’s formula
RAP Reporting and Anal ysis Plan
RBC Red blood cell
RDW Red blood cell distribution width
rhEPO Recombinant human ery thropoietin 
RNA Ribonucleic acid
2015N267693_04 CONFIDENTIA L
[ADDRESS_351744] deviation
SGOT Serum glutamic oxaloacetic transaminase
SGPT Serum glutamic -pyruvic transaminase
sPAP Systolic Pulmonary  Artery Pressu re
SRM Study  Reference Manual
T1/[ADDRESS_351745] Upper limit of normal
URR Urea reducti on ratio
WBC White blood cells
Trademark Information
Trademarks of the GlaxoSmithKline 
group of companiesTrademarks not owned by [CONTACT_288629]
2015N267693_04 CONFIDENTIA L
[PHONE_5985].2. Appendix 2: Liver Safety  Required A ctions and Follow up 
Assessments
The procedures listed below are to be followed if a subject meets the liver chemistry 
stoppi[INVESTIGATOR_103034] 5.5.3 :
Immediately  withdraw the subject from study  treatment
Notify  the Medi cal Monitor within [ADDRESS_351746]’s study  treatment cessation and follow -up.
Complete the “Safet y Follow -Up Procedures” listed below.
Complete the liver event case report forms.  If the event also meets the crit eria of an 
SAE (see Section 12.4), the SAE data collection tool will be completed separatel y 
with the relevant details.
Upon completion of the safet y follow -up withdraw the subject from the study  unless 
further safet y follow up is required
Do not restart stud y treatment
Refer to the Flow chart for a visual presentation of the procedures listed below.
Safety Follow -Up Procedures for subjects with ALT 3xULN:
Monitor subjects weekl yuntil liver chemistries (ALT, AS T, alkaline phosphatase, 
bilirubin) resolve, stabilize or return to within baseline values.
Safety Follow -Up Procedures for subjects with ALT 3xULN and total bilirubin 
2xULN (>35% direct bilirubin); or ALT 3xULN and INR1> 1.5:
This event is considered an SAE (see Section 12.4)  Serum bilirubin fractionation 
should be performed if testing is available.  If fractionation is unavailable, urinary  
bilirubin is to be measured via dipstick (a measurement of direct bilirubin, which 
would suggest liver injury).
Make every  reasonable attempt to have subjects return to the clinic within 24 hr for 
repeat liver chemistries, additional testing, and close monitoring (with specialist or 
hepatology  consultation recommended).
Monitor subjects twice weekl yuntil liver chemistries (ALT, AST, alkaline 
phosphatase, bilirubin) resolve, stabilize or return to within baseline values.
1 INR testing not required per protocol and the threshold value does not apply to subjects receiving a nticoagulants.
2015N267693_04 CONFIDENTIA L
205665
59In addition, for allsubjects with ALT 3xULN, every attempt must be made to also 
obtain the following:
Viral hepatitis serology  including:
oHepatitis A IgM antibody.
oHepatitis B surface antigen and Hepatitis B Core Antibody  (IgM). 
oHepatiti s C ribonucleic acid (RNA ).
oCytomegalovirus IgM antibody .
oEpstein -Barr viral capsid antigen IgM antibod y (or if unavailable, obtain 
heterophile antibod y or monospot testing).
oHepatitis E IgM antibody.
Blood sample for pharmacokinetic (PK) anal ysis, obtaine d within [ADDRESS_351747] the date/time of the PK blood sample draw and the date/time of the last dose 
of study  treatment prior to blood sample draw on the CRF.  If the date or time of the 
last dose is unclear, provide the subject’s best approxima tion.  I f the date/time of the 
last dose cannot be approximated ORa PK sample cannot be collected in the time 
period indicated above, do not obtain a PK sample .  Instructions for sample 
handling and shippi[INVESTIGATOR_278796].
Serum creatine phospho kinase (CPK) and lactate dehy drogenase (LDH).
Fractionate bilirubin, if total bilirubin 2xUL N.
Assess eosinophilia
Record the appearance or worsening of clinical s ymptoms of hepatitis (fatigue, 
nausea, vomiting, right upper quadrant pain or tenderness, f ever, rash or eosinophilia) 
on the AE CRF.
Record use of concomitant medications, acetaminophen, herbal remedies, other over 
the counter medications, or putative hepatotoxins on the Concomitant Medications 
CRF.
Record alcohol use on the L iver Events CRF.
The following are required for subjects with ALT 3xUL N andbilirubin 2xUL N 
(>35% direct) but are optional for other abnormal liver chemistries:
Anti-nuclear antibody , anti -smooth muscle antibody , and Ty pe 1 anti -liver kidney  
microsomal antibodies.
Serum acetaminophen adduct high performance liquid chromatograph y(HPL C)
assay  (quantifies potential acetaminophen contribution to liver injury  in subjects 
with definite or likely  acetaminophen use in the preceding week [ James , 2009].
Liver imaging (ultrasound, magnetic resonance, or computerized tomography ) to 
evaluate liver disease.
The L iver Imaging and/or L iver Biopsy  CRFs are also to be completed if these tests 
are performed.
2015N267693_04 CONFIDENTIA L
205665
60Refer to the diagram below for a visual presentation of the procedures listed above.

2015N267693_04 CONFIDENTIA L
205665
61Additional charts are provided below for reference .
Liver Chemistry Stoppi[INVESTIGATOR_2121] –Liver Stoppi[INVESTIGATOR_53053]-absolute ALT 5xULN
ALT Increase ALT 3xULN persists for 4 weeks
Bilirubin 1, 2ALT 3xULN andbilirubin 2xULN (>35% direct bilirubin)
INR2ALT 3xULN andINR>1.5, if INR measured
Cannot Monitor ALT 3xULN and cannot be monitored weekly for 4 weeks
Symptomatic 3ALT  3xULN associated with symptoms (new or worsening) believed to be 
related to liver injury o r hypersensitivity
Required Actions and Follow up Assessments following ANY Liver Stoppi[INVESTIGATOR_90567]
Immediately discontinue study treatment 
Report the e vent to [COMPANY_004] within 24 hours
Complete the liver event CRF and complete an 
SAE data collection tool if the event also meets 
the criteria for an SAE 2
Perform liver event follow up assessments 
Monitor the subject until liver chemistries
resolve, stabilize, or return to within baseline 
(see MONITORING below)
Do not restart/rechalle ngesubject with study 
treatment. If restart/rechallenge not allowed 
per protocol or not granted , permanently 
discontinue study treatment and may 
contin ue subject in the study for any protocol 
specified follow up assessments 
MONITORING:
For bilirubin or INR criteria:
Repeat liv er chemistries (include ALT, AST, 
alkaline phosphatase, biliru bin) and perform 
liver event follow up assessments withi n24 hrs
Monitor subjects twice weekly until liver 
chemistries resolve, stabilize or return to within Viral hepatitis serology 4
Blood sample for pharmacokinetic (PK) 
analysis, obtained within [ADDRESS_351748] dose 5
Serum creatine phosphokinase (CPK) 
and lactate dehydrogenase (LDH).
Fractionate bilirubin, if total 
bilirubin 2xULN
Obtain complete blood count with 
differential to assess eosinophilia
Record the appearance or worsening of 
clinical symptoms of liver injury, or 
hypersensitivity, on the AE report form
Record use of concomitant medicatio ns 
on the concomitant medications report 
form including acetaminophen, herbal 
remedies, other over the counter 
medications .
Record alcohol use on the liver event 
alcohol intake case report form
2015N267693_04 CONFIDENTIA L
205665
62baseline 
Aspecialist or hepatology consultation is 
recommended
For All other criteria: 
Repeat liver chemistries (include ALT, AST, 
alkaline phosphatase, bilirubin) and perform 
liver event follow up assessments within 24-72 
hrs 
Monitor subjects weekly until liver chemistries 
resolve, stabilize or return to within baselineFor bilirubin or INR criteria:
Anti-nuclear antibody, anti -smooth 
muscle antibody, Type 1 anti -liver 
kidney microsomal antibodies, and 
quantitative total immunoglobulin G 
(IgG or gamma globulins).
Serum acetaminophen adduct HPLC 
assay (quantifies potential 
acetaminophen contribution to liver 
injury in subjects with definite or likely 
acetaminophen use in the preceding 
week [ James ,2009]). NOTE: not 
required in China
Liver imaging (ultrasound, magnetic 
resonance, or computerised 
tomography) and /or liver biopsy to 
evaluate liver disease ; comple te Liver 
Imaging and/or Liver Biopsy CRF 
forms.
1.Serum bilirubin fractionation should be performed if testing is available. If serum bilirubin fractionation is not 
immediately available, discontinue study treatment for that subject if ALT 3xULN andbilirubin 2xULN. 
Additionally, if serum bilirubin fractionation testing is unavailable, record presence of detectable urinary 
bilirubin on dipstick , indicating direct bilirubin elevations and suggesting liver injury. 
2.Allevents of ALT 3xULN andbilirubin 2xULN (>35% direct bilirubin) or ALT 3xULN andINR>1.5, if INR 
measured which may indicate severe liver injury (possible ‘Hy’s Law’), must be reported as an SAE (excluding 
studies of hepatic impairment or cirrhosis) ; INR measurement is no t required and the threshold value stated 
will not apply to subjects receiving anticoagulants
3.New or worsening symptoms believed to be related to liver injury (such as fatigue, nausea, vomiting, right upper 
quadrant pain or tenderness, or jaundice) or beli eved to be related to hypersensitivity (such as fever, rash or 
eosinophilia)
4.Includes: Hepatitis A IgM antibody; Hepatitis B surface antigen and Hepatitis B Core Antibody (IgM); Hepatitis C 
RNA; Cytomegalovirus IgM antibody; Epstein -Barr viral capsid antig en IgM antibody (or if unavailable, obtain 
heterophile antibody or monospot testing); Hepatitis E IgM antibody 
5.PK sample may not be required for subjects known to be receiving placebo or non -[COMPANY_004] comparator treatments.)  
Record the date/time of the PK bloo d sample draw and the date/time of the last dose of study treatment prior to 
blood sample draw on the CRF. If the date or time of the last dose is unclear, provide the subject’s best 
approximation. If the date/time of the last dose cannot be approximated O R a PK sample cannot be collected in 
the time period indicated above, do not obtain a PK sample. Instructions for sample handling and shippi[INVESTIGATOR_131971].   
References
James L P, Letzig L, Simpson PM, Capparelli E, Roberts DW, Hinson JA, Davern TJ, 
Lee WM. Pharmacokinetics of Acetaminophen -Adduct in Adults with 
Acetaminophen Overdose and Acute L iver Failure. Drug Metab Dispos 2009; 
37:1779 -1784 .
2015N267693_04 CONFIDENTIA L
205665
63Liver Chemistry Increased Monitoring Criteria –Liver Monitoring Event
Criteria Actions
ALT 3xULN and <5xULN andbilirubin 
<2xULN , without symptoms believed to 
be related to liver injury or 
hypersensitivity, andwho can be 
monitored weekly for 4 weeksNotify the [COMPANY_004] medical monitor within [ADDRESS_351749] safety. 
Subject can continue study treatment .  Subject must 
return weekly for repeat liver chemistries (ALT, AST, 
alkaline phosphatase, bilirubin) until they resolve, 
stabilise or return to within baseline 
If at any time subject meets the liver chemistry 
stoppi[INVESTIGATOR_288594], proceed as described above
If, after 4 weeks of monitoring, ALT <3xULN and 
bilirubin <2xULN, monitor subjects twice monthly 
until liver chemistries normalize or return to within 
baseline.
2015N267693_04 CONFIDENTIA L
[PHONE_5986].3. Appendix 3: Daprodustat Risk A ssessment
Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
Excessive erythropoiesis leading to 
thrombosis and/or tissue ischemiaIn animal studies, excessive erythropoiesis (Hgb/Hct > upper limit normal) 
attributed to daprodustat was as sociated with vascular 
congestion /inflammation , microthrombi, and tissue ischemia in a number of 
organs.
In the phase 2 proof of concept study, a high incidence of discontinuation due 
to hemoglobin stoppi[INVESTIGATOR_3418] (Hgb > 13.5 g/dL or Hgb increased > 1 g/ dL 
over any 2 -week period) was observed.  In non -dialysis subjects administered 
10 mg, 25 mg, 50 mg or 100 mg of daprodustat daily, a total of 21 of 61 
subjects (34%) met these criteria.  In hemodialysis -dependent subjects 
administered either 10 mg or 25 m g of daprodustat daily, a total of 8 of 31 
subjects (26%) met these criteria.
Phase 2 dose -ranging studies, and associated statistical and exposure 
response modelling has informed Phase 3 dose rationale, starting doses, 
dose levels, and dose adjustment sc heme to optimize Hgb management.
Integrated AE data [including 2 global phase 2b studies (24 -week treatment 
duration) and 2 Japanese phase 3 studies (52 -week treatment duration)]: Few 
subjects experienced a possible thrombosis related adverse event in the 
setting of excessive erythropoiesis [3/688 (0.5% ) subjects on daprodustat vs. 
0/404 on rhEPO].
Following review of clinical data received to date, this has not been identified 
as a safety concern for daprodustat when dose is managed appropriately 
accordin g to target Hgb. However, experience with daprodustat is currently 
insufficient to fully characterize this risk .Specific eligibility criteria related to requirements 
for entry Hgb are detailed in Section 5
Hgb will be closely monitored throughout the 
dosing period as outlined in the Time and Events 
Table (Section 7.1)
Specific guidance for dose adjustment, dose 
interruption, or discontinuation of daprodustat 
based on achieved Hgb (including rate of 
change )is provided in Section [IP_ADDRESS]
Instream m onitoring of safety data by [CONTACT_288630] a dog cardiovascular study, single oral dos es of daprodustat (up to 90 
mg/kg) did not produce effects on blood pressure.
Marketed rhEPO and its analogues have been associated with risks related to  Specific eligibility criteria related to blood 
pressure, including exclusion of subjects with 
uncontrolled hyp ertension, are detailed in 
Section 6.2
2015N267693_04 CONFIDENTIA L
205665
65Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
uncontrolled hypertension, including the need for initiation of or increases in 
antihypertensive thera py when used in patients with anemia of CKD (i.e. 25% 
Epogen, 27% Mircera, and 40% Aranesp treated patients with renal anemia 
required initiation or increase in their anti -hypertensive medications; 
hypertensive encephalopathy and seizures have been reporte d. The 
contribution of rhEPO -associated hypertension to the unfavourable effects on 
cardiovascular outcomes remains uncertain).
Integrated AE data from clinical trials with daprodustat [including 2 global 
phase 2b studies (24 -week treatment duration) and 2 Japanese phase 3 
studies (52 -week treatment duration)]: 
oThe majority (>90% ) of subjects had baseline history of hypertension.
oNo meaningful difference was seen between treatment groups in AEs 
(preferred term) of “hypertension” [29/688 (4% ) daprodustat vs . 19/404 
(4%) rhEPO; 0.91 relative risk (RR) (95% confidence interval: 0.5, 1.67)] 
or “blood pressure increased” [16 (2% ) daprodustat vs. 7 (2%) rhEPO; 
RR 1.22 (0.48,3.11)]. Results were not substantively different between 
non-dialysis and haemodialysis su bjects.
oAlthough no clinically meaningful changes in blood pressure were 
observed, subjects in both treatment groups required increases in anti -
HTN medications:
oIn the 24 -week global phase 2b studies, 25/170 (15%) of ND 
subjects receiving daprodustat vs. 1 8/80 (14% ) control and 
22/177 (12% ) of HD subjects receiving daprodustat vs. 2/39 
(5%) control.
oIn the 52 -week Japan phase 3 studies, 57/149 (38%) of ND 
subjects receiving daprodustat vs. 68/150 (45% )  rhEPO and 
51/136 (38% ) of HD subjects receiving daprod ustat vs. 66/135  Blood pressure will be closely monitored 
throughout the dosing period as outlined in the 
Time and Events Table Section 7.1.
Monitoring of emerging safety data by [CONTACT_288631].
2015N267693_04 CONFIDENTIA L
205665
66Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
(49% ) for rhEPO.
The data received to date from completed clinical trials with daprodustat are 
insufficient to refute this risk.
Death, MI, stroke, heart failure , 
thromboembolic events , thrombosis of 
vascular access at Hgb levels which are within 
the normal range (i.e. not polycythemic 
conditions)Marketed rhEPO and its analogs have been assoc iated with an increased risk 
for death and serious cardiovascular events when used in patients with 
anemia of CKD.   Clinical studies with marketed rhEPO/analogs have 
suggested “higher” target hemoglobin, rate of hemoglobin rise of greater than 
1 g/dL in an y 2-week period, and/or higher doses may contribute to these 
risks.
In non -clinical studies conducted to date, not observed at tolerated doses 
when hemoglobin/hematocrit within normal range for species.
Integrated AE data from clinical trials with daprodus tat [including 2 global 
phase 2b studies (24 -week treatment duration) and 2 Japanese phase 3 
studies (52 -week treatment duration)]: No meaningful difference was seen 
between treatment groups in the overall incidence of this AESI: [39/688 
(5.5% ) daprodustat vs. 25/404 (6%) rhEPO; 0.92 relative risk (95 % confidence 
interval: 0.55, 1.53)]. Within this composite AESI, the most frequent event 
types were heart failure (at least [ADDRESS_351750] 13 events 
rhEPO) and thrombosis (at least [ADDRESS_351751] 8 event 
rhEPO); and a numerical imbalance was noted in events of myocardial 
ischemia (at least [ADDRESS_351752] 1 event rhEPO). The small 
number of events makes it difficult to draw any firm conclusions.
The clini cal data received to date from completed clinical trials with 
daprodustat are insufficient to substantiate or refute this risk.Specific eligibility criteria related to CV risk are 
outlined in Section 5.3
Hgb wi ll be closely monitored throughout the 
dosing period as outlined in the Time and Events 
Table Section 7.1
Instream m onitoring of safety data by [CONTACT_288632], undesirable GI effects including emesis, abnormal feces 
and/or decreased food consumption/body weight loss and stomach erosions/ 
ulcers with hemorrhage were observed with daprodustat.
In rodents, stomach erosions were observed with intrave nous and oral Suspected GI bleeding or significant symptoms 
consistent with erosion should be investigated 
diagnostically (i.e. endo scopic examination) as 
clinically warranted
Instream m onitoring of safety data by [CONTACT_43057] 
2015N267693_04 CONFIDENTIA L
205665
67Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
administration of daprodustat.
Gender -averaged systemic exposure (AUC) at the no observed adverse effect 
levels (NOAEL) are 3.3 -fold (monkeys) and 737 -fold (rats) above human 
exposure (25 mg daprodustat).
In clinical trials to date with dap rodustat, mild -moderate GI signs and 
symptoms represent the most frequently reported adverse event, however 
causal association has not been established.
Integrated AE data from clinical trials with daprodustat [including 2 global 
phase 2b studies (24 -week treatment duration) and 2 Japanese phase 3 
studies (52 -week treatment duration)] : No meaningful difference was seen 
between treatment groups in reports of this AESI [17 (2.7 %) daprodustat vs. 
10 (2.3% ) rhEPO; 1.16 relative risk (95% confidence interval: 0. 52, 2.58)].
Following review of clinical data received to date, GI erosions have not been 
identified as a safety concern for daprodustat.safety review team
Cancer -related mortality and tumor 
progression and recurrenceMarketed r hEPO and its analogs have been associated with increased risk of 
canc er related morbidity and mortality when used in patients with cancer.
Administration of 60mg/kg daprodustat to mice caused minimal increases in 
circulating VEGF while significant EPO increases were observed.
In clinical studies with daprodustat up to 4 wee ks duration, a dose -ordered 
increase in VEGF plasma concentrations, an angiogenic factor that has been 
implicated in tumor growth, was observed at doses ranging from 10 to 150 
mg.  In clinical studies up to 24 weeks duration at doses up to 25 mg, changes 
in VEGF plasma concentrations were variable but similar relative to control.
Integrated AE data [including 2 global phase 2b studies (24 -week treatment 
duration) and 2 Japanese phase 3 studies (52 -week treatment duration)]: No 
meaningful difference was seen between treatment groups in the occurrence 
of this AESI: [8/688 (1.1 %) daprodustat vs. 4/404 (0.9%) rhEPO; 1.14 relative 
risk (95% confidence interval: 0.31, 4.28)].
Clinical experience to date is not yet sufficient to substantiate or refute this as Specific eligibility criteria related to personal 
history of malignancy or subjects with complex 
kidney cyst are outlined in Section 5.3.
Stoppi[INVESTIGATOR_288595] t 
emergent malignancy are outlined in Section 
5.5.1 .
Instream m onitoring of safety data by [CONTACT_288633]
2015N267693_04 CONFIDENTIA L
205665
68Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
a saf ety concern for daprodustat.
Pulmonary artery hypertension (PAH)A role for HIF -regulated pathways in the pathophysio logy of PAH has been 
suggested based on well established effects of acute and chronic hypoxia in 
man on the pulmonary vasculature (vasoconstriction), and by [CONTACT_288634] [ Smith , 2006; Formenti , 2011].
There have been no histopathologic findings suggestive of PAH in pre -clinical 
safety studies (up to 13 -weeks duration dog s, up to 2 years in rat s and mice , 
and up to 39 -weeks in monkeys.
Acute hypoxic challenge (rats): Daprodustat produced increases in peak right 
ventricular pressure (PRVP) during acute hypoxia that were slightly higher 
than the vehicle control group.  These hypoxia -induced PRVP chang es fall 
within the range of PRVP differences noted among non -treated rats.
Results from a clinical study of acute hypoxic challenge in healthy 
volunteers demonstrated that short -term (5 days) therapy with daprodustat 
5mg or 100mg ha dno clinically signific ant effect on transthoracic 
echocardiographically (ECHO) estimate s ofpulmonary artery systolic 
pressure (PA SP) under either normoxic or hypoxic conditions. ECHO 
assessments performed in Phase 2b studies (24 weeks treatment duration) 
did not identify any c linically meaningful changes in PASP in participants
not on dialysis for daprodustat . In hemodialysis participants , mean absolute 
change from baseline in PASP was similar for both treatment groups; 
however, there was a numeric imbalance (Daprodustat Total :8 [7%]; 
Control 0) in participants reaching the PASP PCI (>20 mmHg increase from 
baseline). Regarding this imbalance, there were a number of confounding 
factors in the study, most notably a 4.5:1 randomization scheme and 
inconsistency in timing of ECHOs r elative to dialysis day.  Additionally, 2 of 
3 participants with resolution of PASP on safety follow -up ECHOs had 
confounding conditions that could contribute to resolution other than 
discontinuation of study drug; and there was no dose relationship for 
participants meeting the PASP percutaneous coronary intervention( PCI)Instream m onitoring of safety data by [CONTACT_288633]
2015N267693_04 CONFIDENTIA L
205665
69Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
criterion. Overall, there is insufficient evidence to conclude a relationship to 
treatment with daprodustat .A post -hoc analysis was performed using a 
definition of PAH commonly cited in t he literature [ Navaneethan , 2016].
Subjects with sPAP >35 mmHg and/or tricuspid regurgitation maximum jet 
velocity (TRV) >2.5 m/s were considered as having PAH.   Regardless of 
baseline status of PAH, there was n o clinically meaningful difference in the 
proportion of subjects with on -treatment PAH between the two treatment 
groups:
oSubjects with PAH at baseline: 35/113 (31% ) vs. 21/54 (39%) 
(ND) and 37/115 (32% ) vs. 7/21 (33%) (HD), daprodustat vs. 
control, respect ively.
oSubjects without PAH at baseline: 25/113 (22% ) vs. 12/54 
(22% ) (ND) and 22/115 (19%) vs. 6/21 (29% ) (HD), 
daprodustat vs. control, respectively.
Integrated AE data [including 2 global phase 2b studies (24 -week treatment 
duration) and 2 Japanese pha se 3 studies (52 -week treatment duration)] : Four 
(0.5% ) non -serious AEs in the daprodustat group vs 0 in rhEPO. 
Review of subject level information did not suggest adverse treatment 
effect: 2 subjects from phase2b that met protocol specified stoppi[INVESTIGATOR_288596] -serious AEs of ‘pulmonary arterial 
pressure increased’ and 2 subjects from Japan Phase 3 had non -serious 
AE ‘pulmonary hypertension’ in setting of concurrent serious AEs of 
acute pulmonary embolus and mitral regurgitation ide ntified during 
hospi[INVESTIGATOR_288597] .
Following review of clinical data received to date, this has not been identified 
as a safety concern for daprodustat.
Cardiomyopa thy Published data suggest that cardiac effects of HIF stabilization are likely a 
function of the mechanism, extent, and duration of the effects, and can range 
from protective to detrimental depending upon the specific model and 
experimental conditions uti lized.Instream m onitoring of safety data by [CONTACT_288635]
2015N267693_04 CONFIDENTIA L
205665
70Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
Small increases in cardiac troponin in [ADDRESS_351753] at.
Cardiomyopathy has not been associated with naturally occurring mutation in 
man which results in increased HIF stabilization.
ECHO assessments performed in phase 2b studies (24 weeks treatment 
duration) did not identify any clinically meaningful change s in LVEF for 
daprodustat.
Integrated AE data from clinical trials with daprodustat [including 2 global 
phase 2b studies (24 -week treatment duration) and 2 Japanese phase 3 
studies (52 -week treatment duration)]: No meaningful difference was seen 
between tr eatment groups in reports of this AESI [1 (0.1 %) daprodustat vs. 1 
(0.2% ) rhEPO; 0.64 relative risk (95% confidence interval: 0.02, 18.07)].
Following review of clinical data received to date, this has not been identified 
as a safety concern for daprodusta t.
Proliferative retinopathy, macular edema, 
choroidal neovascularizationIncreases in local (ocular) VEGF production with retinal neovascularization 
and macular edema observed in diabe tic retinopathy and to choroidal 
leakage, edema and neovascularization seen in age -related macular 
degeneration [Campochiaro , 2006]
Administration of 60 mg/kg daprodustat to mice caused minimal increases in 
circulati ng VEGF while significant EPO increases were observed.
No ocular abnormalities with daprodustat were seen in non -clinical studies of 
up to 13 weeks duration in mice and dogs, 26 weeks in rats, and 39 weeks in 
monkeys.
In clinical studies up to 4 weeks dura tion, a dose -ordered increase in VEGF 
plasma concentrations was observed at doses ranging from 10 to 150 mg
administered once daily and from 10 to 30 mg administered three times Instream m onitoring of safety data by [CONTACT_288633]
2015N267693_04 CONFIDENTIA L
205665
71Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
weekly . In studies up to 24 weeks duration at doses up to 25 mg, changes in 
VEGF plasma concentrations were variable but similar relative to control.
Ophthalmologic assessments performed in phase 2b studies (24 weeks 
treatment duration) did not identify any clinically meaningful changes in 
proliferative retinopathy, macular edema, o r choroidal neovascularization with 
daprodustat.
Integrated AE data [including 2 global phase 2b studies (24 -week treatment 
duration) and 2 Japanese phase 3 studies (52 -week treatment duration)] : No 
meaningful difference was seen between treatment groups i n reports of this 
AESI [9 (2.9%) daprodustat vs. 6 (2.5% ) rhEPO; 1.19 relative risk; (95% 
confidence interval: 0.42, 3.43)].
Following review of clinical data received to date, this has not been identified 
as a safety concern for daprodustat.
Exacerbation of rheumatoid arthritis In inflamed rheumatic joints, activation of HIF -related genes secondary to 
decreased oxygen and pro -inflammatory cytokines has been postulated to 
contribute to t he neo -angiogenesis, proliferation and infiltration of rheumatoid 
synovial fibroblasts [Westra , 2010; Muz, 2009].
No abnormalities seen in non -clinical studies conducted to date for
daprodustat.
Integrated AE data [including 2 global phase 2b studies (24 -week treatment 
duration) and 2 Japanese phase 3 studies (52 -week treatment duration)]: No 
meaningful difference was seen between treatment groups in reports of this 
AESI [2 (0.3%) da produstat vs. 1 (0.2% ) rhEPO; 1.20 relative risk; (95% 
confidence interval: 0.07, 20.87) and the incidence of musculoskeletal AEs 
was generally lower in the daprodustat treatment group].
Following review of clinical data received to date, this has not bee n identified 
as a safety concern for daprodustat.Instream m onitoring of safety data by [CONTACT_288635]
2015N267693_04 CONFIDENTIA L
205665
72Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
Drug -drug interactions Daprodustat is a substrate of CYP2C8 :Co-administration of daprodustat with 
a strong CYP2C8 inhibitor increased themaximum plasma concentration
(Cmax )and area under curve ( AUC )of daprodustat, 4 -and 19 -fold, 
respectively, while co -administration of a weak inhibitor (i.e., trimethoprim) 
increased the Cmax and AUC of daprodustat by 1.3 -and 1.5 -fold, 
respectively. Population PK analysis from completed Phase 2 studies 
suggests that co -administration of daprodustat with a moderate CYP2C8 
inhibitor (i.e., clopi[INVESTIGATOR_7745]) leads to a ~ 2 -fold increase in AUC, with no 
clinically -significant increase in the measured Hb respon se. Although CYP2C8 
induction studies were not performed, co -administration of daprodustat with 
an inducer of CYP2C8 (e.g., rifampin/rifampi[INVESTIGATOR_2513]) may decrease the exposure 
of daprodustat.
Daprodustat is an inhibitor of CYP2C8 : A clinical drug interaction st udy 
between 25mg and 100mg daprodustat with a CYP2C8 substrate (i.e., 
pi[INVESTIGATOR_051]) showed that there is no PK interaction at these doses of 
daprodustat.  
Daprodustat is a substrate of Breast cancer resistance protein (BCRP) :  
Population PK analysis from Phase 2 studies suggested that while BCRP 
inhibitors were a covariate for daprodustat apparent total body clearance 
(CL/F) (8.6%  lower clearance) the predicted change in exposure was not 
considered to be of clinical relevance.
Daprodustat is an inhibitor o f organic anion transporter polypedtides
(OATP)1B1/1B3 :  A clinical drug interaction study between 25mg and 100mg 
daprodustat with an OATP1B1/1B3 substrate (i.e., rosuvastatin) showed no 
PK interaction at these doses of daprodustat.Co-administration of da produstat with strong 
CYP2C8 inhibitors (e.g., gemfibrozil) and 
inducers (e.g., rifampin/rifampi[INVESTIGATOR_2513]) is not 
permitted as outlined in Section 6.11.3 .
Co-administration of daprodustat with moderate 
CYP2C8 inhibito rs (i.e., clopi[INVESTIGATOR_7745], 
teriflunomide, deferasirox) should be performed 
with caution. If one of these medications is 
started, stopped or the dose is changed, Hgb 
should be monitored every 4 weeks .Specific 
guidance on the management of potential drug -
drug i nteractions and concomitant medications is 
provided in Section 6.11.
Hgb will be closely monitored throughout the 
dosing period as outlined in the Time and Events 
Table (Section 7.1)
Specific guidance for dose adjustment, dose 
interruption, or discontinuation of daprodustat 
based on achieved Hgb is provided in Section 
[IP_ADDRESS] .
Instream m onitoring of safety data by [CONTACT_288636] l  
safety review team.
Cyst progression in patients with autosomal 
dominant polycystic kidney disease (ADPKD)Published data provide in vivo evidence for a potential role of HIF -1a in the 
growth of polycystic kidneys; Hif -1a deletion was sufficient to sig nificantly 
mitigate a progressive polycystic phenotype in an ADPKD mouse model, while 
conversely pharmacologic HIF -1a stabilization was sufficient to convert a mild 
polycystic disease into a severely aggravated phenotype with marked loss of 
renal function. However, the dose of FG -2216 (a PHI) used resulted in a  Kidney function  will be monitored throughout 
the dosing period as outlined in the Time and 
Events Table (Section 7.1).
Monitoring of emerging safety data by [CONTACT_288631].
2015N267693_04 CONFIDENTIA L
205665
73Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
significant erythropoietic response as reflec ted by ≥10%  relative increases in 
hematocrit over the course of the study ( Kraus , 2018; Hofherr , 2018). ( Kraus , 
2018; Hofherr , 2018).
A review of the non -clinical data from toxicity studies conducted with 
daprodustat does not indicate an exacerbation in incidence or severity of 
kidney cysts in daprodustat -treated animals in comparison to controls.  
Howev er, the wild type animals used in these toxicity studies have a very low 
background incidence of renal cysts and are not comparable to the mice used 
in the Kraus article ( Kraus , 2018) which are an inducible kidney epit helium -
specific Pkd1 -deletion model.
There is limited experience with daprodustat in subjects with ADPKD in 
completed clinical trials. In the Japan phase 3 study in non -dialysis subjects, 
there were 5 subjects with ADPKD (all CKD stage 5) in each treatment group.  
Mean baseline eGFR was 10 mL/min/1.73m2 in the daprodustat subjects vs. 
16 mL/min/1.73m2 in the rhEPO subjects.  The mean (SD) percent change 
from baseline at Week 52 in eGFR was: -18% (8) vs. -21% (14) in daprodustat 
vs. rhEPO, respectively.
Following review of clinical data received to date, this has not been identified 
as a safety concern for daprodustat.
Other
rhEPO risks (Control) See risks outlined in table for daprodustat for excessive erythropoiesis leading 
to thrombosis and/or tissue ischemia, death, MI, stroke, heart failure, 
thromboembolic events , thrombosis of vascular access, and for cancer -related 
mortality and tumor progression.
Uncontrolled hypertension
Pure red cell aplasiaSee mitigation strategies outlined in table for 
daprodustat for excessive erythropoies is leading 
to thrombosis and/or tissue ischemia; risk of
death, MI, stroke, heart failure, thromboembolic 
events, thrombosis of vascular access; and for 
increased cancer -related mortality and tumor 
progression.
Specific eligibility criteria related to bloo d 
2015N267693_04 CONFIDENTIA L
205665
74Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
pressure management are outlined in Section 5.
Specific eligibility criteria related to personal 
history of pure red cell aplasia are outlined in 
Section 5.3
2015N267693_04 CONFIDENTIA L
[PHONE_5987].4. Appendix 4: Definition of and Procedures for Recording, 
Evaluating, Follow -Up and Reporting of A dverse Events
12.4.1. Definition of A dverse Events
Adverse Event Definition:
An AE is an y untoward medical occurrence in a patient or clinical investigation 
subject, temp orally associated with the use of a medicinal product, whether or not 
considered related to the medicinal product.
NOTE: An AE can therefore be an yunfavorable and unintended sign (including an 
abnormal laboratory  finding), s ymptom, or disease (new or exac erbated) temporally  
associated with the use of a medicinal product.
Events meeting AE definition include:
Any abnormal laboratory test results (hematology , clinical chemistry , or urinaly sis) 
or other safet y assessments (e.g., ECGs, radiological scans, v ital signs 
measurements), including those that worsen from baseline, and felt to be clinically  
significant in the medical and scientific judgement of the investigator.
Exacerbation of a chronic or intermittent pre -existing condition including either an 
increase in frequency  and/or intensity  of the condition.
New conditions detected or diagnosed after stud y treatment administration even 
though it may  have been present prior to the start of the study .
Signs, sy mptoms, or the clinical sequelae of a suspected i nteraction.
Signs, sy mptoms, or the clinical sequelae of a suspected overdose of either study  
treatment or a concomitant medication (overdose per se will not be reported as an 
AE/SAE unless this is an intentional overdose taken with possible suicidal/self -
harming intent.  This should be reported regardless of sequelae).
"Lack of efficacy " or "failure of expected pharmacological action" per se will not be 
reported as an AE or SAE.  However, the signs and sy mptoms and/or clinical 
sequelae resulting from lack of efficacy  will be reported if they  fulfil the definition 
of an AE or SAE.
Events NOT meeting definition of an AE include:
Any clinically  significant abnormal laboratory  findings or other abnormal safet y 
assessments which are associated with the underl ying disease, unless judged by  [CONTACT_99479]’s condition.
The disease/disorder being studied or expected progression, signs, or s ymptoms of 
the disease/disorder being studied, unless more severe than expec ted for the subject’s 
condition.
Medical or surgical procedure (e.g., endoscop y, appendectom y): the condition that 
2015N267693_04 CONFIDENTIA L
205665
76leads to the procedure is an AE.
Situations where an untoward medical occurrence did not occur (social and/or 
convenience admission to a hosp ital).
Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present 
or detected at the start of the study  that do not worsen.
12.4.2. Definition of Serious A dverse Events
If an event is not an AE per definition above, then it cannot be a n SAE even if serious 
conditions are met (e.g., hospi[INVESTIGATOR_1080]/sy mptoms of the disease under study , 
death due to progression of disease, etc).
Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, 
at any dose:
a.Results in death
b.Is life -threatening
NOTE:
The term 'life -threatening' in the definition of 'serious' refers to an event in which the 
subject was at risk of death at the time of the event.  I t does not refer to an event, which 
hypothetically  might have caused dea th, if it were more severe.
c.Requires hospi[INVESTIGATOR_23916]:
In general, hospi[INVESTIGATOR_5184] (usually  
involving at least an overnight stay ) at the hospi[INVESTIGATOR_23917]/or treatment that would not have been appropriate in the phy sician’s 
office or out -patient setting.  Complications that occur during hospi[INVESTIGATOR_23918].  If a complication prolongs hospi[INVESTIGATOR_288598], 
the event is serious.  When in doubt as to whether “hospi[INVESTIGATOR_059]” occurred or was 
necessary , the AE should be considered serious.
Hospi[INVESTIGATOR_5187] a pre -existing condition that did not worsen 
from baseline is not conside red an AE.
d.Results in disability/incapacity
NOTE:
The term disability  means a substantial disruption of a person’s ability  to conduct 
normal life functions.
This definition is not intended to include experiences of relativel y minor medical 
significance su ch as uncomplicated headache, nausea, vomiting, diarrhea , influenza, 
and accidental trauma (e.g. sprained ankle) which may  interfere or prevent every day 
life functions but do not constitute a substantial disruption
e.Is a congenital anomaly/birth defect
2015N267693_04 CONFIDENTIA L
205665
77f.Other situations:
Medical or scientific judgment should be exercised in deciding whether reporting is 
appropriate in other situations, such as important medical events that may  not be 
immediately  life-threatening or result in death or hospi[INVESTIGATOR_288599].  These should also be considered 
serious.
Examples of such events are invasive or malignant cancers, intensive trea tment in an 
emergency  room or at home for allergic bronchospasm, blood dy scrasias or 
convulsions that do not result in hospi[INVESTIGATOR_059], or development of drug dependency  
or drug abuse
g.Is associated with liver injury andimpaired liver function defined as:
ALT 3xULN and total bilirubin*2xUL N (>35% direct), or
ALT 3xULN and International normalized ratio (INR)**>1.5.
* Serum bilirubin fractionation should be performed if testing is available; if unavailable, 
measure urinary  bilirubin via dipstick.  I f fractionation is unavailable and ALT 3xULN 
and total bilirubin 2xULN, then the event is still to be reported as an SAE.
** INR testing not required per protocol and the threshold value does not apply  to 
subjects receiving anticoagulants.  If INR measureme nt is obtained, the value is to be 
recorded on the SAE form.
12.4.3. Definition of Cardiovascular Events
Cardiovascular Events (CV) Definition:
Investigators will be required to fill out the specific CV event page of the CRF for the 
following AEs and SAEs or an yevent that may  potentially  be one of these categories :
Myocardial infarction/unstable angina
Congestive heart failure
Arrh ythmias
Valvulopathy
Pulmonary  hypertension
Cerebrovascular events/stroke and transient ischemic attack
Peripheral arterial thromboem bolism
Deep venous thrombosis/pulmonary  embolism
Revascularization
2015N267693_04 CONFIDENTIA L
[PHONE_5988].4.4. Recording of A Es and SA Es
AEs and SAE Recording:
When an AE/SAE occurs, it is the responsibility  of the investigator to review all 
documentation (e.g., hospi[INVESTIGATOR_1088], laboratory , and diagnostics reports) 
relative to the event.
The investigator will then record all relevant information regarding an AE/SAE in 
the CRF
It is notacceptable for the investigator to send photocopi[INVESTIGATOR_9238]’s medical 
records to [COMPANY_004] in lieu of com pletion of the [COMPANY_004], AE/SAE CRF page.
There may  be instances when copi[INVESTIGATOR_19952] b y [COMPANY_004].  In this instance, all subject identifiers, with the exception of the 
subject number, will be blinded on the copi[INVESTIGATOR_288600].
The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information.  I n such cases, the diagnosis will be 
documented as the AE/SAE and not the individ ual signs/sy mptoms.
12.4.5. Evaluating AEs and SA Es
Assessment of Intensity
The investigator will make an assessment of intensity  for each AE and SAE reported 
during the stud y and will assign it to one of the following categories:
Mild:  An event that is easily  tolerated by  [CONTACT_423], causing minimal discomfort 
and not interfering with every day activities.
Moderate:  An event that is sufficiently  discomforting to interfere with normal 
every day activities
Severe:  An event that prevents normal every day activitie s. -an AE that is assessed 
as severe will not be confused with an SAE. Severity  is a category  utilized for rating 
the intensity  of an event; and both AEs and SAEs can be assessed as severe.
An event is defined as ‘serious’ when it meets at least one of th e pre -defined 
outcomes as described in the definition of an SAE.
Assessment of Causality
The investigator is obligated to assess the relationship between stud y treatment and 
the occurrence of each AE/SAE.
A "reasonable possibility " is meant to convey  that there are facts/evidence or 
arguments to suggest a causal relationship, rather than a relationship cannot be ruled 
out.
The investigator will use clinical judgment to determine the relationship.
2015N267693_04 CONFIDENTIA L
205665
79 Alternative causes, such as natural history  of the underly ing diseases, concomitant 
therap y, other risk factors, and the temporal relationship of the event to the study  
treatment will be considered and investigated.
The investigator will also consult the I nvestigator Brochure (IB) and/or Product 
Information, for marketed products, in the determination of his/her assessment.
For each AE/SAE the investigator must document in the medical notes that he/she 
has reviewed the AE/SAE and has provided an assessment of causality .
There may  be situations when an SAE has occu rred and the investigator has minimal 
information to include in the initial report to [COMPANY_004].  However, it is very important 
that the investigator always make an assessment of causality for every event 
prior to the initial transmission of the SAE data to [COMPANY_004].
The investigator may  change his/her opi[INVESTIGATOR_19954] -up 
information, amending the SAE data collection tool accordingl y.
The causality  assessment is one of the criteria used when determining regulatory  
reporting requirements.
Follo w-up of A Es and SA Es
The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as may  be indicated or as requested by  [CONTACT_90648]/or causality  of the AE or SAE.
The investigator is obligated to assist.  This may  include additional laboratory  tests 
or investigations, histopathological examinations or consultation with other health 
care professionals.
If a subject dies during participation in the study  or durin g a recognized follow -up 
period, the investigator will provide [COMPANY_004] with a copy  of any  post -mortem findings, 
including histopathology .
New or updated information will be recorded in the originally  completed CRF.
The investigator will submit any  updated SAE data to [COMPANY_004] within the designated 
reporting time frames.
12.4.6. Reporting of SA Es to [COMPANY_004]
SAE reporting to [COMPANY_004] via electronic data collection tool
Primary  mechanism for reporting SAEs to [COMPANY_004] will be the electronic data collection 
tool
If the electronic s ystem is unavailable for greater than 24 hours, the site will use the 
paper SAE data collection tool and fax it to the Medical Monitor.
Site will enter the serious adverse event data into the electronic s ystem as soon as it 
becomes available.
The investigator will be required to confirm review of the SAE causality  by [CONTACT_13158] 
2015N267693_04 CONFIDENTIA L
205665
80the ‘reviewed’ box at the bottom of the eCRF page within 72 hours of submission of 
the SAE.
After the stud y is completed at a given site, the electronic data collection tool (e.g., 
InForm s ystem) will be taken off -line to prevent the entry  of new data or changes to 
existing data
If a site receives a report of a new SAE from a study  subject or receives updated data 
on a previousl y reported SAE after the electronic data collection tool has been ta ken 
off-line, the site can report this information on a paper SAE form or to the Medical 
Monitor by  [CONTACT_756].
Contacts for SAE receipt can be found at the beginning of this protocol on the 
Sponsor/Medical Monitor Contact [CONTACT_23774].
12.4.7. Modified List o f Highly Effective Methods for Avoiding Pregnancy  
in Females of Reproductive Potential (FRP)
This list does not apply  to FRP with same sex partners, when this is their preferred and 
usual lifesty le or for subjects who are and will continue to be abstinent from penile -
vaginal intercourse on a long term and persistent basis.  Periodic abstinence (e.g., 
calendar, ovulation, sy mptothermal, post -ovulation methods) and withdrawal are not 
acceptable methods of contraception.
1.Contraceptive subdermal implant.
2.Intrau terine device or intrauterine s ystem.
3.Combined estrogen and progestogen oral contraceptive [Trussell , 2011].
4.Injectable progestogen [ Trussell , 2011]
5.Contraceptive vaginal rin g [Trussell , 2011]
6.Percutaneous contraceptive patches [ Trussell , 2011]
7.Male partner sterilization prior to the female subject's entry  into the study , and 
this male is the sol e partner for that subject [Trussell , 2011]. The 
documentation on male sterility  can come from the site personnel’s: review of 
subject’s medical records, medical examination and/or semen anal ysis, or 
medical history interview provided by  [CONTACT_163596].
This is an all inclusive list of those methods that meet the [COMPANY_004] definition of highl y 
effective: having a failure rate of less than 1% per y ear when used consistently  and, 
correctly  and, when applicable, in accord ance with the product label.  For non -product 
methods (e.g.  male sterility ), the investigator determines what is consistent and correct 
use. The [COMPANY_004] definition is based on the definition provided b y the ICH.
The investigator is responsible for ensuring t hat subjects understand how to properl y use 
these methods of contraception.
2015N267693_04 CONFIDENTIA L
205665
81References
Trussell J, Contraceptive Efficacy . In: Hatcher RA, Trussell J, Nelson AL , Cates W, 
Kowal D, and Policar M (editors). Contraceptive Technology : Twentieth Revised 
Edition . [LOCATION_001]: Ardent Media, 2011.Table 26 -1
12.4.8. Collection of Pregnancy  Information
Investigator will collect pregnancy  information on any  female subject, who becomes 
pregnant while participating in this study .
Information will be recorded on the appropriate for m and submitted to [COMPANY_004] within [ADDRESS_351754]'s pregnancy .
Subject will be followed to determine the outcome of the pregnancy . The 
investigator will collect follow up information on mother and infant, which will be 
forwarded to [COMPANY_004].  Gener ally, follow -up will not be required for longer than 6 to 8 
weeks bey ond the estimated delivery  date.
Any termination of pregnancy  will be reported, regardless of fetal status (presence or 
absence of anomalies) or indication for procedure.
While pregnancy  itself is not considered to be an AE or SAE, any  pregnancy  
complication or elective termination of a pregnancy will be reported as an AE or 
SAE.
A spontaneous abortion is alway s considered to be an SAE and will be reported as 
such.
Any SAE occurring as a r esult of a post -study  pregnancy  which is considered 
reasonabl y related to the study  treatment by  [CONTACT_093], will be reported to [COMPANY_004] 
as described in Section 12.4.  While the investigator is not obligated t o actively  seek 
this information in former study  participants, he or she may  learn of an SAE through 
spontaneous reporting.
Any female subject who becomes pregnant while participating will discontinue 
study medication andbe withdrawn from the study.
2015N267693_04 CONFIDENTIA L
[PHONE_5989].5. Appendix 5-Country  Specific Requirements
No country -specific requirements exist.
2015N267693_04 CONFIDENTIA L
[PHONE_5990].6. Appendix 6–Ambulatory  Blood Pressure Monitoring Device

2015N267693_04 CONFIDENTIA L
205665
84

2015N267693_04 CONFIDENTIA L
[PHONE_5991].7. Appendix 7 –Protocol Changes
12.7.1. Amendment 1
Summary  of A mendment Changes with Rationale
This protocol amendment app lies to all centers where this study  may  be performed.  
This protocol amendment was written to clarify  specific biomarkers being drawn, modify  
time points of biomarkers, clarify  safety laboratory studies, and clarify day/time of 
assessments.  Additionally , a potential additional study  visit has been added if necessary .
List of Specific Changes
Title Page
REVI SED TEXT, where bolded text has been added
Authors:
 
 
Section 1 Protocol Synopsis for Study 205665
REVI SED TEXT where bolded text has been added
The purpose of this stud y is to compare the effects on blood pressure of daprodustat to
epoetin alfa in hemodial ysis-dependent (HD) subjects with anemia associated with 
chronic kidney  disease ( CKD ).  The stud y will also assess various biomarkers associated 
with blood pressure ph ysiology  that may  provide insight into the mechanism(s) of the 
hypertensive effects associated with erythropoiesis stimulating agent(s) ( ESA s).
Exploratory  Section of the Objective(s)/Endpoint(s) Table
REVI SED TEXT, where text in strikethrough has been removed and bolded text has been 
added.
Objectives Endpoints
Exploratory
To investigate the effect of daprodustat on 
vasoactive mediators of blood pressure Plasma concentrations and derived 
parameters including Cmax, tmax, t½ and 
AUC(0 -24) as appropriate (to include
erythropoietin, endothelin -1,proendothelin -1,
nitric oxide, asymmetric dimethylarginine, 
renin, angiotensin -II, aldosterone and MR-
proadrenomedullin [proADM] noradrenalin )
Evaluate exposure -response relationships for 
daprodustat and: erythropoietin, endothelin -1, 
proendothelin -1,nitric oxide, asymmetric  Further models (as appropriate) to describe the 
daprodustat exposure -response relationship 
with: erythropoietin, endothelin -1, 
[COMPANY_003]
2015N267693_04 CONFIDENTIA L
205665
86Objectives Endpoints
dimethylarginine, renin, angiotensin -II,
aldosterone andMR-proADM noradrenalin .proendothelin -1,nitric oxide, asymmetric 
dimet hylarginine, renin, angiotensin -II,
aldosterone andMR-proADM noradrenalin .
To summarize the effect of daprodustat and 
epoetin alfa on SBP after Acute Challenge 1 
and Acute Challenge 2AUEC of SBP as measured by [CONTACT_288619] [ADDRESS_351755] -dosing
To compare the effect of daprodustat to epoetin 
alfa on SBP after 8 weeks of Hgb maintenance 
therapy Change from Day 1 pre -dose SBP to Week 8 
pre-dose
Section 1 Study Design
PREVI OUS IMAGE
REVI SED I MAGE
REVI SED TEXT where text in strikethrough has been removed and bolded text has been 
added.
Subjects will be screened for eligibility  starting 4 weeks prior to the start of an ESA 
washout period (8 weeks prior to randomization/Day  1).
Subjects that qualify  for enrolment will be washed out of their ESA for 4 weeks; the start 
of the ESA washout should be timed to coincide as closely  as possible with their next 
planned ESA dose.
Following the 4 -week ESA washout, subjects will be randomized 1:1 and stratified b y 
prior ESA dose, based on the average weekl y (for epoetins or darbepoetin) or monthly  
2015N267693_04 CONFIDENTIA L
205665
87(for methoxy  polyethylene gl ycol (PEG) -epoetin beta) dosing during the 12 weeks prior 
to ESA washout (Week -4) as follows:
Low ESA dose: <100 IU/kg/week epoetin alfa OR <0.5 µg/kg/week darbepoetin 
OR <0.6 µg/kg/week methoxy  PEG -epoe tin beta
High ESA dose: ≥100 IU/kg/week epoetin alfa OR ≥0.5 µg/kg/week darbepoetin 
OR 0.6 µg/kg/week methoxy  PEG -epoetin beta
On Day  1, subjects will be randomized and undergo Acute Challenge 1, a single dose 
challenge to compare the acute effects on BP of the hi ghest planned once -daily  
maintenance dose of daprodustat (24 mg) to the highest starting dose of epoetin alfa 
(100 IU/kg).  Subjects will have BP monitored for [ADDRESS_351756] 
serial blood sampling to assess the pharmacokinetics of daprodus tat and the time -course 
of various biomarkers.  Acute Challenge 1 will be started immediatel y following 
completion of a mid -week dialy sis session.
After completing Acute Challenge 1, all subjects will enter the 8 -week Hgb maintenance 
period where doses of either daprodustat or epoetin alfa will be administered and 
adjusted, as needed.
On Day 57 At Week 8 , following the 8 -week Hgb maintenance period, subjects will 
undergo Acute Challenge 2; this challenge will, similar to Acute Challenge 1, involve 
assessing the effect of daprodustat and epoetin alfa on SBP as assessed by  24-hr ABPM 
measurement.  The subjects will be administered the same dose of either daprodustat or 
epoetin alfa that was given in Acute Challenge 1, and serial blood sampling will be 
performe d to assess both daprodustat pharmacokinetics, and to characterize the time 
course of various biomarkers.  Acute Challenge [ADDRESS_351757] Requirement Specification (PRS).  If the 
ABPM fails the QC criteria following Acute Challenge 2, one additional Acute 
Challenge may be made in a subsequent, mid -week dialysis visit [ADDRESS_351758] will receive the same study treatment for 
the repeat Acute Challenge 2 as was administered on Day 57 as a single additional 
dose. No additional clinical chemistry, hematology, pharmacokinetic or biomarker 
sampling will be done, however all other procedure s will be performed. 
Section 1 Treatment Arms and Duration
REVI SED TEXT where the bolded text has been added
Acute Challenge 2 (Day 57) : At the end of the [ADDRESS_351759]’s dial ysis session.
2015N267693_04 CONFIDENTIA L
205665
88Section 3 OBJECTIVE(S) AND ENDPOINT(S)
REVI SED TABLE where where text in strikethrough has been removed and bolded text 
has been added.
Exploratory
To investigate the effect of daprodustat on 
vasoactive mediators of blood pressurePlasma concentrations and derived 
parameters including Cmax, tmax, t½ and 
AUC(0 -24) as appropriate (to include
erythropoietin, endothelin -1, proendothelin -1,
nitric oxide, asymmetric dimethylarginine, 
renin, angiotensin -II, aldosterone and MR -
proadrenomedullin [proADM]) and 
noradrenalin )
Evaluate exposure -response relationships for 
daprodustat and: erythropoietin, endothelin -1, 
proendothel in-1,nitric oxide, asymmetric 
dimethylarginine, renin, angiotensin -II, 
aldosterone and MR -proAdm and 
noradrenalin .Further models (as appropriate) to describe the 
daprodustat exposure -response relationship 
with: erythropoietin, endothelin -1, 
proendothelin -1,nitric oxide, asymmetric 
dimethylarginine, renin, angiotensin -II, 
aldosterone and MR -proAdm and 
noradrenalin .
To summarize the effect of daprodustat and 
epoetin alfa on SBP after Acute Challenge 1 
and Acute Challenge 2AUEC of SBP as measured by [CONTACT_288619] [ADDRESS_351760] -dosing
To compare the effect of daprodustat to epoetin 
alfa on SBP after 8 weeks of Hgb maintenance 
therapy Change from Day 1 pre -dose SBP to Week 8 
pre-dose
Section 4.1 Overall Design
PREVI OUS FIGURE 1

2015N267693_04 CONFIDENTIA L
205665
89REVI SED FIGURE 1
REVI SED T EXT where text in strikethrough has been removed and bolded text has been 
added
Subjects will be screened for eligibility  starting 4 weeks prior to the start of an ESA 
washout period (8 weeks prior to randomization/Day  1).
Subjects that qualify  for enrolme nt will be washed out of their ESA for 4 weeks; the start 
of the ESA washout should be timed to coincide as closely  as possible with their next 
planned ESA dose.
Following the 4 -week ESA washout, subjects will be randomized 1:1 and stratified b y 
prior ESA dose, based on the average weekl y (for epoetins or darbepoetin) or monthly  
(for methoxy  polyethylene gl ycol (PEG) -epoetin beta) dosing during the 12 weeks prior 
to ESA washout (Week -4) as follows:
Low ESA dose: <100 IU/kg/week epoetin alfa OR <0.5 µg/kg/w eek darbepoetin 
OR <0.6 µg/kg/week methoxy  PEG -epoetin beta
High ESA dose: ≥100 IU/kg/week epoetin alfa OR ≥0.5 µg/kg/week darbepoetin 
OR 0.6 µg/kg/week methoxy  PEG -epoetin beta
On Day  1, subjects will be randomized and undergo Acute Challenge 1, a single dose 
challenge to compare the acute effects on BP of the highest planned once -daily  
maintenance dose of daprodustat (24 mg) to the highest starting dose of epoetin alfa 
(100 IU/kg).  Subjects will have BP monitored for [ADDRESS_351761] 
serial blood sampling to assess the pharmacokinetics of daprodustat and the time -course 
of various biomarkers.  Acute Challenge 1 will be started immediatel y following 
completion of a mid -week dialy sis session.
After completing Acute Challenge 1, all subjects will enter the 8 -week Hgb maintenance 
period where doses of either daprodustat or epoetin alfa will be administered and 
adjusted, as needed.
On Day 57 At Week 8 , following the 8 -week Hgb maintenance period, subjects will 
undergo Acute Challenge 2; this cha llenge will, similar to Acute Challenge 1, involve 
assessing the effect of daprodustat and epoetin alfa on SBP as assessed b y 24-hr ABPM 
measurement.  The subjects will be administered the same dose of either daprodustat or 
epoetin alfa that was given in A cute Challenge 1, and serial blood sampling will be 
performed to assess both daprodustat pharmacokinetics, and to characterize the time 
2015N267693_04 CONFIDENTIA L
[ADDRESS_351762] Requirement Specification (PRS).  If the 
ABPM fails the QC criteria following Acute Challenge 2, one additional Acute 
Challenge may be made in a subsequent, mid -week dialysis visit [ADDRESS_351763] will receive the same study treatment for 
the repeat Acute Challenge 2 as was administered on Day 57 as a single additional 
dose. No additional clinical chemistry, hematology, pharmacokinetic or biomarker 
sampling will be done, however all other procedures will be performed as detailed in 
Table 4. 
Section 5.1 Hemoglobin Stability Criteria
REVI SED TEXT, where the text in strikethrough has been removed
Entry  into the study  requires a stable Hgb b etween 9.0 and 11.5 g/dL, inclusive .  This is 
confirmed from an average of three Hgb values obtained during the screening period at 
Weeks -8, -6 and -4 via a validated point -of-care device to measure Hgb (i.e., HemoCue) 
as outlined in Figure 3.  Calculatio ns to determine eligibility  will be performed 
automatically  by [CONTACT_288637]/Web Response Sy stem (IVWRS).   For subjects 
with a three -times weekly  dialysis schedule, Hgb values must not be obtained on the first 
dialy sis session of the week (e.g., if Monday -Wednesday -Friday  schedule, the study  visit 
cannot be on Monday ).  For subjects with a four -to five -times weekl y dialysis schedule, 
Hgb values can be obtained on an y hemodial ysis session of the week.
Section 5.3 Exclusion Criteria
REVI SED TEXT, whe re the text in strikethrough has been removed and bolded text has 
been added
4. Mircera : Planned or recorded administration of Mircera ( methoxy  PEG -epoetin beta ) 
within the 4 weeks prior to start of washout screening through atWeek -4.
Section [IP_ADDRESS] He moglobin Stoppi[INVESTIGATOR_288601] 2 where text in strikethrough has been removed and bolded text has 
been added
2015N267693_04 CONFIDENTIA L
205665
91Table 8 Hgb Stoppi[INVESTIGATOR_288602] -2 & Day  1 (Prior to Acute Challenge 1)
Hgb at Visit Action
<7.5Repeat HemoCue assessment on the sam e sample at same study visit to confirm; take average of [ADDRESS_351764] from the study.
7.5-<11.5decrease of 2.0 in Hgb 
over 2 weeksRepeat HemoCue assessment on the same sample at same study visit 
to confirm; take average of [ADDRESS_351765] from the study.
increase of 1.0 in Hgb 
over 2 weeksRepeat HemoCue assessment on the same sample at same study visit 
to confirm; take average of [ADDRESS_351766] udy.
11.5Repeat HemoCue assessment on the same sample at same study visit to confirm; take average of [ADDRESS_351767] from the study.
Days 15, 29, &43 Weeks 2, 4 & 6
Hgb at Visit Action
<7.5Repeat HemoCue assessm ent on the same sample at same study visit to confirm; take average of [ADDRESS_351768] from the study.
7.5-<12.0decrease of 2.0 in Hgb 
over 2 weeksRepeat HemoCue assessment on the s ame sample at same study visit 
to confirm; take average of [ADDRESS_351769] from the study.
increase of 1.0 in Hgb 
over 2 weeksRepeat HemoCue assessment on the same sample at same stu dy visit 
to confirm; take average of [ADDRESS_351770] from the study.
12.0Repeat HemoCue assessment on the same sample at same study visit to confirm; take average of [ADDRESS_351771] from the study.
Day 57 Week 8 (Prior to Acute Challenge 2)
Hgb at Visit Action
<7.5Repeat HemoCue assessment on the same sample at same study visit to confirm; take average of [ADDRESS_351772] from the study.
7.5-<11.0decrease of 2.0 in Hgb 
over 2 weeksRepeat HemoCue assessment on the same sample at same study visit 
to confirm; take average of [ADDRESS_351773] from the study.
increase of 1.0 in Hgb 
over 2 weeksRepeat HemoCue assessment on the same sample at same study visit 
to confirm; take average of [ADDRESS_351774] from the study.
11.0Repeat HemoCue assessment on the same sample at same study visit to confirm; take average of [ADDRESS_351775] doses adjusted, as required, to target Hgb 
within the range of 10 .0-11.0 g/dL.  Dose adjustments will be assigned automatically via 
the IVWRS based on the subject’s Hgb value via onsite HemoCue assessment according 
to the following algorithms:
2015N267693_04 CONFIDENTIA L
205665
92Day 12
Hgb (g/dL) Action or Dose
<7.5Repeat HemoCue assessment on the same sample at same study visit to confirm; take 
average of [ADDRESS_351776] from the study.
7.5 and <9.0 8 mg daprodustat
9 and <10.0 6 mg daprodustat
10.0 and <11.5 4 mg daprodustat
11.5Repeat HemoCue assessment on the same sample at same study visit to confirm; take 
average of [ADDRESS_351777] from the study.
The 8 week Hgb maintenance dosing will begin on Day 2, following Acute Challenge 
1.
Day 29 Week 4
The available dose steps for daprodustat ar e outlined below (highlighted boxes indicate 
starting doses).  Dose adjustments will result in the daprodustat dose being increased or 
decreased b y one dose step .
4 mg 10 mg 6 mg 8 mg 2 mg
Hgb (g/dL)Hgb change since
Day 1 visitDose Adjustment
<7.5 Any changeRepeat HemoCue ass essment on the same sample at same 
study visit to confirm; take average of [ADDRESS_351778] from 
the study.
7.5 to <9.5 Decreasing or No change Increase to the next higher dose step
7.5 to <9.5 Increasing Maintain dose
9.5 to ≤11.5 Any change Maintain dose
>11.5 to <12.0Increasing or No change Decrease to the next lower dose step
Decreasing Maintain dose
≥12.0 Any changeRepeat HemoCue assessment on the same sample at same 
study visi t to confirm; take average of [ADDRESS_351779] 
from the study.
Section 6.7 Compliance with Study Treatment Administration
REVI SED TEXT where text in strikethrough has been removed and b olded text has been 
added.
Randomized treatment start and stop dates and dosing details, including dates for 
randomized treatment interruptions and/or dose increases/reductions, will be recorded in
the eCRF RAMOS NG .
2015N267693_04 CONFIDENTIA L
[ADDRESS_351780] in strikethrough has been removed and bolded text has been 
added
Protocol waivers or exemptions are not allowed with the exception of immediate safety  
concerns.  Therefore, adherence to the stud y design requirements, includin g those 
specified in the Time and Events Table (Section 7.1), are essential and required for stud y 
conduct.
If assessments are scheduled for the same nominal time, then the assessments 
should occur in the following order:
1.12-lead ECG
2.vital signs
3.blood draw s
Note: The timing of the assessments should allow the blood draw to occur at the 
exact nominal time.
The change in timing or addition of time points for any  planned stud y 
assessments must be documented in a Note to File which is approved b y the 
relevant G SK study  team member and then archived in the study  sponsor and 
site study  files, but this will not constitute a protocol amendment.
The Institutional Review Board (IRB)/Independent Ethics Committee (IEC)
will be informed of an y safety issues that require alteration of the safet y 
monitoring scheme or amendment of the Informed Consent Form.
No more than 550500mL of blood will be collected over the duration of the 
study , including an y extra assessments that may be required.
Supplementary  study  conduct info rmation is provided in the SRM.  The SRM provides 
administrative and detailed technical information that does not impact subject safety .
Section 7.1 Time and Events Table
PREVI OUS TABLE 3
2015N267693_04 CONFIDENTIA L
205665
94Table 3 Study  Procedures and A ssessments
Procedure 1Screening ESA Washout Treatment Period 2Follow -up2
Week -8 Week -6Week -4Week -2Day 1 Week 2 Week 4 Week 6 Week 8 Early WD Week 10
Informed Consent X
Entry Criteria X
Physical, Medical History, Demography X
HemoCue Hgb X X X X X4X X X X4X
IVWRS Call X X X X X X X X X X X
Randomization X
Acute Challenge X4X4
ABPM Assessment X4X4
Initiation of epoetin alfa/daprodustat dosing X
Dose Adjustment X
Females Only: Serum Pregnanc y Test X X X X X X
Females Only: Estradiol & FSH (if required)3X
ECG X X4X4X X
Vital signs & weight (Pre -& Post -dialysis) X X X X4X X4X X
Clinical Chemistry X X X X X X
Hematology X X X X X X
Folate X
Ferritin, transferrin, total iron, unsaturated iron 
binding capacity (UIBC )X X
Pharmacokinetic/Biomarker Assessments X4X4
Hgb Maintenance Period 5=======================================
Blood draw for PGx X
Adver se Events Assessment X6X6X6X6X4X X X X4X X
Review Concomitant Medications X X X X4X X X X4X X
1 All assessments should be done predialysis/predose except as noted.
2 Allowable time window 2 days EXCEPT Follow -up Visit which is 3 days.
3 As det ailed in Inclusion Criteria.
4 Detailed timings for assessments on Acute Challenge Days are given in Table 4 .
5 From the end of Acute Challenge 1 to the beginning of Acute Challenge 2.
6 Only SAEs assessed as related to study participation are collected at this visit. See Section 12.4 for additional details.
2015N267693_04 CONFIDENTIA L
205665
95REVI SED TABLE 3
Table 3 Study  Procedures and Assessments
Procedure 1Screening ESA Washout Treatment Period 2Follow -up2
Week -8 Week -6Week -4Week -2Day 1 Day 15 Day 29 Day 43 Day 57 Early WD Week 1 0
Informed Consent X
Entry Criteria X
Physical, Medical History, Demography X
HemoCue Hgb X X X X X4X X X X4X
IVWRS X X
Randomization X
Acute Challenge X4X4
ABPM Assessment X4X4
Dose Adjustment X
Females Only: Serum Pregnancy Test X X X X X X
Females Only: Estradiol & FSH (if required)3X
ECG X X4X4X X
Vital signs & weight (Pre -& Post -dialysis) X X X X4X X4X X
Clinical Chemistry X X X X X X
Hematology X X X X X X
Folate and Vitamin B12 X
Ferritin, transferrin, total iron ,TSAT, UIBC X X
Pharmacokinetic/Biomarker Assessments X4X4
Hgb Maintenance Period 5=================================== ====
Adverse Events Assessment X6X6X6X6X4X X X X4X X
Review Concomitant Medications X X X X4X X X X4X X
1 All assessments should be done predialysis/predose except as noted.
2 Allowable time window 2 days EXCEPT Follow -up Visit which is 3 days.
3 As detailed in Inclusion Criteria.
4 Detailed timings for assessments on Acute Challenge Days are given in Table 4 .
5 From the end of Acute Challenge 1 to the beginning of Acute Challenge 2.
6 Only SAEs assessed as related to study participation ar e collected at this visit. See Section 12.4 for additional details
.
2015N267693_04 CONFIDENTIA L
205665
96Section 7.1 Time and Events Table
PREVI OUS TABLE 4
Table 4 Study Procedures and Assessments on Acute Challenge Days (Treatment Period Day 1 and Week 8 Visit)
Procedure PredoseTime (in hours relative to dosing)
0 0.5 1 2 3 4 6 8 12 16 24
ABPM Assessment =========================================================================================== 
Administer Study Treatment X
HemoCue Hgb X X
ECG X X
Vitals X X X X
Pharmacokinetic/Biomarker Assessments X X X X X X X X X X X
Adverse Events Assessment X X X X X X X X X X X
Review Concomitant Medications X X
2015N267693_04 CONFIDENTIA L
205665
97REVISED TABLE 4
Table 4 Study Procedures and Assessments on Acute Challeng e Days (Treatment Period Day 1 and Day 57)
ProcedurePre-
DialysisPost -
DialysisPredoseTime (in hours relative to dosing)
0 0.5 1 2 3 4 6 8 12 16 24
HemoCue Hgb 1X X
IVWRS X
ABPM Assessment1X ========================= ================================================================== 
Administer Study Treatment 1X
Serum Pregnancy Test1X
ECG1X X
Vital Signs and Weight1X X X X X
Clinical Chemistry X
Hema tology X
Pharmacokinetic s X X X X X X X X X X X
Erythropoietin X X X X X X X X X X X
Endothelin -1 X X X X X X X
Nitric Oxide X X X X X X X
Asymmetric dimethylarginine X X X X X X X
Renin X X X X X X X
Angiotensin -II X X X X X X X
Noradrenalin X X X X X X X
Adverse Events Assessment1X X X X X X X X X X X
Review Concomitant Medications1X X
Initiate Hgb maintenance dosing2X
1 Procedures to be repeated if Acu te Challenge 2 fails quality control criteria
2 Applies to Acute Challenge 1 only
2015N267693_04 CONFIDENTIA L
205665
98Section 7.3.6 Clinical Safety Laboratory Assessments
PREVI OUS TABLE 5
Table 5 Protocol Required Safety  Laboratory  Assessments
Laboratory 
AssessmentsParameters
Hematolog yPlatelet Count RBC Indices: WBC Count with 
Differential:
RBC Count MCV Neutrophils
Hemoglobin MCH Lymphocytes
Hematocrit MCHC Monocytes
WBC Count (absolute) RDW Eosinophils
Reticulocyte Count CHr Basophils
Clinical 
ChemistryPotassium AST (SGO T) Total and direct/indirect 
bilirubin
Sodium ALT (SGPT) Total Protein
Glucose Calcium (Albumin adjusted) Alkaline Phosphatase
Albumin Phosphate
Other laboratory 
TestsErythropoietin Vascular Endothelial 
Growth FactorHepcidin
Serum ferritin Seru m iron Serum transferrin
Transferrin saturation (% 
saturation)Unbound iron binding 
capacityFolate
Vitamin B [ADDRESS_351781]
NOTE: Details of Liver Chemistry Stoppi[INVESTIGATOR_288603] d Follow -Up Assessments after liver 
stoppi[INVESTIGATOR_31777] 12.2.
1As needed in women of non -child bearing potential only.
Abrreviations: ALT= Alanine transaminase; AST= Aspartate transaminase; CHr=Reticulocyte haemoglobin conten t; 
FSH=follicle stimulating hormone; MCH= Mean corpuscular haemoglobin; MCHC= Mean corpuscular hemoglobin 
concentration; MCV= Mean corpuscular volume; RBC= Red blood cell; RDW= Red blood cell distribution width; 
SGOT=Serum glutamic oxaloacetic transaminase ; SGPT=Serum glutamic -pyruvic transaminase; WBC= White blood 
cells;
2015N267693_04 CONFIDENTIA L
205665
99REVI SED TABLE 5
Table 5 Protocol Required Safety  Laboratory  Assessments
Laboratory 
AssessmentsParameters
HematologyPlatelet Count RBC Indices: WBC Count with 
Differential:
RBC Count MCV Neutrophils
Hemoglobin MCH Lymphocytes
Hematocrit MCHC Monocytes
WBC Count (absolute) RDW Eosinophils
Reticulocyte Count CHr Basophils
Clinical 
ChemistryPotassium AST (SGOT) Total and direct/indirect 
bilirubin
Sodium ALT (SGPT) Total Protein
Glucose Calcium (Albumin adjusted) Alkaline Phosphatase
Albumin Phosphate
Other Screening 
TestsSerum hCG pregnancy test Serum ferritin Folate
Estradiol Serum iron Vitamin B12
FSH Serum transferrin UIBC
TSAT
NOTE: Details of Liver Chemistr y Stoppi[INVESTIGATOR_131963] -Up Assessments after liver 
stoppi[INVESTIGATOR_31777] 12.2.
1As needed in women of non -child bearing potential only.
Abrreviations: ALT= Alanine transaminase; AST= Aspartate transa minase; CHr=Reticulocyte haemoglobin content; 
FSH=follicle stimulating hormone; MCH= Mean corpuscular haemoglobin; MCHC= Mean corpuscular hemoglobin 
concentration; MCV= Mean corpuscular volume; RBC= Red blood cell; RDW= Red blood cell distribution width; 
SGOT=Serum glutamic oxaloacetic transaminase; SGPT=Serum glutamic -pyruvic transaminase; TSAT = transferrin 
saturation;; UIBC = unsaturated iron binding capacity; WBC= White blood cells;
Section 7.5.1 Ambulatory Blood Pressure Monitoring (ABPM)
REVI SED TEX T, where text in strikethrough has been removed and bolded text has been 
added
Blood pressure and pulse will be measured during Acute Challenge 1 and 2 through the 
use of an ambulatory  blood pressure monitoring device.  Subjects will wear the ABPM 
device for two sessions during the stud y (i.e., Acute Challenge 1 and 2), occurring at Day  
1 (randomization) and at Day [ADDRESS_351782]’s arm until [ADDRESS_351783] -dosing.  The ABPM device will automaticall y calculate MAP.
The device planned for use in this study  is the Mortara Ambulo 2400 ; a specification 
sheet for this device can be found in Section 12.6.
2015N267693_04 CONFIDENTIA L
[ADDRESS_351784] Requirement Specification (PRS).  If the 
ABPM fails the QC criteria following Acute Challenge 2, one additional Acute 
Challenge may be made in a subsequent, mid -week dialysis visit [ADDRESS_351785] of daprodustat on blood pressure.  Biomarkers selected will explore the renin -
angiotensin -aldosterone axis, the nitric oxide and endothelin axes, sodiu m retention and 
HIF signalling.
Biomarkers may  include erythropoietin , nitric oxide (NO), as ymmetric dimethy arginine 
(ADMA), renin, angiotensin -II, aldosterone, endothelin -1 (ET -1), proendothelin -1,
prostaglandin E 2(PGE 2), prostaglandin I 2(PGI 2),and noradrenalin, epi[INVESTIGATOR_238], and MR -
proadrenomedullin.
Samples will be collected as specified in the Time and Events Table (Section 7.1).  The 
timing of the collections may  be adjusted on the basis of emerging pharmacokinetic or 
pharmacod ynamic (PD) data from th is study  or other new information in order to ensure 
optimal evaluation of the PD endpoints.
Section 7.6 GENETICS
Summary  of changes:
All genetic research has been removed from this study .  
PREVI OUS TEXT:
Information regarding genetic research is includ ed in Appendix 4 .  
(Note: Appendix 4 has been deleted due to removal of genetic testing.  This may  be 
referenced at the end of Appendix 7, within the eliminated genetics Section 12.4)
REVI SED TEXT:
Genetics are not evaluated in this study .
Section 9.4.3 O ther analyses
REVI SED TEXT where text in strikethrough has been removed and bolded text has been 
added
2015N267693_04 CONFIDENTIA L
205665
101The difference in SBP between pre -dose in Acute Challenge 1 and pre -dose in Acute 
Challenge 2 will be summarized by  [CONTACT_1570].  Similar summaries o f DBP and 
MAP will be performed.
For each acute challenge, change from pre -challenge in SBP, DBP, MAP, and pulse will 
be summarized by  [CONTACT_288624].  I n addition, for each acute 
challenge ,SBP, DBP, MAP, and pulse will be summarized by [CONTACT_180658].  L ine graphs of this information will be provided by  [CONTACT_288638].
For each acute challenge, the concentration of PK parameters for erythropoietin, 
endothelin -1, proendothelin -1,nitric oxide, asymmetric dimethy larginine, renin, 
angiotensin -II, aldosterone, adrenomedullin and MR -proadrenomedullin and 
noradrenalin will be summarized by  [CONTACT_288624].  Line graphs of 
this information will be provided by  [CONTACT_288639] h acute challenge.
Further statistical considerations will be addressed in the RAP.
Section 12.2 Appendix 2 –Liver Safety Required Actions and Follow Up 
Assessments
PREVI OUS DIAGRAM
ALT≥3xULN  ?
Bilirubin≥ 2xULN
(or INR > 1.5 if 
measured )* ?NoNo
Yes
YesContinue investigational product (IP)
Instruct subject to stop IP
Notify [COMPANY_004] within 24 hrs 
Obtain weekly liver chemist ries until resolved, stabilized or returned 
to basel ine values
Perform liver event follow up assessme nts(serology, PK sample,  etc 
as in protocol) 
Compl ete liver event CRF
Withdraw subject from study after live r chemist ry moni toring 
complete + do not re-challenge with IP
Instruct subject to stop IP
Notify [COMPANY_004] and arrange clinical followup within 24 hrs
Perform liver event follow up assessme nts(serology, PK sample etc 
as in protocol) 
Repor t as SAE (excl. hepatic impairment or cirrhosis studies) ; 
compl ete SAE & liver event CRF + liver imaging  
and biopsy CRFs (if these tests are performed)
Obtain twice weekly liver chemistries until resolved, stabilized or 
returned to baseline values 
Consul tation with hepat ologist/specialist recomme nded
Withdraw subject from study after live r chemist ry moni toring 
complete + do not re-challenge with IP*INR threshold does not apply to 
subjects receiving anticoagula nts.
2015N267693_04 CONFIDENTIA L
205665
102REVI SED DIAGRAM

2015N267693_04 CONFIDENTIA L
205665
103ADDED CHARTS
The following two charts and correspo nding text were added to Appendix 2 in their 
entirety .
Additional charts are provided below for reference .
Liver Chemistry Stoppi[INVESTIGATOR_2121] –Liver Stoppi[INVESTIGATOR_53053]-absolute ALT 5xULN
ALT Increase ALT 3xULN persists for 4 weeks
Bilirubin 1, 2ALT 3xULN andbilirubin 2xULN (>35% direct bilirubin)
INR2ALT 3xULN andINR>1.5, if INR measured
Cannot Monitor ALT 3xULN and cannot be monitored weekly for 4 weeks
Symptomatic 3ALT  3xULN associated with symptoms (new or worsening) believed to be 
related to liver injury or hypersensitivity
Required Actions and Follow up Assessments following ANY Liver Stoppi[INVESTIGATOR_90567]
Immediately discontinue  study treatment 
Report the e vent to [COMPANY_004] within 24 hours
Complete the live r event CRF and complete an 
SAE data collection tool if the event also meets 
the criteria for an SAE 2
Perform liver event follow up assessments 
Monitor the subject until liver chemistries
resolve, stabilize, or return to within baseline 
(see MONITORING below)
Do not restart/rechallenge subject with study 
treatment. If restart/rechallenge not allowed 
per protocol or not granted , permanently 
discontinue study treatment and may 
contin ue subject in the study for any protocol 
specified follow up assessments 
MONITORING:
For bilirubin or INR criteria:
Repeat liv er chemistries (include ALT, AST, Viral hepatitis serology 4
Blood sample for pharmacokinetic (PK) 
analysis, obtained within [ADDRESS_351786] dose 5
Serum creatine phosphokinase (CPK) 
and lactate de hydrogenase (LDH).
Fractionate bilirubin, if total 
bilirubin 2xULN
Obtain complete blood count with 
differential to assess eosinophilia
Record the appearance or worsening of 
clinical symptoms of liver injury, or 
hypersensitivity, on the AE report form
Reco rd use of concomitant medications 
on the concomitant medications report 
form including acetaminophen, herbal 
remedies, other over the counter 
medications .
Record alcohol use on the liver event 
2015N267693_04 CONFIDENTIA L
205665
104alkaline phosphatase, biliru bin) and perform 
liver event follow up assessments within  24 hrs
Monitor subjects twice weekly until liver 
chemistries resolve, stabilize o r return to within 
baseline 
A specialist or hepatology consultation is 
recommended
For All other criteria: 
Repeat liver chemistries (include ALT, AST, 
alkaline phosphatase, bilirubin) and perform 
liver event follow up assessments within  24-72 
hrs 
Monit or subjects weekly until liver chemistries 
resolve, stabilize or return to within baselinealcohol intake case report form
For bilirubin or INR criteria :
Anti-nuclear antibody, anti -smooth 
muscle antibody, Type 1 anti -liver 
kidney microsomal antibodies, and 
quantitative total immunoglobulin G 
(IgG or gamma globulins).
Serum acetaminophen adduct HPLC 
assay (quantifies potential 
acetaminophen contribution t o liver 
injury in subjects with definite or likely 
acetaminophen use in the preceding 
week [ James 2009]). NOTE: not 
required in China
Liver imaging (ultrasound, magnetic 
resonance, or computerised 
tomography) and /or liver biopsy to 
evaluate liver disease ; complete Liver 
Imaging and/or Liver Biopsy CRF 
forms.
1. Serum bilirubin fractionation should be performed if testing is available. If serum bilirubin fractionation is not 
immediately available, discontinue study treatment for that subject i f ALT 3xULN andbilirubin 2xULN.. 
Additionally, if serum bilirubin fractionation testing is unavailable, record presence of detectable urinary 
bilirubin on dipstick , indicating direct bilirubin elevations and suggesting liver injury. 
2. Allevents of ALT 3xULN andbilirubin 2xULN (>35% direct bilirubin) or ALT 3xULN andINR>1.5, if INR 
measured which may indicate severe liver injury (possible ‘Hy’s Law’), must be reported as an SAE (excluding 
studies of hepatic impairment or cirrhosis) ; INR measurem ent is not required and the threshold value stated 
will not apply to subjects receiving anticoagulants
3. New or worsening symptoms believed to be related to liver injury (such as fatigue, nausea, vomiting, right upper 
quadrant pain or tenderness, or jaundice ) or believed to be related to hypersensitivity (such as fever, rash or 
eosinophilia)
4. Includes: Hepatitis A IgM antibody; Hepatitis B surface antigen and Hepatitis B Core Antibody (IgM); Hepatitis C 
RNA; Cytomegalovirus IgM antibody;  Epstein -Barr viral ca psid antigen IgM antibody (or if unavailable, obtain 
heterophile antibody or monospot testing);  Hepatitis E IgM antibody 
5. PK sample may not be required for subjects known to be receiving placebo or non -[COMPANY_004] comparator treatments.)  
Record the date/time of the PK blood sample draw and the date/time of the last dose of study treatment prior to 
blood sample draw on the CRF. If the date or time of the last dose is unclear, provide the subject’s best 
approximation. If the date/time of the last dose cannot be app roximated OR a PK sample cannot be collected in 
the time period indicated above, do not obtain a PK sample. Instructions for sample handling and shippi[INVESTIGATOR_131971].   
References
James L P, Letzig L, Simpson PM, Capparelli E, Roberts DW, Hinson JA, Dave rn TJ, Lee 
WM. Pharmacokinetics of Acetaminophen -Adduct in Adults with Acetaminophen 
Overdose and Acute Liver Failure. Drug Metab Dispos 2009; 37:1779 -1784 .
2015N267693_04 CONFIDENTIA L
205665
105Liver Chemistry Increased Monitoring Criteria –Liver Monitoring Event
Criteria Actions
ALT 3xULN and <5xULN andbilirubin 
<2xULN , without symptoms believed to 
be related to liver injury or 
hypersensitivity, andwho can be 
monitored weekly for 4 weeksNotify the [COMPANY_004] medical monitor within [ADDRESS_351787] s afety. 
Subject can continue study treatment  Subject must 
return weekly for repeat liver chemistries (ALT, AST, 
alkaline phosphatase, bilirubin) until they resolve, 
stabilise or return to within baseline 
If at any time subject meets the liver chemistry 
stoppi[INVESTIGATOR_3418], proceed as described above
If, after 4 weeks of monitoring, ALT <3xULN and 
bilirubin <2xULN, monitor subjects twice monthly 
until liver chemistries normalize or return to within 
baseline.
Section 12.4 Appendix 4 –Genetic Research
Summa ry of changes:
Due to genetic research being removed from this study , this section was deleted in 
its entirety .  No revised text was created.
PREVI OUS TEXT:
Genetics –Background
Naturall y occurring genetic variation may  contribute to inter -individual var iability  in 
response to medicines, as well as an individual's risk of developi[INVESTIGATOR_42259]. 
Genetic factors associated with disease characteristics may  also be associated with 
response to therap y, and could help to explain some clinical study outco mes. For 
example, genetic variants associated with age -related macular degeneration (AMD) are 
reported to account for much of the risk for the condition with certain variants reported to 
influence treatment response [Chen , 2012 ]. Thus, knowledge of the gen etic etiology  of 
disease may  better inform understanding of disease and the development of medicines. 
Additionally , genetic variability  may  impact the pharmacokinetics (absorption, 
distribution, metabolism, and elimination), or pharmacod ynamics (relationsh ip between 
concentration and pharmacologic effects or the time course of pharmacologic effects) of a 
specific medicine and/or clinical outcomes (efficacy  and/or safet y) observed in a clinical 
study .
Genetic Research Objectives and A nalyses
The objectives o f the genetic research are to investigate the relationship between genetic 
variants and: 
2015N267693_04 CONFIDENTIA L
205665
106Response to medicine, including an y treatment regimens under investigation in 
this study ;
Anemia associated with chronic kidney  disease
susceptibility , severit y, and progression and related conditions
Genetic data may  be generated while the study  is underway  or following completion of 
the study .  Genetic evaluations may  include focused candidate gene approaches and/or 
examination of a large number of genetic variants throughout the genome (whole genome 
analyses). Genetic anal yses will utilize data collected in the study  and will be limited to 
understanding the objectives highlighted above.  Analy ses may  be performed using data 
from multiple clinical studies to investi gate these research objectives.
Appropriate descriptive and/or statistical analy sis methods will be used. A detailed 
description of an y planned anal yses will be documented in a Reporting and Analy sis Plan 
(RAP) prior to initiation of the anal ysis. Planned analy ses and results of genetic 
investigations will be reported either as part of the clinical RAP and study  report, or in a 
separate genetics RAP and report, as appropriate.
Study Population
Any subject who is enrolled in the study  can participate in gene tic research.  Any  subject 
who has received an allogeneic bone marrow transplant must be excluded from the 
genetic research.
Study Assessments and Procedures
A key  component of successful genetic research is the collection of samples during 
clinical studie s. Collection of samples, even when no a priori hypothesis has been 
identified, may  enable future genetic anal yses to be conducted to help understand 
variability  in disease and medicine response.
A 6 ml blood sample will be taken for Deox yribonucleic acid (DNA) extraction. 
A blood sample is collected at the baseline visit, after the subject has been 
randomized and provided informed consent for genetic research. Instructions for 
collection and shippi[INVESTIGATOR_131977]. The DNA from the blood sample may  undergo quality  control analy ses to 
confirm the integrit y of the sample. If there are concerns regarding the quality  of 
the sample, then the sample may  be destroy ed. The blood sample is taken on a 
single occasion unl ess a duplicate sample is required due to an inabilit y to utilize 
the original sample.
The genetic sample is labelled (or “coded”) with the same stud y specific number used to 
label other samples and data in the study .  This number can be traced or linked b ack to 
the subject by  [CONTACT_132018]. Coded samples do not carry  personal 
identifiers (such as name [CONTACT_42405]).
Samples will be stored securel y and may be kept for up to [ADDRESS_351788] 
completes the study , or [COMPANY_004] may  destroy  the samples sooner.  [COMPANY_004] or those working 
with [COMPANY_004] (for example, other researchers) will only  use samples collected from the study  
2015N267693_04 CONFIDENTIA L
[ADDRESS_351789] will be given a 
choice of one of the following options concerning the genetic sample, if already  
collected:
Continue to participate in the genetic research in which case the genetic DNA 
sample is retained
Discontinue participati on in the genetic research and destroy  the genetic DNA 
sample 
If a subject withdraws consent for genetic research or requests sample destruction for an y 
reason, the investigator must complete the appropriate documentation to request sample 
destruction wit hin the timeframe specified b y [COMPANY_004] and maintain the documentation in 
the site study  records . 
Genoty pe data may  be generated during the study  or after completion of the study  and 
may be anal yzed during the study  or stored for future anal ysis.
If a subject withdraws consent for genetic research and genot ype data has not been 
analyzed, it will not be analy zed or used for future research.
Genetic data that has been anal yzed at the time of withdrawn consent will 
continue to be stored and used, as appropriate.
Screen and Baseline Failures
If a sample for genetic research has been collected and it is determined that the subject 
does not meet the entry  criteria for participation in the study , then the investigator should 
instruct the subject that their genetic samp le will be destro yed. No forms are required to 
complete this process as it will be completed as part of the consent and sample 
reconciliation process.  In this instance ,a sample destruction form will not be available to 
include in the site files.
2015N267693_04 CONFIDENTIA L
[ADDRESS_351790]’s Genetic Data
[COMPANY_004] may  summarize the genetic research results in the clinical study  report, or 
separately  and may  publish the results in scientific journals. 
[COMPANY_004] may  share genetic research data with other scientists to further scientific 
understanding in alignment with the informed consent. [COMPANY_004] does not inform the subject, 
family  members, insurers, or employ ers of individual genoty pi[INVESTIGATOR_131978]’s medical care at the time of the study , unless 
required b y law. This is due to the fact that the information generated from genetic 
studies is generall y preliminary in nature, and therefore the significance and scientific 
validity  of the results are undetermined.  Furth er, data generated in a research laboratory  
may not meet regulatory  requirements for inclusion in clinical care.
Section 12.5, Section 12.6, and Section 12.7
Summary  of changes:
Appendix 5, Appendix 6, and Appendix 7 re -numbered due to removal of Appendix 4.
12.7.2. Amendment 2
Summary of Amendment Changes with Rationale
This protocol amendment applies to all centers where this study  may  be performed.
This protocol amendment was written to clarify  the descript ive statistics and include them 
in the objectives a nd endpoints table(s) as well as remove one blood pressure 
measurement. Additional minor changes were made for clarity  of study  procedures.
List of Specific Changes
Section 1 Protocol Synopsis for Study 205665
Objective(s)/Endpoint(s) Table
REVI SED TEXT, where text in strikethrough has been removed and bolded text has been 
added
Objectives Endpoints
Primary
To compare the effect of daprodustat to epoetin 
alfa on blood pressure (BP) after Acute 
Challenge 2 (8 weeks of hemoglobin [Hgb ]
maintenance therap y)Average of systolic blood pressure (SBP) as 
measured by [CONTACT_288617] (ABPM) over [ADDRESS_351791] -dosing after 
8 weeks of Hgb maintenance therapy
Secondary
To compare the initial effect of daprodustat to 
epoetin alfa on BP after Acute Challenge 1 (4 
weeks of erythropoiesis -stimulating agent [ESA]Average of SBP , diastolic blood pressure 
(DBP), mean arterial blood pressure (MAP), 
and heart rate (HR) as measured by [CONTACT_44117] 
2015N267693_04 CONFIDENTIA L
205665
109Objectives Endpoints
washout) over [ADDRESS_351792] -dosing at Day 1
Average of diastolic blood pressure (DBP) as 
measured by [CONTACT_288619] [ADDRESS_351793] -dosing at 
Day 1
Area under the effect curve (AUEC )of SBP ,
DBP, MAP, and HR as measured by [CONTACT_288618] [ADDRESS_351794] -dosing at Day 1
To compare the effect of daprodustat to epoetin 
alfa on BP after Acute Chall enge 2 Average of DBP ,MAP, and HR as measured 
by [CONTACT_288619] [ADDRESS_351795] -dosing at Week 8 Day 
57.
AUEC of SBP ,DBP, MAP, and HR as 
measured by [CONTACT_288619] [ADDRESS_351796] -dosing at 
Week 8 Day 57.
To estimate the initial effect of daprodustat on 
SBP, DBP, pulse HR andMAP mean arterial 
blood pressure (MAP) after Acute Challenge 1 Change from pre -dose in SBP, DBP, pulse HR
and MAP at each timepoint at Day 1
To characterize the pharmacokinetics of 
daprodustatPlasma concentrations of daprodustat and 
metabolites and d erived pharmacokinetic 
parameters including maximum observed 
concentration (Cmax ), time of occurrence of 
Cmax (tmax ), terminal phase half -life (t½)and 
area under concentration -time curve from time 
zero to 24 hours (AUC [0-24])as appropriate
To assess the safety and tolerability of 
daprodustatIncidence and severity of adverse events ( AEs)
and serious adverse events ( SAEs )
Reasons for discontinuation of study treatment
Absolute values and changes from baseline 
over time in laboratory parameters, 
electrocar diograms ( ECGs )and vital signs
Exploratory
To investigate the effect of daprodustat on 
vasoactive mediators of blood pressure Plasma concentrations and derived 
parameters including Cmax, tmax, t½ and 
AUC(0 -24) as appropriate (to include 
erythropoietin, endothelin -1, nitric oxide, 
asymmetric dimethylarginine, renin, 
angiotensin -IIand metabolites , and 
noradrenalin) 
Evaluate exposure -response relationships for 
daprodustat and: erythropoietin, endothelin -1, 
nitric oxide, asymmetric dimethylarginine, renin , 
angiotensin -II(and metabolites) , and 
noradrenalin  Further models (as appropriate) to describe the 
daprodustat exposure -response relationship 
with: erythropoietin, endothelin -1, nitric oxide, 
asymmetric dimethylarginine, renin, 
angiotensin -II(and metab olites) , and 
noradrenalin. 
2015N267693_04 CONFIDENTIA L
205665
110Objectives Endpoints
To summarize the effect of daprodustat and 
epoetin alfa on SBP after Acute Challenge 1 
and Acute Challenge 2AUEC of SBP as measured by [CONTACT_288619] [ADDRESS_351797] -dosing
To compare the effect of daprodustat to epoetin 
alfa on SBP af ter 8 weeks of Hgb maintenance 
therapy Change from Day 1 pre -dose SBP to Week 8
Day 57 pre-dose
Section 1 Protocol Synopsis for Study 205665
Study  Design
REVI SED TEXT, where text in strikethrough has been removed and bolded text has been 
added
Subjects will be screened for eligibility  starting 4 weeks prior to the start of an ESA 
washout period (8 weeks prior to randomization/Day  1).
Subjects that qualify  for enrolment will be washed out of their ESA for 4 weeks; the start 
of the ESA washout should be t imed to coincide as closely  as possible with their next 
planned ESA dose.
Following the 4 -week ESA washout, subjects will be randomized 1:1 and stratified b y 
prior ESA dose, based on the average weekl y (for epoetins or darbepoetin) or monthly  
(for methoxy  polyethylene gl ycol (PEG) -epoetin beta) dosing during the 12 weeks prior 
to ESA washout (Week -4) as follows:
Low ESA dose: <100 IU/kg/week epoetin alfa OR <0.5 µg/kg/week darbepoetin 
OR <0.6 µg/kg/week methoxy  PEG -epoetin beta
High ESA dose: ≥100 IU/kg/we ek epoetin alfa OR ≥0.5 µg/kg/week darbepoetin 
OR 0.6 µg/kg/week methoxy  PEG -epoetin beta
On Day  1, subjects will be randomized and undergo Acute Challenge 1, a single dose 
challenge to compare the acute effects on BP of the highest planned once -daily  
maintenance dose of daprodustat (24 mg) to the highest starting dose of epoetin alfa 
(100 IU/kg).  Subjects will have BP monitored for [ADDRESS_351798] 
serial blood sampling to assess the pharmacokinetics of daprodustat and the time -course 
of various biomarkers.  Acute Challenge 1 will be started immediatel ypromptly
following completion of a mid -week dial ysis session.
After completing Acute Challenge 1, all subjects will enter the 8 -week Hgb maintenance 
period where doses of either daprodustat or epoetin alfa will be administered and 
adjusted, as needed.
On Day  57, following the 8 -week Hgb maintenance period, subjects will undergo Acute 
Challenge 2; this challenge will, similar to Acute Challenge 1, involve assessing the 
effect of daprodustat an d epoetin alfa on SBP as assessed by  24-hr ABPM measurement.  
The subjects will be administered the same dose of either daprodustat or epoetin alfa that 
was given in Acute Challenge 1, and serial blood sampling will be performed to assess 
2015N267693_04 CONFIDENTIA L
[ADDRESS_351799] Requirement Specif ication (PRS).  If the ABPM fails the 
QC criteria following Acute Challenge 2, one additional Acute Challenge may  be made 
in a subsequent, mid -week dialy sis visit [ADDRESS_351800] involvement is up to 18 weeks (Screening to Follow -up) as 
described below:
Screening : Screening will be for at least 4 weeks prior to starting the ESA 
washout.
ESA Washout : Subjects that meet eligibility  criteria will begin the [ADDRESS_351801] 
been the next scheduled dose of ESA (or as close as practicable).
oFor subjects with a three -times weekly  dialy sis schedule, this day  must not 
occur on the first dialy sis session of the week (e.g., if Monday -Wednesday -
Friday  schedule, the study  visit cannot be on Monday ).
oFor subjects with a four -to five -times weekl y dialysis schedule, this day can 
be on an y hemodial ysis session of the week.
Randomization & Acute Challenge 1 (Day  1): Subjects will be randomized 1:[ADDRESS_351802]’s dial ysis session.
2015N267693_04 CONFIDENTIA L
205665
112Hgb Maintenance Period : Subjects randomized to dapr odustat will start an 8 -week 
Hgb maintenance period based on a starting dose and dose adjustment algorithm.  
Subjects randomized to epoetin alfa will begin an 8 -week Hgb maintenance 
period where Hgb will be managed in accordance with local labelling.
Acute Challenge 2 (Day  57): At the end of the [ADDRESS_351803]’s dialy sis session.
Follow -up: A Follow -up visit will be scheduled to occur 14 3 day s after 
completing treatment.
Section 1 Protocol Synopsis
Analy sis
REVI SED TEXT, where text in strikethrough has been removed and bolded text has been 
adde d
The primary  endpoint for this study  is average s ystolic blood pressure (SBP) over [ADDRESS_351804] -dose during Acute Challenge 2 will 
be an analy sis of covariance (ANCOVA) with terms for treatment, and post -HD/pre -
Acute Challenge [ADDRESS_351805] -HD/pre -Acute Challenge [ADDRESS_351806]-HD/pre -Acute Challenge 1 SBP, and treatment by  (difference in post -HD SBP 
between Acute Challenge 1 and 2) interaction.  Note that the pre -challenge SBP may  
change over time between Acute Challenge [ADDRESS_351807] -HD/pre -Acute 
Challenge 1 SBP.  The primary  model will provide a point estimate a nd two -sided 95% 
CI for the treatment effect and a p -value for the superiority  assessment.  Superiority  will 
be established if the p -value is <0.05.
The comparison of daprodustat versus epoetin alfa on [ADDRESS_351808] -HD/pre -Acute Challenge [ADDRESS_351809] Acute Challenge 2 and 1 will be anal yzed 
using ANCOVA with terms for treatment with 95% CI s and p -values provided for the 
treatment effect.
Null Hy pothesis: The difference between 24 mg daprodustat versus 100 IU/kg epoetin 
alfa on 6 hr average SBP under a background of treatment (i.e., during Acute Challenge 
2) is zero.
Alternative Hy pothesis: The difference between 24 mg daprodustat versus 100 IU/kg 
epoetin alfa on 6 hr average SBP under a background of treatment (i.e. during Acute 
Challenge 2) is not ze ro.
An interim anal ysis will be conducted after approximately  [ADDRESS_351810] completed 
Acute Challenge 2.
If the mean change in SBP from pre -Acute Challenge 1 to the 6 -hour mean following 
both Acute Challenge 1 and Acute Challenge 2 is less than 5 mmHg in the epoetin alfa 
group, then the study  will be stopped.  However, if a clinicall y meaningful difference 
between the two treatment groups in mean change in SBP from pre -Acute Challenge 1 to 
the 6 -hour mean following Acute Challenge 1 (i.e., >5 mmHg) is ob served, then the 
study  will be continued in order to further characterize the effects of daprodustat on blood 
pressure.
Simulations show that under assumptions of a true mean change in SBP of 0 mmHg and 
SD of 18 mmHg for both treatment groups at Acute Chal lenge 1 and the epoetin alfa 
group at Acute Challenge 2, this stoppi[INVESTIGATOR_288604] >99% 
of the time.  Under the assumptions of a true mean change in SBP of 8 mmHg and SD of 
18 mmHg for both treatment groups at Acute Challeng e 1 and the epoetin alfa group at 
Acute Challenge 2, this rule will result in stoppi[INVESTIGATOR_21356] <1% of the time.
While the above is a guideline for stoppi[INVESTIGATOR_288605] , the totality  of the data 
will be considered when making the decision at the time of the interim analy sis.
Section 3 OBJECTIVE(S) AND ENDPOINT(S)
REVI SED TEXT, where text in strikethrough has been removed and bolded text has been 
added
2015N267693_04 CONFIDENTIA L
205665
114Objectives Endpoints
Primary
To compare the effect of daprodustat to epoetin 
alfa on blo od pressure (BP) after Acute 
Challenge 2 (8 weeks of hemoglobin [Hgb ]
maintenance therapy)Average of systolic blood pressure (SBP) as 
measured by [CONTACT_288617] (ABPM) over [ADDRESS_351811] -dosing after 
8 weeks of Hgb maintenance therapy
Secondary
To compare the initial effect of daprodustat to 
epoetin alfa on BP after Acute Challenge 1 (4 
weeks of erythropoiesis -stimulating agent [ESA]
washout)Average of SBP , diastolic blood pressure 
(DBP), mean arterial blood pressure (MAP), 
and heart r ate (HR) as measured by [CONTACT_288618] [ADDRESS_351812] -dosing at Day 1
Average of diastolic blood pressure (DBP) as 
measured by [CONTACT_288619] [ADDRESS_351813] -dosing at 
Day 1
Area under the effect curve (AUEC )of SBP ,
DBP, MAP, and HR as measured by [CONTACT_288618] [ADDRESS_351814] -dosing at Day 1
To compare the effect of daprodustat to epoetin 
alfa on BP after Acute Challenge 2 Average of DBP ,MAP, and HR as measured 
by [CONTACT_288619] [ADDRESS_351815] -dosing at Week 8 Day 
57.
AUEC of SBP , DBP, MAP, and HR as 
measured by [CONTACT_288619] [ADDRESS_351816] -dosing at 
Week 8 Day 57.
To estimate the initial effect of daprodustat on 
SBP, DBP, pulse HR and MAP mean arterial 
blood pressure (MAP) after Acute Challenge 1 Change from pre -dose in SBP, DBP, pulse HR
and MAP at each timepoint at Day 1
To characterize the ph armacokinetics of 
daprodustatPlasma concentrations of daprodustat and 
metabolites and derived pharmacokinetic 
parameters including maximum observed 
concentration (Cmax ), time of occurrence of 
Cmax (tmax ), terminal phase half -life (t½)and 
area under conce ntration -time curve from time 
zero to 24 hours (AUC [0-24])as appropriate
To assess the safety and tolerability of 
daprodustatIncidence and severity of adverse events ( AEs)
and serious adverse events ( SAEs )
Reasons for discontinuation of study treatment
Absolute values and changes from baseline 
over time in laboratory parameters, 
electrocardiograms ( ECGs )and vital signs
Exploratory
To investigate the effect of daprodustat on 
vasoactive mediators of blood pressure Plasma concentrations and derived 
param eters including Cmax, tmax, t½ and 
AUC(0 -24) as appropriate (to include 
erythropoietin, endothelin -1, nitric oxide, 
2015N267693_04 CONFIDENTIA L
205665
115Objectives Endpoints
asymmetric dimethylarginine, renin, 
angiotensin -IIand metabolites , and 
noradrenalin) 
Evaluate exposure -response relationships for 
daprodu stat and: erythropoietin, endothelin -1, 
nitric oxide, asymmetric dimethylarginine, renin, 
angiotensin -II(and metabolites) , and 
noradrenalin Further models (as appropriate) to describe the 
daprodustat exposure -response relationship 
with: erythropoietin, e ndothelin -1, nitric oxide, 
asymmetric dimethylarginine, renin, 
angiotensin -II(and metabolites) , and 
noradrenalin. 
To summarize the effect of daprodustat and 
epoetin alfa on SBP after Acute Challenge 1 
and Acute Challenge 2 AUEC of SBP as measured by [CONTACT_29642] M over [ADDRESS_351817] -dosing
To compare the effect of daprodustat to epoetin 
alfa on SBP after 8 weeks of Hgb maintenance 
therapy Change from Day 1 pre -dose SBP to Week 8
Day 57 pre-dose
Section 4.1 Overall Design
REVI SED TEXT, where text in strikethrough h as been removed and bolded text has been 
added
Subjects will be screened for eligibility  starting 4 weeks prior to the start of an ESA 
washout period (8 weeks prior to randomization/Day  1).
Subjects that qualify  for enrolment will be washed out of their E SA for 4 weeks; the start 
of the ESA washout should be timed to coincide as closely  as possible with their next 
planned ESA dose.
Following the 4 -week ESA washout, subjects will be randomized 1:1 and stratified b y 
prior ESA dose, based on the average weekl y (for epoetins or darbepoetin) or monthly  
(for methoxy  polyethylene gl ycol (PEG) -epoetin beta) dosing during the 12 weeks prior 
to ESA washout (Week -4) as follows:
Low ESA dose: <100 IU/kg/week epoetin alfa OR <0.5 µg/kg/week darbepoetin 
OR <0.6 µg/kg/we ek methoxy  PEG -epoetin beta
High ESA dose: ≥100 IU/kg/week epoetin alfa OR ≥0.5 µg/kg/week darbepoetin 
OR 0.6 µg/kg/week methoxy  PEG -epoetin beta
On Day  1, subjects will be randomized and undergo Acute Challenge 1, a single dose 
challenge to compare the acute effects on BP of the highest planned once -daily  
maintenance dose of daprodustat (24 mg) to the highest starting dose of epoetin alfa 
(100 IU/kg).  Subjects will have BP monitored for [ADDRESS_351818] 
serial blood sampling to assess the pharmacokinetics of daprodustat a nd the time -course 
of various biomarkers.  Acute Challenge 1 will be started immediatel ypromptly 
following completion of a mid -week dial ysis session.
2015N267693_04 CONFIDENTIA L
205665
116After completing Acute Challenge 1, all subjects will enter the 8 -week Hgb maintenance 
period where doses of either daprodustat or epoetin alfa will be administered and 
adjusted, as needed, based on dosing guidance as described in Section 6.4.
On Day  57, following the 8 -week Hgb maintenance period, subjects will undergo Acute 
Challenge 2; this challenge will, similar to Acute Challenge 1, involve assessing the 
effect of daprodustat and epoetin alfa on SBP as assessed by  24-hr ABPM measurement.  
The subjects will be administered the same dose of either daprodustat or epoetin alfa that 
was given in Acute Challen ge 1, and serial blood sampling will be performed to assess 
both daprodustat pharmacokinetics, and to characterize the time course of various 
biomarkers.  Acute Challenge [ADDRESS_351819] Requirement Specification (PRS).  If the ABPM fails the 
QC criteria following Acute Challenge 2, one additional Acute Challenge may  be made 
in a subsequent, mid -week dialy sis visit [ADDRESS_351820] i nvolvement is up to 18 weeks (Screening to Follow -up) as 
described below:
Screening : Screening will be for at least 4 weeks prior to starting the ESA 
washout.
ESA Washout : Subjects that meet eligibility  criteria will begin the [ADDRESS_351821] 
been the next scheduled dose of ESA (or as close as practicable).
oFor subjects with a three -times weekly  dialy sis schedule, this day  must not 
occur on the first dialy sis session of the week (e.g., if Monday -Wednesday -
Friday  schedule, the study  visit cannot be on Monday ).
oFor subjects with a four -to five -times weekl y dialysis schedule, this day can 
be on an y hemodial ysis session of the week.
2015N267693_04 CONFIDENTIA L
205665
117Randomization & Acute Challenge 1 (Day  1): Subjects will be randomized 1:[ADDRESS_351822]’s dialy sis session.
Hgb Maintenance Period : Subjects randomized to daprodustat will start an 8 -week 
Hgb maintenance period based on a starting dose and dose adjustment algorithm 
as described in Section 6.4.1 .  Subjects randomized to epoet in alfa will begin an 
8-week Hgb maintenance period where Hgb will be managed in accordance with 
local labelling.
Acute Challenge 2 : At the end of the [ADDRESS_351823]’s dialy sis session.
Follow -up: A Follow -up visit will be scheduled to occur 14 3 day s after 
completing treatment.
Section 4.4. D esign Justification
REVI SED TEXT, where text in strikethrough has been removed.
This study  will be an open -label, multi -center, randomized, parallel -group design in HD 
subjects with anemia associated with CKD.  There will be a 4 -week screening period, a 
4-week ESA washout period, an 8 -week Hgb -maintenance period including two 24 -hr 
acute challenges and a follow -up visit 14 ± 3 day s after completing treatment.
It is preferred that no changes are made to estimated dry  weight (EDW) and 
antihy pertensive medica tions while the subject is participating in this study.  However, if 
changes in EDW and/or antihy pertensive medications are necessary , these must be 
documented in the electronic case report form (eCRF) along with the reasons.   Subjects 
will remain in the s tudy regardless of an y changes.
(Note: No changes made to the bullet points within this section)
Section 6.7 Compliance with Study Treatment Administration
REVI SED TEXT, where text in strikethrough has been removed and bolded text has been 
added
For subje ctsrandomized to daprodustat , treatment start and stop dates and dosing 
details including dates for randomized treatment interruptions and/or dose 
increases/reductions, will be recorded in RAMOS NG.
2015N267693_04 CONFIDENTIA L
205665
118For subjects randomized to daprodustat, for Acute Challe nge 1 and 2, stud y site 
personnel will confirm compliance.  When daprodustat is administered at home (Hgb 
maintenance period), subjects will be instructed to return all unused randomized 
treatment at each clinic visit.  A record of the number of daprodusta t tablets dispensed to 
and taken b y each subject will be maintained and reconciled with randomized treatment 
and compliance records.
For subjects randomized to epoetin alfa, they  will receive all study  treatment directly  
from the investigator or designee, under medical supervision.  The date and time of each 
dose administered in the clinic will be recorded in the source documents.  The dose of 
study  treatment and study  subject identification will be confirmed at the time of dosing 
by a member of the study s ite staff other than the person administering the study  
treatment.
Section 6.10.[ADDRESS_351824] to meals. 
All subjects will be instructed to limit caf feine -or xanthine -containing products 
(e.g., coffee, tea, cola drinks, chocolate) for 24h prior to both Acute Challenge [ADDRESS_351825] does not need to limit the products listed above.
Section 6.11 Concomitant Medications and Non -Drug Therapi[INVESTIGATOR_288606], where text in strikethrough has been removed.
Concomitant medications, including over -the-counter medications and supplements, 
taken during the stud y will be recorded in th e eCRF.  Start/stop dates and route of 
administration will be recorded for general concomitant medications , while additional 
details will be recorded for certain medications (e.g., anti -hypertensive medications).
Section 6.11.1 Estimated Dry Weight and An tihypertensive Medication Changes
REVI SED TEXT, where text in strikethrough has been remov ed.
It is preferred that changes to EDW and antihy pertensive medication(s) are not made 
while the subject is part of this study .  If changes in EDW and/or antihy pertensive 
medications are necessary, these changes as well as the reason(s) for the change must be 
documented in the eCRF.   Subjects should remain in the study  regardless of any  changes.
Section 7.1 Time and Events Table
Table 3 Study  Procedures and Assessme nts
REVI SED TEXT, where text in strikethrough has been removed.
2015N267693_04 CONFIDENTIA L
205665
119(Note: Changes are difficult to see on table.  Superscript 6 has been removed from 
Adverse Events Assessment in columns Weeks –4 and Week –2)
2015N267693_04 CONFIDENTIA L
205665
120Procedure 1Screening ESA Washout Treatment Per iod2Follow -up2
Week -8 Week -6Week -4Week -2Day 1 Day 15 Day 29 Day 43 Day 57 Early WD Week 10
Informed Consent X
Entry Criteria X
Physical, Medical History, Demography X
HemoCue Hgb X X X X X4X X X X4X
IVWRS X X
Randomization X
Acute Challenge X4X4
ABPM Assessment X4X4
Dose Adjustment X
Females Only: Serum Pregnancy Test X X X X X X
Females Only: Estradiol & FSH (if required)3X
ECG X X4X4X X
Vital signs & weight (Pre -& Post -dialysis) X X X X4X X4X X
Clinical Chemistry X X X X X X
Hematology X X X X X X
Folate and Vitamin B12 X
Ferritin, transferrin, total iron ,, TSAT, UIBC X X
Pharmacokinetic/B iomarker Assessments X4X4
Hgb Maintenance Period 5=======================================
Adverse Events Assessment X6X6X6X6X4X X X X4X X
Review Concomitant Medications X X X X4X X X X4X X
1 All assessments should be done pre dialysis/predose except as noted.
2 Allowable time window 2 days EXCEPT Follow -up Visit which is 3 days.
3 As detailed in Inclusion Criteria.
4 Detailed timings for assessments on Acute Challenge Days are given in Table 4 .
5 From the end of Acute Challen ge 1 to the beginning of Acute Challenge 2.
6 Only SAEs assessed as related to study participation are collected at this visit. See Section 12.4 for additional details.
Table 4 Study  Procedures and Assessments on Acute Challenge Day s (Treatment Period Day 1 and Day  57)
2015N267693_04 CONFIDENTIA L
205665
121REVI SED TEXT, where text in strikethrough has been removed and bolded text has been added.  
(Note: The box for ABPM Assessment in the Post -Dialy sis column has been gray ed out as well as the X removed)
ProcedurePre-
DialysisPost -
DialysisPredoseTime (in hours relative to dosing)
0 0.5 1 2 3 4 6 8 12 16 24
HemoCue Hgb 1X X
IVWRS X
ABPM Assessment1, 3X =========================================================================================== 
Administer Study Treatment 1X
Serum Pregnancy Test1X
ECG1X X
Vital Signs and Weight1X X X X X
Clinical Chemistry X
Hematology X
Pharmacokinetic s4X X X X X X X X X X X
Erythropoiet in X X X X X X X X X X X
Endothelin -1 X X X X X X X
Nitric Oxide X X X X X X X
Asymmetric dimethylarginine X X X X X X X
Renin X X X X X X X
Angiotensin -II X X X X X X X
Noradrenalin X X X X X X X
Adverse Events Assessment1X X X X X X X X X X X
Review Concomitant Medications1X X
Initiate Hgb maintenance dosing2X
1 Procedures to be repeated if Acute Challenge 2 fails quality control criteria
2 Applies to Acute Challenge 1 o nly
3. Timing of ABPM measurements does not correlate with specified time points in Table 4.
4. PK to be drawn from daprodustat subjects only.
2015N267693_04 CONFIDENTIA L
[ZIP_CODE] 5
122Section [IP_ADDRESS] Time Period and Frequency for C ollecting AE and SAE information
REVI SED TEXT, where text in st rikethrough has been removed and bolded text has been 
added
Any SAEs assessed as related to study  participation (e.g., protocol -mandated 
procedures, invasive tests, or change in existing therap y) or related to a [COMPANY_004] 
product will be recorded from the time a subject consents to participate in the 
study  up to and including any  follow -up contact.
AEs will be collected from the start of washout (Week –4)study  treatment (Day  
1)until the follow -up contact (see Section [IP_ADDRESS]), at the timepoints specified in 
the Time and Events Table (Section 7.1).
Medical occurrences that begin prior to the start of washout study  treatment but 
after obtaining informed consent may  be recorded on the Medical History /Current 
Medical Conditions section of the CRF.
All SAEs will be recorded and reported to [COMPANY_004] within 24 hours, as indicated in 
Section 12.4.
Investigators are not obligated to activel y seek AEs or SAEs in former study 
subjects.  However, if the investigator learns of any  SAE, including a death, at any  
time after a subj ect has been discharged from the study , and he/she considers the 
event reasonabl y related to the study  treatment or study  participation, the 
investigator must promptly  notify  [COMPANY_004].
NOTE: The method of recording, evaluating and assessing causalit y of AEs and SAEs 
plus procedures for completing and transmitting SAE reports to [COMPANY_004] are provided in 
Section 12.4.
Section [IP_ADDRESS] Adverse Events of Special Interest 
REVI SED TEXT, where text in strikethrough has been removed and bolded text has been 
added
The inves tigator or site staff will be responsible for detecting, documenting and reporting 
any AEs of special interest or any  event that may  potentially  be one of the categories 
listed below (using preferred terms):
Death, myocardial infarction ( MI), stroke, heart failure, thromboembolic events,
venous thromboembolism, thrombosis of vascular access
Thrombosis and/or tissue ischemia secondary  to excessive ery thropoiesis
Cardiomy opath y
Pulmonary  artery  hypertension (see also Section [IP_ADDRESS] )
Cancer -related mortality  and tumor progression and recurrence
Esophageal and gastric erosions
Proliferative retinopathy , macular edema, choroidal neovascularization
2015N267693_04 CONFIDENTIA L
[ZIP_CODE] 5
123Exacerbation of rheumatoid arthritis
The results of an y investigation should be recorded in the relevant sections of the 
subject’s eCRF.
Section 7.3.5 Electrocardiogram (ECG)
REVI SED TEXT, where text in strikethrough has been removed and bolded text has been 
added
ECG measurements will be taken at the time points specified in the Time and Events 
Table (Section 7.1).  Full [ADDRESS_351826] in a supi[INVESTIGATOR_12251].  Heart rate ( HR), PR interval, QRS duration, and QT (uncorrected) interval will 
be measured.  QTcB will be calculated (machine -read or manually ).
At the Screening visit ( Week –4Wee k -8)  two additional ECGs are required if the 
initial ECG indicates prolonged QTc (see Section 5.3) using the automated or manually  
calculated QTcB value.  The average QTcB value of all three ECGs will be used to 
determine eligibility .  Additional details are provided in the SRM.
ECG data will be read locally .
All ECGs will be performed before measurement of vital signs and collection of blood 
samples for laboratory  testing.
Section 7.5.1 Ambulatory Blood Pressure Monitoring (ABPM)
REVI SED TEXT, where tex t in strikethrough has been removed and bolded text has been 
added
Blood pressure and pulse will be measured during Acute Challenge 1 and 2 through the 
use of an ambulatory  blood pressure monitoring device.  Subjects will wear the ABPM 
device for two sess ions during the stud y (i.e., Acute Challenge 1 and 2), occurring at Day  
1 (randomization) and at Day 57.  The ABPM device will be placed [ADDRESS_351827]’s arm until [ADDRESS_351828] -dosing.  The ABPM device will automatically  
calculate MAP.
The device planned for use in this study  is the Mortara Ambulo 2400 ; a specification 
sheet for this device can be found in Section 12.6.
After both Acute Challenge [ADDRESS_351829] Requirement Specification (PRS).  If the ABPM fails the 
2015N267693_04 CONFIDENTIA L
[ADDRESS_351830] of daprodustat on blood pressure.  Biomarkers selected will explore the renin -
angiotensin -aldosterone axis, the nitric oxide and endothelin axes, sodium retention and
HIF signalling.
Biomarkers may  include erythropoietin, nitric oxide (NO), as ymmetric dimethy arginine 
(ADMA), renin, angiotensin -II (1-8)and metabolites (1 -7 and 1 -5),endothelin -1 (ET -
1), and noradrenalin .Samples will be collected as specified in the Ti me and Events Table 
(Section 7.1).  The timing of the collections may  be adjusted on the basis of emerging 
pharmacokinetic or pharmacod ynamic (PD) data from this study or other new 
information in order to ensure optimal evaluation of the PD endpoints.
Section 9.4.[ADDRESS_351831] -HD/pre -Acute Chal lenge [ADDRESS_351832] Acute Challenge 2 and 1 will be anal yzed 
using ANCOVA with terms for treatment with 95% CI s and p -values provided for the 
treatment effect.
Section 9.4.3 Other Analyses
REVI SED TEXT, where text in strikethrough has been removed and bolded text has been 
added
The difference in SBP between pre -dose in Acute Challenge 1 and pre -dose in Acute 
Challenge 2 will be summarized by  [CONTACT_1570].  Simila r summaries of DBP ,and 
MAP, and HR will be performed.
2015N267693_04 CONFIDENTIA L
[ZIP_CODE] 5
125For each acute challenge, change from pre -challenge in SBP, DBP, MAP , and pulse HR
willbe summarized by  [CONTACT_288624].  I n addition, for each acute 
challenge ,SBP, DBP, MAP, and pulseHRwill be summarized by  [CONTACT_288640].  L ine graphs of this information will be provided by  [CONTACT_288641].
For each acute challenge, the concentration of erythropoietin, endothelin -1, nitric oxide, 
asymme tric dimethy larginine, renin, angiotensin -IIand metabolites ,and noradrenalin
will be summarized by  [CONTACT_288624].  L ine graphs of this 
information will be provided by  [CONTACT_288626].
Further statistical consi derations will be addressed in the RAP.
2015N267693_04 CONFIDENTIA L
205665
126Section 12.3 Appendix 3: Daprodustat Risk Assessment
REVI SED TEXT, where text in strikethrough has been removed and bolded text has been added
Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
Excessive erythropoiesis (polycythemia) leading 
to thrombosis and/or tissue ischemiaIn animal studies, excessive erythropoiesis attributed to 
daprodustat was associated with vascular congestion, 
microthrombi, and tissue ischemia in a number of organs.
Following review of clinical data received to date, this has not 
been identified as a safety concern for daprodustat.
Phase 2 dose -ranging studies, and associated statistical and 
exposure response modelling has informed Phase 3 dose
rationale, starting doses, dose levels, and dose adjustment 
scheme to optimize Hgb management. Specific eligibility criteria related to 
requirements for entry Hgb are detailed in 
Section 5
Hgb will be closely monitored throughout 
the dosing period as outl ined in the Time 
and Events Table (Section 7.1)
Specific guidance for discontinuation of 
daprodustat based on achieved Hgb is 
provided in Section [IP_ADDRESS]
Monitoring of emerging safety data by [CONTACT_288642], MI, stroke, heart fai lure congestive HF , 
thromboembolic events venous 
thromboembolism , thrombosis of vascular 
access at Hgb levels which are within the normal 
range (i.e. not polycythemic conditions)Marketed rhEPO/ESAs have been associated with an increased 
risk for death and serious cardiovascular events when used in 
patients with anemia of CKD.
Not observed at tolerated doses when 
hemoglobin/hematocrit within normal range for species.
The clinical data received to date are insufficient to 
conclude or refute this risk. Follow ing review of clinical data 
received to date, this has not been identified as a safety concern 
for daprodustat.Specific eligibility criteria related to CV risk 
are outlined in Section 5.3
Hgb will be closely monitored throughout 
the dosing period as outli ned in the Time 
and Events Table Section 7.1
Monitoring of emerging safety data by [CONTACT_288643], undesirable GI effects including emesis, 
abnormal feces and/or decreased food consumpt ion/body  Suspected GI bleeding or significant 
symptoms consistent with erosion should 
2015N267693_04 CONFIDENTIA L
205665
127Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
weight loss and stomach erosions/ ulcers with hemorrhage were 
observed with daprodustat.
In rodents rats stomach erosions were observed with 
intravenous and oral administration of daprodustat.
Stomach erosions/ulcers also reported in rats with 
marketed rhEPOs/ESAs.
Gender -averaged systemic exposure (AUC) at the no observed 
adverse effect levels (NOAEL) are 3.3 -fold (monkeys) and 737 -
fold (rats) above human exposure (25 mg daprodustat).
In clinical trials to date with daprodustat, mild -moderate GI signs 
and symptoms represent the most frequently reported adverse 
event, however causal association has not been established.
Following review of clinical data received to date, GI erosions 
have not been identified as a safety concern for daprodustat.be investigated diagnostically (i.e. 
endoscopic examination) as clinically 
warranted
Monitoring of emerging safety data by [CONTACT_288644] -related mortalit y and tumor progression 
and recurrenceMarketed reEPOs have been associated with increased risk of 
cancer related morbidity and mortality when used in patients 
with cancer.
Administration of 60mg/kg daprodustat to mice caused minimal 
increases in circulati ng VEGF while significant EPO increases 
were observed.
There were no daprodustat -related neoplastic findings in a 
2-year rat oral carcinogenicity study (lifetime study).
In clinical studies conducted to date, administration of 
daprodustat has been associat ed with:
Once daily administration: Specific eligibility criteria related to 
personal history of malignancy or subjects 
with complex kidney cyst are outlined in 
Section 5.3.
Stoppi[INVESTIGATOR_278797] 5.5.1 .
Monitoring of emerging safety data by [CONTACT_288631]
2015N267693_04 CONFIDENTIA L
205665
128Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
In studies up to 4 weeks duration, a dose -ordered 
increase in VEGF plasma concentrations at doses 
ranging from 10 to 150 mg. 
In studies up to 24 weeks duration at doses up to 
25mg, changes in VEGF plasma concentration w ere 
variable but similar relative to control.
Systemic EPO concentrations within the physiologic 
range.
Three times weekly administration:
In studies up to 4 weeks duration at doses of 10 to 30 
mg:
oDose dependent increases in plasma VEGF 
and EPO concentrat ions were observed.
oPre-dose concentrations of EPO and VEGF 
were near or below baseline indicating no 
accumulation of EPO or VEGF after three times 
weekly dosing.
In clinical studies with daprodustat up to 4 weeks duration, a 
dose -ordered increase in VEGF plasma concentrations , an 
angiogenic factor that has been implicated in tumor growth, was 
observed at doses ranging from 10 to 150 mg. In clinical studies 
up to 24 weeks duration at doses up to 25 mg, changes in 
VEGF plasma concentrations were variable but similar relative 
to control.
Following review of clinical data received to date, this has not 
been identified as a safety concern for daprodustat.
2015N267693_04 CONFIDENTIA L
205665
129Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
Pulmonary artery hypertension (PAH)A role for HIF -regulated pathways in the pathophysiology of 
PAH has been suggested based on well established effects of 
acute and chronic hypoxia in man on the pulmonary vasculature 
(vasoconstriction), and by [CONTACT_288645] t in decreased HIF degradation 
[Smith , 2006; Formenti , 2011].
There have been no histopathologic findings suggestive of PAH 
in pre -clinical safety studies (up to 13 -weeks duration in mice 
and dog, up to 26 -weeks in rat, and up to 39 -weeks in monkeys.
Acute hypoxic challenge (rats): Daprodustat produced increases 
in peak right ventricular pressure (PRVP) during acute hypoxia 
that were slightly higher than the vehicle control group.  These 
hypoxia -induced PRVP changes fall within the range of PRVP 
differences noted among non -treated rats.
Results from a clinical study of acute hypoxic challenge in 
healthy volunteers demonstrated that short -term (5 days) 
therapy with daprodustat 5mg or 100mg has no clinically 
significant effect on echocardiographically estimate d systolic 
pulmonary artery pressure (sPAP) under either normoxic or 
hypoxic conditions.
ECHO assessments performed in Phase 2b studies (24 weeks 
treatment duration) did not identify any clinically meaningful 
changes in sPAP in subjects not on dialysis. In hemodialysis 
subjects, mean absolute change from baseline in sPAP was 
similar for both treatment groups; however, there was a numeric 
imbalance (Daprodustat: 8 [7%]; Control 0) in subjects reaching 
the sPAP PCI (>20 mmHg increase from baseline). Regarding
this imbalance, there were a number of confounding factors in 
the study, most notably a 4.5:1 randomization scheme and  Monitoring of emerging safety data by [CONTACT_288631]
2015N267693_04 CONFIDENTIA L
205665
130Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
inconsistency in timing of ECHOs relative to dialysis day.  
Additionally, 2 of 3 subjects with resolution of sPAP on safety 
follow -up EC HOs had confounding conditions that could 
contribute to resolution other than discontinuation of study 
treatment; and there was no dose relationship for subjects 
meeting the sPAP PCI criterion. Overall, there is insufficient 
evidence to conclude a relation ship to treatment with 
daprodustat .
Following review of clinical data received to date, this has not 
been identified as a safety concern for daprodustat.
Cardiomyopathy Published dat a suggest that cardiac effects of HIF stabilization 
are likely a function of the mechanism, extent, and duration of 
the effects, and can range from protective to detrimental 
depending upon the specific model and experimental conditions 
utilized.
With lifet ime exposure to daprodustat in a 2 -year rat oral 
carcinogenicity study, an exacerbation of r atspontaneous, 
progressive cardiomyopathy (PCM) (focal myofiber 
degeneration/necrosis with inflammatory infiltrates) was 
observed at doses of 0.8 mg/kg/day and abov e, although 
total incidence and severity distribution within any 
daprodustat -group w erewithin historical control ranges .  
This is consistent with an equivocal threshold for 
exacerbation of spontaneous, progressive cardiomyopathy 
at 0.8 mg/kg/day which is also the threshold dose for 
observing increased Hct values in individual rats. Small 
increases in cardiac troponin in 6 month rat study were 
consistent with the background finding of spontaneous rodent 
cardiomyopathy.  There were no elevations observed in cardiac  Monitoring of emerging safety data by [CONTACT_288646]
2015N267693_04 CONFIDENTIA L
205665
131Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
troponin in 9 month monkey study with daprodustat.
Cardiomyopathy has not been associated with naturally 
occurring mutation in man which results in increased HIF 
stabilization.
ECHO assessments performed in phase 2b studies (24 weeks 
treatment dura tion) did not identify any clinically meaningful 
changes in LVEF for daprodustat.
Following review of clinical data received to date, this has not 
been identified as a safety concern for daprodustat.
Proliferative retinopathy, macular edema, 
choroidal neovascularizationIncreases in local (ocular) VEGF production with retinal 
neovascularization and macular edema observed in diabetic 
retinopathy and to choroidal leakage, edema and 
neov ascularization seen in age -related macular degeneration
Administration of 60 mg/kg daprodustat to mice caused minimal 
increases in circulating VEGF while significant EPO increases 
were observed.
Aside from congestion of retinal vessels and optic disc 
hyper emia secondary to markedly increased red cell mass, 
there were no ocular abnormalities observed in non -clinical 
studies. No ocular abnormalities were seen in non -clinical 
studies of up to 13 weeks duration in mice and dogs, 26 weeks 
in rats, and 39 -weeks i n monkeys.   
In clinical studies up to 4 weeks duration, a dose -ordered 
increase in VEGF plasma concentrations was observed at 
doses ranging from 10 to 150 mg administered once daily and 
from 10 to 30mg administered three times weekly . In studies Suspected p roliferative retinopathy, 
macular edema, choroidal 
neovascularization or symptoms 
consistent with these events should be 
investigated by [CONTACT_288647].
Monitoring of emerging safety data by [CONTACT_288631]
2015N267693_04 CONFIDENTIA L
205665
132Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
up to 24 weeks duration at doses up to 25 mg, changes in 
VEGF plasma concentrations were variable but similar relative 
to control.
Ophthalmologic assessments performed in phase 2b studies (24 
weeks treatment duration) did not identify any clinically 
meaningful cha nges in proliferative retinopathy, macular edema, 
or choroidal neovascularization with daprodustat.
Following review of clinical data received to date, this has not 
been identified as a safety concern for daprodustat.
Exacerbation of rhe umatoid arthritis In inflamed rheumatic joints, activation of HIF -related genes 
secondary to decreased oxygen and pro -inflammatory cytokines 
has been postulated to contribute to the neo -angiogenesis, 
proliferation and infiltration of rheumatoid synovial f ibroblasts 
[Westra , 2010; Muz, 2009].
No abnormalities seen in non -clinical studies conducted to date 
for daprodustat.
Following review of clinical data received to date, this has not 
been identified as a safety concern for daprodustat. Monitoring of emerg ing safety data by [CONTACT_288648] -drug interactions Co-administration of daprodustat with a strong CYP2C8 inhibitor 
increased the Cmax and AUC of daprodustat, 4 -and 19 -fold, 
respectively, while co -administration of a weak inhibit or 
increased the Cmax and AUC of daprodustat by 1.3 -and 1.5 -
fold, respectively. Although CYP2C8 induction studies were 
not performed, co -administration of daprodustat with an 
inducer of CYP2C8 (e.g., rifampin/rifampi[INVESTIGATOR_2513]) may decrease 
the exposure of dapro dustat. Co-administration of daprodustat with 
strong CYP2C8 inhibitors (e.g., 
gemfibrozil) and inducers (e.g., 
rifampin/rifampi[INVESTIGATOR_2513]) is not permitted as 
outlined in Section 6.11.3.
Co-administration of daprodustat with 
moderate CYP2C8 inhibitors (i.e., 
clopi[INVESTIGATOR_7745], teriflunomide, deferasirox) 
2015N267693_04 CONFIDENTIA L
205665
133Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
Although co-administration of daprodustat with strong 
inhibitors and inducers of CYP2C8 is prohibited , 
inadvertent co -administration may occur. Due to the known 
time delay in enhancing erythropoiesis by [CONTACT_288649], co -
administration with strong C YP2C8 inhibitors for up to 14 
days is not anticipated to lead to immediate marked 
increases in hemoglobin levels. Therefore, there is 
adequate time to change to alternate therapy that does not 
inhibit CYP2C8.
Additionally, as the time for maximum induction of CYP2C8 
occurs approximately 10 -14 days of dosing with rifampin 
(Brodie et al, 2013 and Ohnhaus et al, 1989), daprodustat 
systemic exposure will decrease over time which will result 
in a lag period before an effect on Hgb is recognized and is 
of clinica l concern.
Population PK analysis from completed Phase 2 studies 
suggests that co -administration of daprodustat with a moderate 
CYP2C8 inhibitor, leads to a ~ 2 -fold increase in AUC, with no 
clinically -significant increase in the measured Hgb response.
Daprodustat is an inhibitor of CYP2C8 in vitro, with an IC 50value 
of 21 µM.
Population PK analysis from completed Phase 2 studies 
suggests that co -administration of daprodustat with clopi[INVESTIGATOR_7745] 
(a moderate CYP2C8 inhibitor) leads to a ~ 2 -fold increase in 
AUC, with no clinically -significant increase in the measured Hgb 
response
Co-administration of daprodustat with potent BCRP inhibitors should be performed with caution. Specific 
guidance on the management of potential 
drug-drug interactions and concomitant 
medications is pro vided in Section 6.11.
Hgb will be closely monitored throughout 
the dosing period as outlined in the Time 
and Events Table (Section 7.1)
Specific guidance for discontinuation of 
daprodustat based on achieved Hgb is 
provided in Section [IP_ADDRESS] .
Monitoring o f emerging safety data by [CONTACT_288631].
2015N267693_04 CONFIDENTIA L
205665
134Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
has the potential to increase exposure of daprodustat.  Use of 
BCRP inhibitors (mostly weak) was found to result in a small
change in metabolite exposure (20% increase in AUC).
Daprodustat is an inhibitor of OATP1B1/1B3 in vitro, with IC 50
values of 6 µM and 11 µM, respectively. A clinical drug 
interaction study between 25 mg daprodustat with either a 
CYP2C8 substrate or an OA TP1B1/1B3 substrate showed that 
there is no PK interaction at this dose of daprodustat.
Other
rhEPO risks (Control) See risks outlined in table for daprodustat for excessive 
erythropoiesis (polycythemia) leading to thrombosis and/or 
tissue ischemia, death, MI, stroke, heart fai lure, 
thromboembolic events venous thromboembolism , thrombosis 
of vascular access, and for cancer -related mortality and tumor 
progression.
Uncontrolled hypertension
Pure red cell aplasiaSee mitigation strategies outlined in table 
for daprodustat for excessive 
erythropoiesis (polycythemia) leading to 
thrombosis and/or tissue ischemia; death, 
MI, stroke, heart failure, 
thromboembolic events venous 
thromboembolism , thrombosis of vascular 
access; and for cancer -related mortality 
and tumor progression.
Specif ic eligibility criteria related to blood 
pressure management are outlined in 
Section 5.
Specific eligibility criteria related to 
personal history of pure red cell aplasia 
are outlined in Section 5.[ADDRESS_351833] of Specific Changes
Title Page
A Short Title has been added:  
Short Title: Anemia S tudies in C KD: Erythropoiesis via a N ovel PHI D aprodustat –
Blood Pressure ( ASCEND -BP)
Medical Monitor Page
REVI SED TEXT, where text in strikethrough has been removed and bolded text has been 
added
Role NameDay Time Phone 
Number and email 
addressAfter -hours (Cell) 
NumberFax Number
Primary 
Medical 
Monitor, MD, 
PhDTel:
Secondary 
Medical 
Monitor MD, PhD
, MD, 
FACCTel:
Tertiary 
Medical 
Monitor MDTel:
Site and 
SAE 
Contact 
[CONTACT_2761]:GlaxoSmithKline
1250 S. Collegeville Roa d, UP4400
Collegeville, PA [ZIP_CODE]
Regulatory  Agency  Identify ing Number(s): IND Number: 101,291
Section 1 Protocol Synopsis for Study 205665
Objective(s)/Endpoint(s) Table
REVI SED TEXT, where text in strikethrough has been removed and bolded text has be en 
added.  (Within secondary endpoints, 4 weeks changed to 2 weeks)
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
2015N267693_04 CONFIDENTIA L
205665
136Objectives Endpoints
Primary
To compare the effect of daprodustat to epoetin 
alfa on blood pressure (BP) after Acute 
Challenge 2 (8 weeks of hemoglobin [Hgb] 
maintenance therapy)Average of systolic blood pressure (SBP) as 
measured by [CONTACT_288617] (ABPM) over [ADDRESS_351834] -dosing after 
8 weeks of Hgb maintenance therapy
Secondary
To compare the initial effect of daprodustat to 
epoetin alfa on BP after Acute Challenge 1 (4 2
weeks of erythropoiesis -stimulating agent [ESA]
washout)Average of SBP, diastolic blood pressure 
(DBP), mean arterial blood pressure (MAP), 
and heart rate (HR) as measured by [CONTACT_288618] [ADDRESS_351835] -dosing at Day 1
Area under the effect curve (AUEC )of SBP , 
DBP, MAP, and HR as measured by [CONTACT_288618] [ADDRESS_351836] -dosing at Day 1
To compare the effect of daprodustat to epoetin 
alfa on BP after Acute Challenge 2Average of DBP , MAP, and HR as measured 
by [CONTACT_288619] [ADDRESS_351837] -dosing at Day 57.
AUEC of SBP , DBP, MAP, and HR as 
measured by [CONTACT_288619] [ADDRESS_351838] -dosing at 
Day 57.
To estimate the initial effect of daprodustat on 
SBP, DBP, HRandMAP after Acute Challenge 
1 Change from pre -dose in SBP, DBP, HR, and 
MAP at each timepoint at Day 1
To characterize th e pharmacokinetics of 
daprodustatPlasma concentrations of daprodustat and 
metabolites and derived pharmacokinetic 
parameters including maximum observed 
concentration (Cmax ), time of occurrence of 
Cmax (tmax ), terminal phase half -life (t½)and 
area under c oncentration -time curve from time 
zero to 24 hours (AUC [0-24])as appropriate
To assess the safety and tolerability of 
daprodustatIncidence and severity of adverse events ( AEs)
and serious adverse events ( SAEs )
Reasons for discontinuation of study treatm ent
Absolute values and changes from baseline 
over time in laboratory parameters, 
electrocardiograms ( ECGs )and vital signs
Exploratory
To investigate the effect of daprodustat on 
vasoactive mediators of blood pressure Plasma concentrations and derived 
parameters including Cmax, tmax, t½ and 
AUC(0 -24) as appropriate (to include 
erythropoietin, endothelin -1, nitric oxide, 
asymmetric dimethylarginine, renin, 
angiotensin -IIand metabolites , and 
noradrenalin) 
Evaluate exposure -response relationships for 
daprodustat and: erythropoietin, endothelin -1, 
nitric oxide, asymmetric dimethylarginine, renin, Further models (as appropriate) to describe the 
daprodustat exposure -response relationship 
with: erythropoieti n, endothelin -1, nitric oxide, 
2015N267693_04 CONFIDENTIA L
205665
137Objectives Endpoints
angiotensin -II(and metabolites) , and 
noradrenalin asymmetric dimethylarginine, renin, 
angiotensin -II(and metabolites) , and 
noradrenalin. 
To summarize the effect of daprodustat and 
epoetin alfa on SBP after Acute Challenge 1 
and Acute Challenge 2AUEC of SBP as measured by [CONTACT_288619] [ADDRESS_351839] -dosing
To compare the effect of daprodustat to epoetin 
alfa on SBP after 8 weeks of Hgb maintenance 
therapy Change from Day 1 pre -dose SBP to Day 57
pre-dose
Section 1 Overall Design
REVI SED TEXT, where text in strikethrough has been removed and bolded text has been 
added .
This study  will be an open -label, randomized, parallel -group design in HD subjects with 
anemia associated with CKD.  There will be a 4-week screening period, a 42-week ESA 
washout period, an initial 24 -hour ac ute challenge , an 8-week Hgb -maintenance period, 
twoa second 24-hr acute challenge sand a follow -up visit 14±3 day s after completing 
treatment.  The stud y design is outlined below:
Section 1 Study Design
PREVI OUS IMAGE
REVI SED I MAGE
Week -2: ESA 
Washout
Day 1: Ran domize & 
Acute Challenge 1Day 29: Dose Adjustment  
(as n eeded)
Day 57: Acute Challenge 2Hgb Maintena nce Period 
Week 10: Follow -up
Screen ing: Between  7 and 30  
days prior to ESA Washout

2015N267693_04 CONFIDENTIA L
205665
138REVI SED TEXT, where text in strikethrough has been removed and bolded text has been 
added .
Subjects will be screened for eligibility  starting 4 weeks within 7 -30 days prior to the 
start of antheESA washout period (8 weeks prior to randomization/Day  1).
Subjects th at qualify  for enrolment will be washed out of their ESA for 42weeks; the 
start of the ESA washout should be timed to coincide as closel y as possible with their 
next planned ESA dose.   Subjects are enrolled once they enter the ESA washout 
period.
Followi ng the 42-week ESA washout, subjects will be randomized 1:1 and stratified by  
[CONTACT_278823], based on the average weekl y (for epoetins or darbepoetin) or monthly  
(for methoxy  polyethylene gl ycol (PEG) -epoetin beta) dosing during the 12 weeks prior 
to ESA washout (Week -4)as follows:
Low ESA dose: <100 IU/kg/week epoetin alfa OR <0.5 µg/kg/week darbepoetin 
OR <0.6 µg/kg/week methoxy  PEG -epoetin beta
High ESA dose: ≥100 IU/kg/week epoetin alfa OR ≥0.5 µg/kg/week darbepoetin 
OR 0.6 µg/kg/week methoxy  PEG -epoetin beta
On Day  1, subjects will be randomized and undergo Acute Challenge 1, a single dose 
challenge to compare the acute effects on BP of the hi ghest planned once -daily  
maintenance dose of daprodustat (24 mg) to the highest starting dose of epoetin alfa 
(100 IU/kg).  Subjects will have BP monitored for [ADDRESS_351840] 
serial blood sampling to assess the pharmacokinetics of daprodus tat and the time -course 
of various biomarkers.  Acute Challenge 1 will be started promptl yfollowing completion 
of a mid -week dial ysis session.
After completing Acute Challenge 1, all subjects will enter the 8 -week Hgb maintenance 
period where doses of eit her daprodustat or epoetin alfa will be administered and 
adjusted, as needed.
On Day  57, following the 8 -week Hgb maintenance period, subjects will undergo Acute 
Challenge 2; this challenge will, similar to Acute Challenge 1, involve assessing the 
effect o f daprodustat and epoetin alfa on SBPBPas assessed b y 24-hr ABPM 
measurement.  The subjects will be administered the same dose of either daprodustat or 
epoetin alfa that was given in Acute Challenge 1, and serial blood sampling will be 
performed to asses s both daprodustat pharmacokinetics ,and to characterize the time 
course of various biomarkers.  Acute Challenge [ADDRESS_351841] Requirement Specification (PRS).  If the ABPM fails the 
QC criteria following Acute Challenge 2, one additional Acute Challenge ma y be made 
inaftera subsequent, mid -week dial ysis visit [ADDRESS_351842]’s Hgb ≥11.5.  
Section [ADDRESS_351843] involvement is up to 1816 weeks (Screening to 
Follow -up) as described below:
Screening : Screening will occur at least one week prior to but not more than 
[ADDRESS_351844] 4 weeks prior to starting the ESA 
washout
ESA Washout : Subjects that meet eligibility  criteria will begin the 42-week ESA 
washout at Week -4.
oThis should be timed such that this da y occurs on the date that would have 
been the next scheduled dose of ESA (or as close as practicable).
oFor subjects with a three -times weekly  dialy sis schedule, this day  must not 
occur on the first dialy sis session of the week (e.g., if Monday -Wednesday -
Friday schedule, the study  visit cannot be on Monday ).
oFor subjects with a four -to five -times weekl y dialysis schedule, this day can 
be on an y hemodial ysis session of the week.
Randomization & Acute Challenge 1 (Day  1): Subjects will be randomized 1:[ADDRESS_351845]’s dialy sis session.
Hgb Maintenance Period : Subjects rand omized to daprodustat will start an 8 -week 
Hgb maintenance period based on a starting dose and dose adjustment algorithm.  
(See Section 6.4) Subjects randomized to epoetin alfa will begin an [ADDRESS_351846] ance with local 
labelling.
Acute Challenge 2 (Day  57): At the end of the [ADDRESS_351847]’s dialy sis session.
Follow -up: A Follow -up visit will be scheduled to occur 14 3 day s after 
completing treatment.
Section 1 Type and Number of Subjects
REVI SED TEXT, where text in strikethrough has been removed and bolded text has been 
added .
The study  will enroll hemodialy sis-dependent subjects with anemia associated with 
CKD currently  treated with an ESA.  Subjects with Hgb values of 9.08.5-11.5 g/dL, 
inclusive at both Screening and Day [ADDRESS_351848] .with total weekly  doses that varied by  
[CONTACT_23818] 50% during the 4 weeks prior to the Screening visit.
Approximately  124 subjects will be screened to achieve approximately  62 
randomiz ed and 50 evaluable subjects for a total of 25 evaluable subjects per 
treatment group.
If subjects prematurel y discontinue the study, additional replacement subjects may be 
randomized and assigned to the same treatment arm at the discretion of the Sponsor in 
consultation with the investigator
Section 1 Analysis
This section was bulleted for clarit y onl y.  No text was changed.
Section 2 Introduction
REVI SED TEXT, where text in strikethrough has been removed and bolded text has been 
added .
After the bull eted section:
Hypoxia -inducible factor (HIF) prol yl hydroxylase inhibitors (PHI s) are an emerging new 
class of agents under investigation for the treatment of anemia associated with CKD.  
These molecules stimulate ery thropoiesis through inhibition of HI F-prolyl hydroxylase 
domain enzy mes (PHD1, PHD2, PHD3).  This activity  results in the accumulation of 
HIFα transcription factors which leads to increased transcription of HIF -responsive 
genes, stimulating components of the natural response to hy poxia.  During hy poxia, the
PHD enzy mes are inhibited, resulting in the accumulation of unhy droxylated HIFα 
subunits, which dimerize with HIFβ subunits to effect affect the transcription of HIF -
responsive genes, including EPO and others involved in increasing ox ygen availability  
and utilization.  Other functions regulated b y HIF s include iron metabolism and 
utilization, angiogenesis, extracellular matrix metabolism, apoptosis, energy and glucose 
metabolism, vascular tone, cell adhesion, and motility  [Haase, 2013].
Daprodustat ([COMPANY_004]1278 863) is a small molecule, oral inhibiter of the HIF -PHD enzy mes 
which may  present several important advantages over other ESAs.  It is an oral 
medication and does not require cold -chain storage as do some ESAs, thus increasing 
ease of use for patients.  Mo reover, data indicate that daprodustat can effectively  raise 
2015N267693_04 CONFIDENTIA L
205665
141Hgb concentrations with lower EPO levels than those observed after administration of 
ESAs [Provenzano, 2011].  Because of the increased CV risk associated with raising Hgb 
concentrations through large increases in EPO levels [Pfeffer, 2009], daprodustat has the 
potential to raise Hgb with less CV risk than other ESAs. 
.
Section 2.1 Study Rationale
REVI SED TEXT, where text in strikethrough has been removed and bolded text has been 
added.
Current labelling for all ESAs includes a contraindicat ion in patients with uncontrolled 
hypertension, and increases in blood pressure (BP) and/or antihy pertensive medication 
use has been observed in several clinical trials with ESAs.  While the mechanism for this 
hypertensive effect is not known, hy pertension has been consistentl y observed in 
approximately  25 to 30% of CKD patients initiating ESA therapy , and varies between an 
average of approximately 5 to 8 mmHg in sy stolic blood pressure (SBP), and 4 to 6 
mmHg in diastolic blood pressure (DBP) reviewed in [K rapf, 2009 ].  Additionally , 
increases in BP are a well -recognized risk factor for CV events, in particular heart failure, 
ischemic stroke and m yocardial infarction [Rodriguez , 2014 ].  Finally , treatment with 
ESAs has been associated with increased risk of major CV events including m yocardial 
infarction, stroke and death.
Daprodustat has been shown to effectivel y raise and manage Hgb levels in subjects with 
CKD with lower levels of EPO than the ESAs.  As the hy pertensive effects of ESAs 
appear dose -related [ Abraham , 1991 ], there is the potential that daprodustat can treat 
anemia in CKD patients without the hy pertensive effects observed with the ESAs.  This 
study  will use two 24- hr Acute Challenges to compare the effect of daprodustat to rhEPO 
on BP as measure d by [CONTACT_288650] (ABPM) following both a 4 
2-week ESA washout period (Acute Challenge 1) and an 8- week Hgb -maintenance 
period (Acute Challenge 2).
TheTherefore, the purpose of this study  is to compare the effects on blood pressure of 
daprodustat to epoetin alfa in hemodialy sis-dependent (HD) subjects with anemia 
associated with CKD.  The study  will also assess various biomarkers associated with 
blood pressure ph ysiology  that may  provide insight into the mechanism(s) of the 
hyperten sive effects associated with ESAs .
Section 2.2 Brief Background
A reference was added here. (Holdstock 2016 )
Section 3 Objectives and Endpoints
REVI SED TEXT, where text in strikethrough has been removed and bolded text has been 
added.  (Within secondar y endpoints, 4 weeks changed to 2 weeks)
CCI
CCI
CCI
CCI
2015N267693_04 CONFIDENTIA L
205665
142Objectives Endpoints
Primary
To compare the effect of daprodustat to epoetin 
alfa on blood pressure (BP) after Acute 
Challenge 2 (8 weeks of hemoglobin [Hgb] 
maintenance therapy)Average of systolic blood pressure (SBP) as 
measured by [CONTACT_288617] (ABPM) over [ADDRESS_351849] -dosing after 
8 weeks of Hgb maintenance therapy
Secondary
To compare the initial effect of daprodustat to 
epoetin alfa on BP after Acute Challenge 1 ( 4 2
weeks of erythropoi esis-stimulating agent [ESA]
washout)Average of SBP, diastolic blood pressure 
(DBP), mean arterial blood pressure (MAP), 
and heart rate (HR) as measured by [CONTACT_288618] [ADDRESS_351850] -dosing at Day 1
Area under the effect curve (AUEC )of SBP , 
DBP, MAP, and HR as measured by [CONTACT_288618] [ADDRESS_351851] -dosing at Day 1
To compare the effect of daprodustat to epoetin 
alfa on BP after Acute Challenge 2Average of DBP , MAP, and HR as measured 
by [CONTACT_288619] [ADDRESS_351852] -dosing at Day 57.
AUEC of SBP , DBP, MAP, and HR as 
measured by [CONTACT_288619] [ADDRESS_351853] -dosing at 
Day 57.
To estimate the initial effect of daprodustat on 
SBP, DBP, HRandMAP after Acute Challenge 
1 Change from pre -dose in SBP, DBP, HR, and 
MAP at each timepoint at Day 1
To characterize the pharmacokinetics of 
dapro dustatPlasma concentrations of daprodustat and 
metabolites and derived pharmacokinetic 
parameters including maximum observed 
concentration (Cmax ), time of occurrence of 
Cmax (tmax ), terminal phase half -life (t½)and 
area under concentration -time curve fro m time 
zero to 24 hours (AUC [0-24])as appropriate
To assess the safety and tolerability of 
daprodustatIncidence and severity of adverse events ( AEs)
and serious adverse events ( SAEs )
Reasons for discontinuation of study treatment
Absolute values and cha nges from baseline 
over time in laboratory parameters, 
electrocardiograms ( ECGs )and vital signs
Exploratory
To investigate the effect of daprodustat on 
vasoactive mediators of blood pressure Plasma concentrations and derived 
parameters including Cmax, t max, t½ and 
AUC(0 -24) as appropriate (to include 
erythropoietin, endothelin -1, nitric oxide, 
asymmetric dimethylarginine, renin, 
angiotensin -IIand metabolites , and 
noradrenalin) 
Evaluate exposure -response relationships for 
daprodustat and: erythropoieti n, endothelin -1, 
nitric oxide, asymmetric dimethylarginine, renin, Further models (as appropriate) to describe the 
daprodustat exposure -response relationship 
with: erythropoietin, endothelin -1, nitric oxi de, 
2015N267693_04 CONFIDENTIA L
205665
143Objectives Endpoints
angiotensin -II(and metabolites) , and 
noradrenalin asymmetric dimethylarginine, renin, 
angiotensin -II(and metabolites) , and 
noradrenalin. 
To summarize the effect of daprodustat and 
epoetin alfa on SBP after Acute Challenge 1 
and Acute Challenge 2AUEC of SBP as measured by [CONTACT_288619] [ADDRESS_351854] -dosin g
To compare the effect of daprodustat to epoetin 
alfa on SBP after 8 weeks of Hgb maintenance 
therapy Change from Day 1 pre -dose SBP to Day 57
pre-dose
Section 4.1 Overall Design
REVI SED TEXT, where text in strikethrough has been removed and bolded te xt has been 
added.  
This study  will be an open -label, randomized, parallel -group design in HD subjects with 
anemia associated with CKD.  There will be a 4-week screening period, a 42-week ESA 
washout period, an initial 24 -hour Acute C hallenge , an 8-week Hgb-maintenance 
period, twoa second 24-hr Acute C hallenge sand a follow -up visit 14±3 day s after 
completing treatment.  The study  design is outlined in Figure 1.
Figure 1
PREVI OUS IMAGE
REVI SED I MAGE
Week -2: ESA 
Washout
Day 1: Ran domize & 
Acute Challenge 1Day 29: Dose Adjustment  
(as n eeded)
Day 57: Acute Challenge 2Hgb Maintena nce Period 
Week 10: Follow -up
Screen ing: Between  7 and 30  
days prior to ESA Washout

2015N267693_04 CONFIDENTIA L
205665
144Subjects will be screened for eligibility  startin g 4 weeks within 7 -30 days prior to the 
start of antheESA washout period (8 weeks prior to randomization/Day  1).
Subjects that qualify  for enrolment will be washed out of their ESA for 42weeks; the 
start of the ESA washout should be timed to coincide as closel y as possible with their 
next planned ESA dose.   Subjects are enrolled once they enter the ESA washout 
period.
Following the 42-week ESA washout, subjects will be randomized 1:1 and stratified by  
[CONTACT_278823], based on the average weekl y (for epoetins or darbepoetin) or monthly  
(for methoxy  polyethylene gl ycol (PEG) -epoetin beta) dosing during the 12 weeks prior 
to ESA washout (Week -4)as follows:
Low ESA dose: <100 IU/kg/week epoetin alfa OR <0.5 µg/kg/week darbepoetin 
OR <0.6 µg/kg/week meth oxy PEG -epoetin beta
High ESA dose: ≥100 IU/kg/week epoetin alfa OR ≥0.5 µg/kg/week darbepoetin 
OR 0.6 µg/kg/week methoxy  PEG -epoetin beta
On Day  1, subjects will be randomized and undergo Acute Challenge 1, a single dose 
challenge to compare the acute ef fects on BP of the highest planned once -daily  
maintenance dose of daprodustat (24 mg) to the highest starting dose of epoetin alfa 
(100 IU/kg).  Subjects will have BP monitored for [ADDRESS_351855] 
serial blood sampling to assess the pharmac okinetics of daprodustat and the time -course 
of various biomarkers.  Acute Challenge 1 will be started promptl yfollowing completion 
of a mid -week dial ysis session.
After completing Acute Challenge 1, all subjects will enter the 8 -week Hgb maintenance 
period where doses of either daprodustat or epoetin alfa will be administered and 
adjusted, as needed.
On Day  57, following the 8 -week Hgb maintenance period, subjects will undergo Acute 
Challenge 2; this challenge will, similar to Acute Challenge 1, involve a ssessing the 
effect of daprodustat and epoetin alfa on SBPBPas assessed b y 24-hr ABPM 
measurement.  The subjects will be administered the same dose of either daprodustat or 
epoetin alfa that was given in Acute Challenge 1, and serial blood sampling will be 
performed to assess both daprodustat pharmacokinetics ,and to characterize the time 
course of various biomarkers.  Acute Challenge [ADDRESS_351856] Requirement Specification (PRS).  If the ABPM fails the 
QC criteria following Acute Challenge 2, one addition al Acute Challenge may  be made  
inaftera subsequent, mid -week dial ysis visit [ADDRESS_351857]’s Hgb ≥11.5.  See 
Section [IP_ADDRESS] for guidance.
Section 4.[ADDRESS_351858] involvement is up to 1816 weeks (Screening to Foll ow-up) 
as described below:
Screening : Screening will occur at least one week prior to but not more than 
[ADDRESS_351859] 4 weeks prior to starting the ESA 
washout
ESA Washout : Subjects that meet eligibility  criteria will begin the 42-week ESA 
washout at Week -4.
oThis should be timed such that this day  occurs on the date that would have 
been the next scheduled dose of ESA (or as close as practicable).
oFor subjects with a three -times weekly  dialy sis schedule, this day  must not 
occur on the first dialy sis session of the week (e.g., if Monday -Wednesday -
Friday  schedule, the study  visit cannot be on Monday ).
oFor subjects with a four -to five -times weekl y dialysis schedule, this day can 
be on an y hemodial ysis session of the week.
Randomiz ation & Acute Challenge 1 (Day  1): Subjects will be randomized 1:[ADDRESS_351860]’s dialy sis session.
Hgb Maintenance Period : Subjects randomized to daprodustat will start an 8 -week 
Hgb maintenance period based on a starting dose and dose adjustment algorithm.  
(See Section 6.4) Subjects randomized to epoetin alfa will be gin an 8 -week Hgb 
maintenance period where Hgb will be managed in accordance with local 
labelling.
Acute Challenge 2 (Day  57): At the end of the [ADDRESS_351861]’s dialy sis session.
2015N267693_04 CONFIDENTIA L
205665
146Follow -up: A Follow -up visit will be scheduled to occur 14 3 day s after 
completing treatment.
Section 4.3 Type and Number o f Subjects
REVI SED TEXT, where text in strikethrough has been removed and bolded text has been 
added.
The study  will enroll hemodialy sis-dependent subjects with anemia associated with CKD 
currentl y treated with an ESA.  Subjects with Hgb values of 9.08.5to11.5 g/dL, 
inclusive at both Screening and Day [ADDRESS_351862] .with total weekl y doses that varied by [CONTACT_288651] 50% during the 4 weeks prior to the Screening visit.
Approx imately  124 subjects will be screened to achieve approximately  62 randomized 
and 50 evaluable subjects for a total of 25 evaluable subjects per treatment group.
If subjects prematurel y discontinue the study, additional replacement subjects may be 
randomize d and assigned to the same treatment arm at the discretion of the Sponsor in 
consultation with the investigator .
Section 4.4 Design Justification
REVI SED TEXT, where text in strikethrough has been removed and bolded text has been 
added.  Note: no change was made to Figure 2 at the end of this section.
This study  will be an open -label, multi -center, randomized, parallel -group design in HD 
subjects with anemia associated with CKD.  There will be a 4-week screening period, a 4
2-week ESA washout period, an 8-week Hgb -maintenance period including two 24 -hr 
acute challenges and a follow -up visit 14 ± 3 day s after completing treatment.
It is preferred that no changes are made to estimated dry  weight (EDW) and 
antihy pertensive medications while the subject is pa rticipating in this study.  Subjects 
will remain in the study  regardless of an y changes.
This will be an open -label study  since the primary  endpoint (SBP by  [CONTACT_44117]) is an 
objective measure and unlikely  to be influenced b y knowledge of the treatment 
received.   Additionally , an open label design will facilitate the conduct of the 
interim analy sis.  Lastly, blinding of an injectable comparator and oral study 
drug is impractical in this case.
A 4-week screening period will be used to assess Hgb stability  in order to 
minimize the potential for enrolling patients with highl y variable Hgb despi[INVESTIGATOR_288607].
A 4-week ESA washout will be used as this is the timeframe which was used in a 
published study  which demonstrated an acute increase in MAP following IV 
admini stration of epoetin alfa as measured using ABPM over a 24 -hr period 
starting from the end of the dialy sis session following a single dose of epoetin 
alfa(both subcutaneous and intravenous) [ Kang , 1998].  The results of the 
2015N267693_04 CONFIDENTIA L
205665
147published MAP assessments are dem onstrated in Figure 2.  Of note, inInaour
previous daprodustat study  (PHI113633) experience in Phase 2b , HD -dependent 
subjects with anemia associated with CKD were administered placebo for 4 
weeks, with a mean decrease of between 0.61 and 0.72 g/dL in H gb.  No subject 
met either the Hgb stoppi[INVESTIGATOR_288588].  Therefore, 
the risk of a subject meeting Hgb withdrawal criteria is considered low during this 
phase.
The Acute Challenge days have been designed to be consistent with t he 
methodology  used in a published study  [Kang , 1998 ](See Figure 2) .  Although 
the goal of the current study  is to attempt to replicate the blood pressure results 
from the IV administration of epoetin alfa in thethat publication by. [Kang , 
1998], in order to compare the response to daprodustat, SBP will be the primary  
endpoint rather than MAP since SBP is the overall best predictor of future 
cardiovascular risk in a hypertensive population, and MAP is biased toward DBP 
[Agarwal , 201 5].
Acute Challenge 1 wi ll assess whether there are any  immediate effects of 
daprodustat or epo etin alfa on blood pressure.  This assessment will also 
determine the abilit y to replicate the findings in the published study and will 
provide information for an interim analy sis (See Section 9.3.2 ).
The 8 -week Hgb Maintenance Phase will replicate the management procedures 
planned for the Phase 3 studies as described in Section 6.4.  The duration was 
chosen to be consistent with the timeframe in which the hy pertensive effects of 
ESAs ha ve been observed (i.e., 4 to 8 weeks) [ Samtleben , 1988 ].
Acute Challenge 2 will again assess the effects of daprodustat or epoetin alfa on 
BP following 8 weeks of anemia treatment utilizing the same assessment as Acute 
Challenge 1.  The purpose of Acute Ch allenge 2 is to assess any  BP effects of 
ESA administration that may  be potentiated (or possibly  diminished) following 
long-term administration of an ESA .
Section 4.5 Dose Justification
REVI SED TEXT, where text in strikethrough has been removed and bolde d text has been 
added.
Daprodustat Treatment Group
Acute Challenge 1 & 2 : The dose to be used for this group will be the highest planned 
maintenance dose for a once -daily regimen (i.e., 24 mg) for treatment of anemia 
associated with CKD.  In a previous GlaxoSmithKline ([COMPANY_004] )study  (PHI112843 ), a 
single, oral dose of [ADDRESS_351863] been defined at Week 8 Day 5 7to minimize marked increases in 
Hgb.
Hgb Maintenance Phase : Starting doses of daprodustat will be based on Hgb levels, 
2015N267693_04 CONFIDENTIA L
[ADDRESS_351864] dose adjustment, and are based on modelling and simulation 
of the dose -Hgb response results from Phase 2 studies.  Additionally , Hgb levels will 
be assessed at 2 and 6 weeks after start of the maintenan ce period with specific Hgb 
stoppi[INVESTIGATOR_3418] (See Table 2).
Epoetin alfa Treatment Group
Acute Challenge 1 & 2 : The dose to be used for this group will be the highest labelled 
starting dose for epoetin alfa (100 U/kg, IV) which is consistent with the epoe tin alfa 
dose used in the published study  where an acute increase in MAP with rhEPO was 
observed [ Kang , 1998 ].  As subjects in this group will have been washed off ESA for 
[ADDRESS_351865] been defined at Week 8
Day 57 to minimize marked increases in Hgb (See Table 2).
Hgb Maintenance Phase : The d osage of epoetin alfa during the 8 -week Hgb 
maintenance phase will be adjusted (if necessary ) according to the local labelling in 
order to manage the subject’s Hgb within the target range (10.0 -11.0 g/dL).  I n a 
previous study  ([COMPANY_004] Study  PHI113633), HD sub jects that had a similar 4-week ESA 
washout were initiated on a mean dose of rhEPO of 89 IU/kg/week (n=39), with the 
dose increased to a mean of 102 IU/kg/week 4 weeks later .
Section 5.1 Hemoglobin Stability Criteria
REVI SED TEXT, where text in strikethr ough has been removed and bolded text has been 
added.  Note: Figure 3 has been removed from the end of this section.  There is no 
revised figure to insert.  As some values were already  in bold, they  are underlined below 
to indicate addition of this text.
Entry  into the study  requires a stable Hgb between 9.08.5and 11.5 g/dL, inclusive .  
This is confirmed from an average of three twoHgb values obtained during atthe 
Sscreening Visit and Washout Visit, with both values between 8.5 and 11.5 g/dL.   
period a t Weeks -8, -6 and -4These will be taken via a validated point -of-care device to 
measure Hgb (i.e., HemoCue )prior to the dialysis session of the day . as outlined in 
Figure 3.   The value at the Washout Visit must not have decreased by [CONTACT_726] 1.0 
g/dL f rom the Screening Visit value. For subjects with a three -times weekly  dialysis 
schedule, Hgb values must not be obtained on the first dialysis session of the week (e.g., 
if Monday -Wednesday -Friday  schedule, the study  visit cannot be on Monday ).  For 
subje cts with a four -to five -times weekl y dial ysis schedule, Hgb values can be obtained 
on any  hemodial ysis session of the week.
Section 5.[ADDRESS_351866] will be eligible for inclusion in this study onl y if all of the following criteria 
apply :
AGE
1.   ≥[ADDRESS_351867] AND DIAGNOSIS INCLUDING DISEASE SEVERITY
2.   Hemoglobin: Stable Hgb 9.08.5to 11.5 g/dL inclusive (See Section 5.1).
3.   Dialysis frequency: On hemodialy sis (HD, hemofiltration or hemodiafiltration) 
three -to five -times weekly  for at least 4 weeks prior to screening .
4.  Dialysis adequacy : A single pool Kt/V urea 1.2 based on a historical value obtained 
within the 3 months prior to screening in order to ensure the adequacy  of dialy sis.  If 
Kt/V urea is not available, then an average of the last [ADDRESS_351868] ion ratio 
(URR) is at least 65%.  NOTE : Only  needs confirming at screening.
5.   ESA dose treatment :Treated with the same anESA (epoetins or their biosimilars, 
darbepoetin, or methoxy  PEG -epoetin beta ) with total weekl y dose varying by  [CONTACT_288651] 50% d uring the for at least 4 weeks prior to screening.
6.  Iron replacement therapy : Subjects may  be on stable maintenance oral or IV 
(≤100 mg/week) iron supplementation.  If subjects are on oral or IV iron, then doses 
must be stable for the 4 weeks prior to screening through Day  1Washout .
7.  Estimated Dry Weight (EDW):   Mid-week averag e weight gain between dial ysis 
treatments <5% as assessed pre -and post -dialysis from screening to Washout Day 1.
8.Antihypertensive Medication: Meets the following criteria:
On at least 2 1different antihy pertensive medication sof different classes
[excludi ng diuretics]
AND
On that same medication and the same dose for at least [ADDRESS_351869] will not be eligible for inclusion in this study  if an y of the following criteria 
apply :
2015N267693_04 CONFIDENTIA L
205665
150CKD -RELATED CRITERIA
1.Dialysis modality : Planned ch ange from HD to peritoneal dialy sis within the study  
time period, or on home dialy sis.
2.Renal transplant : Planned for kidney  transplant within the 18 16weeks following 
the Screening visit.
3.High ESA dose : An epoetin alfa dose of ≥360 IU/kg/week IV or ≥250 I U/kg/week 
subcutaneous (SC), or darbepoetin dose of ≥1.8 µg/kg/week IV or SC, or methoxy  
PEG -epoetin beta dose of 2.2 µg/kg/week within the 8 weeks prior to screening 
through Week -4.
4.Mircera : Planned or recorded a dministration of Mircera ( methoxy  PEG -epoetin beta ) 
within the 4 weeks prior to start of the W washout visit at Week -4.
CARDIOVASCULAR DISEA SE-RELATED CRITERIA
5.Myocardial infarction or acute coronary syndrome: Within the 4 weeks 3 months
prior to screening through Day  1Washout.
6.Stroke or trans ient ischemic attack: Within the 4 weeks 3 months prior to 
screening through Day  1Washout.
7.Heart failure: Chronic Class I V heart failure ( HF), as defined b y the [LOCATION_001] 
Heart Association (NYHA) functional classification sy stem diagnosed prior to 
screenin g through Day  1Washout.
8.QT interval corrected for heart rate using Bazett’s formula (QTcB ):QTcB >500 
msec, or QTcB >530 msec in subjects with Bundle Branch Block.  There is no QTc 
exclusion for subjects with a predominantly  paced rhy thm.
9.Current uncontro lled hypertension: Resting s ystolic blood pressure >160 mmHg; 
or diastolic blood pressure >100 m mHg at screening.
10.Atrial Fibrillation: Presence of atrial fibrillation or a history  of atrial fibrillation .
OTHER DISEASE -RELATE D CRITERIA
11.Inflammatory diseas e:Active chronic inflammatory  disease that could impact 
erythropoiesis (e.g., scleroderma, s ystemic lupus ery thematos us, rheumatoid arthritis, 
celiac disease) diagnosed prior to screening through Day  1Washout.
12.Aplasias: History  of bone marrow aplasia or pure red cell aplasia.
13.Other causes of anemia: Pernicious anemia, thalassemia major, sickle cell disease or 
myelodysplastic s yndrome.
14.Liver disease (any one of the following):
Alanine transaminase (ALT) >2x upper limit of normal (ULN) (screening only )
Bilirubin >1.5xUL N (screening only )
NOTE: Isolated bilirubin >1.5xUL N is acceptable if bilirubin is fractionated and 
direct bilirubin <35%.
Current unstable liver or biliary  disease per investigator assessment, generally  
defined b y the presence of ascites, enc ephalopathy, coagulopath y, 
hypoalbuminaemia, esophageal or gastric varices, persistent jaundice, or cirrhosis.
NOTE: Stable chronic liver disease (including asymptomatic gallstones, chronic 
2015N267693_04 CONFIDENTIA L
205665
151hepatitis B or C, or Gilbert’s sy ndrome) are acceptable if subject otherwise meets 
entry  criteria.
15.Major surgery: Major surgery  (excluding vascular access surgery ) within the 8 
weeks 3months prior to screening through Day  1Washout ,or planned during the 
study .
16.Transfusion: Blood transfusion within the 8weeks prior to screening through Day  1
Washout , or an anticipated need for blood transfusion during the stud y.
17.Gastrointestinal (GI) bleeding: Evidence of actively  bleeding gastric, duodenal, or 
esophageal ulcer disease ORclinically  significant GI bleeding within the 4 8 weeks
prior to screening through Day  1Washout .
18.Acute Infection: Clinical evidence of acute infection or history  of infection requiring 
intravenous (IV) antibiotic therap y within the 48weeks prior to Screening through 
Day 1Washout.
NOTE: IV antibiotic s as prophy laxis are allowed.
19.Malignancy: History  of malignancy  within the two y ears prior to screening through 
Day [ADDRESS_351870] (e.g., Bosniak Category  IIF, III or IV) 3 cm.
NOTE: ONL Y exception is localized squamous cell or basal cell carcinoma of the 
skin that has been definitively  treated more than 4 weeks prior to screening.
20.Blood Pressure Measurement: Subjects with an upper arm diameter which cannot 
be measured b y oscillometer/ sph ygmomanometer cuff ORfor whom blood pressure 
cannot be measured in the opposite arm of current vascular access.
2015N267693_04 CONFIDENTIA L
205665
152CONCOMITANT MEDICATIONS
21.Severe allergic reactions: History  of severe allergic or anaphy lactic reactions or 
hypersensitivity  to excipi[INVESTIGATOR_190845] t he investigational product (see Daprodustat IB for 
list of excipi[INVESTIGATOR_840] [ GlaxoSmithKline Document Number RM2008/[ZIP_CODE]/07 ]).
22.Drugs and supplements: Use of an y prescription or non -prescription drugs or 
dietary  supplements that are prohibited (See Section 6.11. 3), from screening until Day 
1Washout .
23.Prior investigational product exposure : The subject has participated in a clinical 
trial and has received an experimental investigational product within the [ADDRESS_351871] 
prior to screening, whichever is longer.
GENERAL HEALTH RELATED CRITERIA
24.Other conditions: Any other condition, clinical or laboratory  abnormality , or 
examination finding that the investigator considers would put the s ubject at 
unacceptable risk, which may  affect study  compliance or prevent understanding of the 
aims or investigational procedures or possible consequences of the stud y.
25.Females ONLY: Subject is pregnant [as confirmed by  a positive serum human 
chorionic gon adotrophin (hCG) test for females of reproductive potential (FRP) 
only], subject is breastfeeding, or subject is of reproductive potential and does not 
agree to follow one of the contraceptive options listed in the L ist of Highl y Effective 
Methods for Avoi ding Pregnancy  in Section 12.4.7 .
DIAGNOSTIC ASSESSMENTS AND OTHER CRITERIA
26.Vitamin B 12:At or below the lower limit of the reference range (may  rescreen in a 
minimum of 8 weeks , following treatment ).
27.Folate: <2.0 ng/mL (4.5 nmol/L) (may  rescreen in a mi nimum of 4 weeks , following 
treatment ).
28.Ferritin: <100 ng/mL
29.Transferrin saturation (TSAT): <20%.
Section 5.4 Screening/Baseline/Run -in Failures
REVI SED TEXT, where text in strikethrough has been removed and bolded text has been 
added.  
Screen failure s are defined as subjects who consent to participate in the clinical trial but 
who never enter the washout period are never subsequently randomized .  In order to 
ensure transparent reporting of screen failure subjects, meet the Consolidated Standards 
of Re porting Trials (CONSORT) publishing requirements, and respond to queries from 
Regulatory  authorities, a minimal set of screen failure information is required including 
Demograph y, Screen Failure details, Eligibility Criteria, and Serious Adverse Events (se e 
Section [IP_ADDRESS] ).
Section 5.5 Withdrawal/Stoppi[INVESTIGATOR_288608], where text in strikethrough has been removed and bolded text has been 
added.  
2015N267693_04 CONFIDENTIA L
[ADDRESS_351872] may  withdraw from the study  at any  time at his/her own request, or may  be 
withdrawn at an ytime at the discretion of the investigator for safety , behavioral or 
administrative reasons.  If a subject withdraws from the study , he/she may  request 
destruction of an y samples taken, and the investigator must document this in the site 
study  records .
Ifa decision is made to withdraw a subject, he/she should return to the clinic as soon as 
possible to complete the Earl y Withdrawal assessments .  The andFollow -up visit should 
be performed 14 ± [ADDRESS_351873] dose. (see Time and Events Table Section 7.1).
In all cases, the reason for withdrawal from the study  and date of the last dose of study  
treatment will be recorded in the eCRF.
Section [IP_ADDRESS] Hemoglobin Stoppi[INVESTIGATOR_288608], where text in strikethrough has been removed and bolded text ha s been 
added.  
[COMPANY_004] will supply  a point -of-care Hgb anal yzer (HemoCue) to each site for rapid and 
convenient monitoring of Hgb levels and to ensure consistency  of Hgb measurements 
across sites participating in the study .
Blood samples for measurement of H gb concentrations via HemoCue will be collected 
(Table 23) and recorded in the eCRF.  The table below summarizes the Hgb values and 
corresponding a ction to be taken at each visit. If the subject meets the below 
condition(s), then IP must be permanently st opped.
Table 2 Hgb Stoppi[INVESTIGATOR_288602] 2 & Day 1 (Prior to Acute Challenge 1)
Hgb at Visit Action
<7.5Repeat HemoCue assessment on the same sample at same study visit to confirm; take average of [ADDRESS_351874] from the study .
7.5-<11.5decrease of 2.0 in Hgb 
over 2 weeksRepeat HemoCue assessment on the same sample at same study visit 
to confirm; take average of [ADDRESS_351875] from the study.
increase of 1.03in Hgb 
over 2 weeksRepeat HemoCue assessment on the same sample at same study visit 
to confirm; take average of [ADDRESS_351876] 
from the study.
11.5Repeat HemoCue assessment on the same sample at same study visit to confirm; take average of [ADDRESS_351877] from the study avoid dosing and continue 
washout for one additional week.  Progress with Acute Challenge 1 one week later if Hgb has 
decreased below 11.5; if not then withdraw subject from study.
2015N267693_04 CONFIDENTIA L
205665
154Days 15, 29, & 43
Hgb at Visit Action
<7.5Repeat HemoCue assessment on the same sample at same study visit to confirm; take average of [ADDRESS_351878] from the study.
7.5-<12.0decrease of 2.0 in Hgb 
over 2 weeksRepeat HemoCue assessment on the same sample at same study visit 
to confirm; take average of [ADDRESS_351879] from the study.
increase of 1.03in Hgb 
over 2 w eeksRepeat HemoCue assessment on the same sample at same study visit 
to confirm; take average of [ADDRESS_351880] from the study.
12.0Repeat HemoCue assessment on the same sample at s ame study visit to confirm; take average of [ADDRESS_351881] from the study.
Day 57 (Prior to Acute Challenge 2)
Hgb at Visit Action
<7.5Repeat HemoCue assessment on the same sample at same study visit to confirm; take average of [ADDRESS_351882] from the study.
7.5-<11.50decrease of 2.0 in Hgb 
over 2 weeksRepeat HemoCue assessment on the same sample at same stu dy visit 
to confirm; take average of [ADDRESS_351883] from the study.
increase of 1.0 3in Hgb 
over 2 weeksRepeat HemoCue assessment on the same sample at same study visit 
to confirm; take average of [ADDRESS_351884] from the study.
11.50Repeat HemoCue assessment on the same sample at same study visit to confirm; take average of [ADDRESS_351885] and Other Study Treatment
REVI SED TEXT, where text in strikethrough has been removed and bolded text has been 
added.  
The term ‘stud y treatment’ is used throughout the protocol to describe an y combination 
of products received b y the subject as per the protocol design.  Study  treatment may  
therefore refer to the individual study  treatments or the combination of those study  
treatments.
Product name: [CONTACT_288659]: Tablet
Unit dose strength(s)/Dosage level(s): 1 mg, 2 mg, 4 mg, 6 mg, 8 mg, 10 mg tablet strengths/ 1 mg, 2 mg, 4 mg, 
6 mg, 10 mg , 12 mg & 24 mg dosage levels
Route of Administration Oral
Physical description: 1 mg, 2 mg & 4 mg tablets: 7.0 mm round, compound radius, white film 
coated tablets
6 mg, 8 mg & 10 mg tablets: 9.0 mm round, compound radius, white film 
coated tablets
Method for individualizing dosage: See Section 6.4.[ADDRESS_351886] dialy sis ses sion of the 
week (e.g., if Monday -Wednesday -Friday  schedule, the study  visit cannot be on 
Monday ).  For subjects with a four to five times weekl y dial ysis schedule, randomization 
can be on an y hemodial ysis session of the week.
Subjects can take their table ts without regard to food.  For all stud y visits, it is 
recommended for subjects not to eat a heav y meal before coming to the clinic in order to 
avoid lipemia of the blood sample collected for the anal ysis of transferrin, iron and total 
iron binding capaci ty (TIBC).
Section 6.4.[ADDRESS_351887] doses adjusted, as required, to target Hgb 
within the ran ge of 10.0 -11.0 g/dL.  Dose adjustments will be assigned automatically via 
the IVWRS based on the subject’s Hgb value via onsite HemoCue assessment according 
to the following algorithms:
Day 1 (HemoCue Prior to Acute Challenge 1)
Hgb (g/dL) Action or Dose
<7.5Repeat HemoCue assessment on the same sample at same study visit to confirm; take 
average of [ADDRESS_351888] from the study.
7.5 and <9.0 8 mg daprodustat
7.59and <10.0 6 mg daprodustat
10.0 and <11.5 4 mg daprodusta t
11.5Repeat HemoCue assessment on the same sample at same study visit to confirm; take 
average of [ADDRESS_351889] from study.
The 8 week Hgb maintenance dosing will begin on Day  2, following Acute Challenge 1.
Acute Challenge dosing is the same for all subjects on the daprodustat arm: 24 mg.
Days 15, 29, and 43
The available dose steps for daprodustat a re outlined below (highlighted boxes indicate 
starting doses).  Dose adjustments will result in the daprodustat dose being increased or 
decreased b y one dose step .
2015N267693_04 CONFIDENTIA L
205665
156PREVI OUS IMAGE
REVI SED I MAGE
Hgb (g/dL)Hgb change since
Day 1 previous study
visitDose Adjustment
<7.5 Any changeRepeat HemoCue assessment on the same sample at same study 
visit to confirm; take average of [ADDRESS_351890] from the study.
7.5 to <9.5 Decreasing or No ch ange 1Increase to the next higher dose step
7.5 to <9.5 Increasing 2Maintain dose
9.5 to ≤11.5 Any change Maintain dose
>11.5 to <12.0Increasing or No change Decrease to the next lower dose step
Decreasing Maintain dose
≥12.0 Any changeRepeat HemoCue assessment on the same sample at same study 
visit to confirm; take average of [ADDRESS_351891] from the study.
HOLD dosing for 2 weeks until next study visit. 3
1No change is defined as an increase < 0.5 g/dL
2Increase is defined as an increase ≥ 0.5 g/dL
3If Hgb remains ≥12.[ADDRESS_351892] to meals.
All subjects will be instructed to limit caffeine -or xanthine -containing products (e.g., 
coffee, tea, cola drinks, chocolate) for 24h prior to both Acute Challenge [ADDRESS_351893] does not 
need to limit the products listed above.
Section 6.11.1 Estimated Dry Weight and Antihypertensive Medication Changes
REVI SED TEXT, where text in strikethrough has been removed and bol ded text has been 
added.  
It is preferred that changes to EDW and antihy pertensive medication(s) are not made 
while the subject is part of this study , however, Subjects subjects should remain in the 
2015N267693_04 CONFIDENTIA L
205665
157study  regardless of an y changes.   All medication and do se changes should be recorded 
in the eCRF.
Section 6.11.3    Prohibited Medications and Non -Drug Therapi[INVESTIGATOR_288606], where text in strikethrough has been removed a nd bolded text has been 
added. 
Use of an y of the following prescription drugs from scre ening (Week -8)until [ADDRESS_351894] dose of randomized treatment is prohibited and will constitute a protocol 
violation.
The s Strong inhibitor sof CYP2C8 (e.g., gemfibrozil , high dose clopi[INVESTIGATOR_7745] [300 
mg])
Strong inducer sof CYP2C8 (e.g.,rifampin/ rifampi[INVESTIGATOR_2513] )
Section 7.1 Time and Events Table
Table 3 Study  Procedures and Assessments
REVI SED TEXT, where text in strikethrough has been removed and bolded text has been 
added. 
2015N267693_04 CONFIDENTIA L
2056 65
158Procedure 1Screening ESA Washout Treatment Period 2Follow -up2
Week -8 Week -6Week -4Week -2Day 1 Day 15 Day 29 Day 43 Day 57 Early WD Week 10
Informed Consent X
Entry Criteria X
Physical, Medical History, Demography X
HemoCue Hgb X X X X X4X X X X4X X
Enro llment X
IVWRS X X X X
Randomization X
Acute Challenge X4X4
ABPM Assessment X4X4
Dose Adjustment X X X
Females Only: Serum Pregnancy Test X X X X X X X
Females Only: Estradiol & FSH (if required)3X X
ECG X X4X4X X
Vital signs & weight (Pre -& Post -dialysis) X X X X X4X X4X X
Clinical Chemistry X X X X X X X
Hematology X X X X X X X
Folate and Vitamin B12 X
Ferritin, transferrin, total iron ,, TSAT, UIBC X X
Pharmacokin etic/Biomarker Assessments X4X4
Hgb Maintenance Period 5=======================================
Adverse Events Assessment X6X6X X X4X X X X4X X
Review Concomitant Medications X X X X4X X X X4X X
1 All assessments should be done predialysis/predose except as noted.
2 Allowable time window 2 days EXCEPT Follow -up Visit which is 3 days.
3 As detailed in Inclusion Criteria.
4 Detailed timings for assessments on Acute Challenge Days are given in Table 4 .
5 From the end of Acute Cha llenge 1 to the beginning of Acute Challenge 2.
6 Only SAEs assessed as related to study participation are collected at this visit. See Section 12.4 for additional details.
2015N267693_04 CONFIDENTIA L
205665
159Section 7.2 Screening and Critical Baseline Assessments
REVI SED TEXT, where text in strikethrough has been removed.  
Medical history , including cardiovascular disease and associated risk factors, (as detailed 
in the eCRF) will be assessed at screening.
The following demographic parameters will be captured: y ear of birth, sex, race a nd 
ethnicity .
Medical/medication/family  history  will be assessed as related to the inclusion/exclusion 
criteria listed in Section 5.
Procedures conducted as part of the subject’s routine clinical management [e.g., Hgb 
monitoring] and obtained prior to sign ing of informed consent may  be utilized for 
Screening or baseline purposes provided the procedure meets the protocol -defined criteria 
and have been performed in the timeframe of the study .
Section [IP_ADDRESS] Time Period and Frequency for Collecting AE and SA E Information
REVI SED TEXT, where text in strikethrough has been removed.  
Any SAEs assessed as related to study  participation (e.g., protocol -mandated 
procedures, invasive tests, or change in existing therap y) or related to a [COMPANY_004] 
product will be recorde d from the time a subject consents to participate in the 
study  up to and including any  follow -up contact.
AEs will be collected from the start of washout (Week –4)until the follow -up 
contact (see Section [IP_ADDRESS] ), at the timepoints specified in the Time and Events 
Table (Section 7.1).
Medical occurrences that begin prior to the start of washout but after obtaining 
informed consent may  be recorded on the Medical History /Current Medical 
Conditions section of the CRF.
All SAEs will be recorded and reported t o [COMPANY_004] within 24 hours, as indicated in 
Section 12.4.
Investigators are not obligated to activel y seek AEs or SAEs in former study 
subjects.  However, if the investigator learns of any  SAE, including a death, at any  
time after a subject has been discharged from the study , and he/she considers the 
event reasonabl y related to the study  treatment or study  participation, the 
investigator must promptly  notify  [COMPANY_004].
NOTE: The method of recording, evaluating and assessing causalit y of AEs and SAEs 
plus procedures fo r completing and transmitting SAE reports to [COMPANY_004] are provided in 
Section 12.4.
Section 7.3.5 Electrocardiogram (ECG)
REVI SED TEXT, where text in strikethrough has been removed.  
2015N267693_04 CONFIDENTIA L
205665
160ECG measurements will be taken at the time points specified in the Time and Events 
Table (Section 7.1).  Full [ADDRESS_351895] in a supi[INVESTIGATOR_12251].  Heart rate ( HR), PR interval, QRS duration, and QT (uncorrected) interval will 
be measured.  QTcB will be calculated (machine -read or manually ).
At the Screening visit (Week -8)  two additional ECGs are required if the initial ECG 
indicates prolonged QTc (see Section 5.3) using the automated or manually  calculated 
QTcB value.  The average QTcB value of all three ECGs will be used to determine 
eligibility .  Additional details are provided in the SRM.
ECG data will be read locally .
All ECGs will be performed before measurement of vital signs and collection of blood 
samples for laboratory  testing.
Section 7.3.6 Clinical safety Laboratory Assessments
A spell ing error was corrected in the notes of Table 5.
Section 7.4.1 Blood Sample Collection
REVI SED TEXT, where bolded text has been added.
Blood samples for pharmacokinetic (PK) anal ysis of daprodustat and its metabolites 
([COMPANY_004]2391220 [M2], [COMPANY_004]2531403 [M3], [COMPANY_004] 2487818 [M4], [COMPANY_004]2506102 [M5], 
[COMPANY_004]2531398 [M6], and [COMPANY_004]2531401 [M13]) will be collected at the time points 
indicated in Section 7.1, Time and Events Table.  The actual date and time of each blood 
sample collection will be recorded.  The timing of PK sample s may  be altered and/or PK 
samples may  be obtained at additional time points to ensure thorough PK monitoring.
Details of PK blood sample collection (including volume to be collected), processing, 
storage and shippi[INVESTIGATOR_42232].
Ifthe subject is unable to provide a sufficient blood quantity per time point or there 
is significant concern for this by [CONTACT_288623], these serial blood draws 
may be omitted.
Section [IP_ADDRESS] ABPM Delay Due to High Hgb
REVI SED TEXT, where b olded text has been added.
Day 1:  If the HemoCue Hgb is confirmed to be ≥11.5 g/dL then avoid dosing and 
continue washout for one additional week.  No other assessments should be 
performed for that subject during the visit.  When the subject returns 7 da ys later, 
re-draw the Hgb for HemoCue and assess.  If confirmed to be <11.5 g/dL, then 
progress with the remainder of assessments and perform Acute Challenge [ADDRESS_351896] be withdrawn. 
Day 57 :  If the HemoCue Hgb is confir med to be ≥11.5 g/dL then hold the dose (s) of 
IPfor [ADDRESS_351897] returns 7 days later, re -draw the Hgb for HemoCue and 
assess.  If confirmed to be <11.5 g/dL, then progress w ith the remainder of 
2015N267693_04 CONFIDENTIA L
[ADDRESS_351898] of daprodustat on blood pressure.  Biomarkers selected will explore the renin -
angiotensin -aldosterone axis, the nitric oxide and endothelin axes, sodium retention and 
HIF signalling.
Biomarkers may include erythropoietin, nitric oxide (NO), as ymmetric dimethy arginine 
(ADMA), renin, angiotensin -II (1-8) and metabolites (1 -7and 1 -5), endothelin -1 (ET -1), 
and noradrenalin. Samples will be collected as specified in the Time and Events Table 
(Section 7.1).  The timing of the collections may  be adjusted on the basis of emerging 
pharmacokinetic or pharmacod ynamic (PD) data from this study or other new 
information in order to ensure optimal evaluation of the PD endpoints.
If the subject is unable to provide a sufficient blood quantity per time point or there 
is significant concern for this by [CONTACT_288623], these serial blood draws 
may be omitted.
Section 11 References
The following reference was added:
Holdstock L , Meadowcroft AM, Maier R, Johnson BM, Jones D, Rastogi A, Zeig S, 
Lepore JJ, Cobitz AR. Four -week studies of oral hy poxia -inducible factor -proly l 
hydroxylase inhibitor [COMPANY_004]1278863 for treatment of anemia. JASN 2016; 27:1234 -1244
Section 12.1 Appendix 1 –Abbreviations and Trademark s
REVI SED TEXT, where text in strikethrough has been removed and bolded text has been 
added
ABPM Ambulatory  blood pressure monitoring
ADMA Asymmetric dimethy arginine
AE Adverse event
ALT Alanine transaminase
AMD Age-Related Macular Deg eneration
ANCOVA Analy sis of Covariance
AST Aspartate transaminase
AUEC Area under the effect curve
AUC (0 -24) Area under concentration -time curve from time zero to [ADDRESS_351899] C High Performance Liquid Chromatograph y
HR Hour/heart rate
IB Investigator’s Brochure
ICH International Conference on Harmonization
IEC Independent Ethics Committee
INR International Nnormalized Rratio
IRB Institutional Review Board
ITT Intent -to-treat
IU International Unit
IV Intravenous
IVWRS Interactive Voice/Web Response Sy stem
KDIGO Kidney  Disease Improving Global Outcomes
KG Kilogram
LDH Lactate deh ydrogenase 
MAP Mean Arterial Blood Pressure
MCH Mean corpuscular hemoglobin
MCHC Mean corpuscular hemoglobin concentration
MCV Mean corpuscular volume
MedDRA Medical Dictiona ry for Regulatory  Activities
MG Milligram
MI Myocardial infarction
ML Milliliter 
2015N267693_04 CONFIDENTIA L
[ADDRESS_351900] Requirement Specification
PRVP Peak Right Ventricular Pressure
PSRAE Possible suicidality  related adverse event
QC Quality Control
QTc QT interval corrected for heart rate
QTcB QT interval corrected for heart rate using Bazett’s formula
RAP Reporting and Anal ysis Plan
RBC Red blood cell
RDW Red blood cel l distribution width
rhEPO Recombinant human ery thropoietin 
RNA Ribonucleic acid
SAE Serious adverse event
SBP Systolic blood pressure
SC Subcutaneous
SD Standard deviation
SGOT Serum glutamic oxaloacetic transaminase
SGPT Serum glutamic -pyruvic t ransaminase
sPAP Systolic Pulmonary  Artery Pressure
SRM Study  Reference Manual
T1/[ADDRESS_351901] Upper limit of normal
URR Urea reduction ratio
WBC White blood cells
2015N267693_04 CONFIDENTIA L
205665
[ZIP_CODE].7.4. Amendment 4
Summary of Amendment Changes with Rationale
This protocol amendment applies to all centers where this study  may  be performed.
This protocol amendment was writt en to remove the interim anal ysis from the statistical 
section due to more rapid recruitment than anticipated.   During the update, the objectives 
and endpoints were streamlined, the stratification variable of previous ESA dose was 
added to the models as it was inadvertently  left out, the daprodustat dosing algorithm was 
updated, and exploratory  endpoints were added to further clarify  results. 
During this time the safety  language was updated as well as clarification of 
inclusion/exclusion criteria in response to an internal audit.
List of Specific Changes
Title Page
REVI SED TEXT, where text in strikethrough has been removed and bolded text has been 
added :
Author (s):  
 
Sponsor Name [CONTACT_29560]:
GlaxoSmithKline Research & Development Limited
[ADDRESS_351902] Information can be found in the Study 
Reference Manual (SRM).
Regulatory Agency Identifying Number(s): IND Number: 101,291
Medical Monitor Page
REVI SED TEXT, where text in strikethrough has been removed :
Medical Monitor/SAE Contact [CONTACT_7171]:
Role NameDay Time Phone 
Number and email 
addressAfter -hours (Cell) 
NumberFax Number
[COMPANY_003]
2015N267693_04 CONFIDENTIA L
205665
165Primary 
Medical 
Monitor, MD, 
PhDTel:
Secondary 
Medical 
Monitor, MD, 
FACCTel:
 
Tertiary 
Medical 
Monitor, MDTel:
Site and 
SAE 
Contact 
[CONTACT_2761]:GlaxoSmithKline
[ADDRESS_351903], UP4400
Collegeville, PA [ZIP_CODE]
Sponsor Legal Registered Address:
GlaxoSmithKline Research & Development Limited
[ADDRESS_351904]
Middlesex, TW8 9GS
[LOCATION_006]
In some countries, the clinical trial sponsor may be the local GlaxoSmithKli ne Affiliate 
Company  (or designee).  If applicable, the details of the alternative Sponsor and contact 
[CONTACT_131980].
Regulatory  Agency  Identify ing Nu mber(s): IND Number: 101,291
Section 1 PROTOCOL SYNOPSIS FOR STUDY 205665 
(Objective(s)/Endpoints(s))
REVI SED TEXT, where text in strikethrough has been removed and bolded text has been 
added. 
Objectives Endpoints
Primary
To compare the effect of dapr odustat to epoetin 
alfa on blood pressure (BP) after Acute 
Challenge 2 (8 weeks of hemoglobin [Hgb] 
maintenance therapy)Average of systolic blood pressure (SBP) as 
measured by [CONTACT_288617] (ABPM) over [ADDRESS_351905] -dosing after 
8 weeks of Hgb maintenance therapy
Secondary
To compare the initial effect of daprodustat to 
epoetin alfa on BP after Acute Challenge 1 ( 2 
weeks of erythropoiesis -stimulating agent [ESA ]
washout) Average of SBP, diastolic blood pressure 
(DBP), mean arterial blo od pressure (MAP), 
and heart rate (HR) as measured by [CONTACT_288618] 6- hr post -dosing at Day 1
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
2015N267693_04 CONFIDENTIA L
205665
166Objectives Endpoints
Area under the effect curve (AUEC )of SBP , 
DBP, MAP, and HR as measured by [CONTACT_288618] [ADDRESS_351906] -dosing at Day 1
To compare the effect of daprodustat to epoetin 
alfa on BP after Acute Challenge 2Average of DBP , MAP, and HR as measured 
by [CONTACT_288619] [ADDRESS_351907] -dosing at Day 57.
AUEC of SBP , DBP, MAP, and HR as 
measured by [CONTACT_288619] [ADDRESS_351908] -dosing at 
Day 57.
To estimate the initial effect of daprodustat on 
SBP, DBP, HRandMAP after Acute Challenge 
1Change from pre -dose in SBP, DBP, HR, and 
MAP at each timepoint at Day 1
To characterize the pharmacokinetics of 
daprodustatPlasma concentrations of daprodustat and 
metabolites and derived pharmacokinetic 
parameters incl uding maximum observed 
concentration (Cmax ), time of occurrence of 
Cmax (tmax ), terminal phase half -life (t½)and 
area under concentration -time curve from time 
zero to 24 hours (AUC [0-24])as appropriate
Safety
To assess the safety and tolerability of 
daprodustat Incidence and severity of adverse events ( AEs)
and serious adverse events ( SAEs )
Reasons for discontinuation of study treatment
Absolute values and changes from baseline 
over time in laboratory parameters, 
electrocardiograms ( ECGs )and vital sign s
Exploratory
To investigate the effect of daprodustat and 
epoetin alfa on vasoactive mediators of blood 
pressurePlasma concentrations and derived 
parameters including Cmax, tmax, t½ and 
AUC(0 -24) as appropriate (to include 
erythropoietin, endothelin -1,nitric oxide, 
asymmetric dimethylarginine, renin, 
angiotensin -IIand metabolites , and 
noradrenalin) 
Evaluate exposure -response relationships for 
daprodustat and: erythropoietin, endothelin -1, 
nitric oxide, asymmetric dimethylarginine, renin, 
angiotensin -II (and metabolites), and 
noradrenalin Further models (as appropriate) to describe the 
daprodustat exposure -response relationship 
with: erythropoietin, endothelin -1, nitric oxide, 
asymmetric dimethylarginine, renin, 
angiotensin -II (and metabolites), and 
noradrenalin. 
To summarize the effect of daprodustat and 
epoetin alfa on SBP after Acute Challenge 1 
and Acute Challenge 2AUEC of SBP as measured by [CONTACT_288619] [ADDRESS_351909] -dosing
2015N267693_04 CONFIDENTIA L
205665
167Objectives Endpoints
To compare the effect of daprodustat to epoetin 
alfa on SBP after 8 weeks o f Hgb maintenance 
therapy Change from Day 1 pre -dose SBP to Day 57
pre-dose
To compare the effect of daprodustat to 
epoetin alfa on SBP at Cmax of each study 
treatment , as measured by [CONTACT_44117] Change in SBP from pre -dose on Day 1 to 
Cmax of the study treatmen t on Day 1
Change in SBP from pre -dose on Day 1 to 
Cmax of the study treatment on Day 57
Change in SBP from pre -dose on Day 57 to 
Cmax of the study treatment on Day 57
To compare the effect of daprodustat to 
epoetin alfa on SBP at Cmax of the 
erythropoiet in level , as measured by [CONTACT_44117] Change in SBP from pre -dose on Day 1 to 
Cmax of erythropoietin on Day 1
Change in SBP from pre -dose on Day 1 to 
Cmax of erythropoietin on Day 57
Change in SBP from pre -dose on Day 57 to 
Cmax of erythropoietin  on Day 57
Stud y Design
PREVI OUS IMAGE
Week -2: ESA 
Washout
Day 1: Ran domize & 
Acute Challenge 1Day 29: Dose Adjustment  
(as n eeded)
Day 57: Acute Challenge 2Hgb Maintena nce Period 
Week 10: Follow -up
Screen ing: Between  7 and 30  
days prior to ESA Washout
REVI SED I MAGE
Week -2: ESA 
Washout
Day 1: Randomize & 
Acute Challenge 1Day 15, 29 & 43: Dose 
Adjustment (as needed)
Day 57: Acute Challeng e 2Hgb Maintenance Period 
Week 10: Follow -up
Screening: Between 7 and 30 
days prior to ESA W ashout

2015N267693_04 CONFIDENTIA L
205665
168REVI SED TEXT, where text in strikethrough has been removed:
Following the 2-week ESA washout, subjects will be randomized 1:1 and stratified b y 
prior ESA dose, based on the average weekl y (for epoetins or d arbepoetin) or monthly  
(for methoxy  polyethylene gl ycol (PEG) -epoetin beta) dosing during the 12 weeks prior 
to ESA washout as follows:
Low ESA dose: <100 IU/kg /week epoetin alfa OR <0.5 µg/kg/week darbepoetin 
OR <0.6 µg/kg/week methoxy  PEG -epoetin beta
High ESA dose: ≥100 IU/kg /week epoetin alfa OR ≥0.5 µg/kg/week darbepoetin 
OR 0.6 µg/kg/week methoxy  PEG -epoetin beta
On Day  1, subjects will be randomized and undergo Acute Challenge 1, a single dose 
challenge to compare the acute effects on BP of the high est planned once -daily  
maintenance dose of daprodustat (24 mg) to the highest starting dose of epoetin alfa 
(100 IU/kg ).  Subjects will have BP monitored for [ADDRESS_351910] 
serial blood sampling to assess the pharmacokinetics of daprodusta t and the time -course 
of various biomarkers.  Acute Challenge 1 will be started promptl yfollowing completion 
of a mid -week dial ysis session.
Analysis
REVI SED TEXT, where text in strikethrough has been removed and bolded text has been 
added. 
The primary  endpoint for this study  is average s ystolic blood pressure (SBP) over 
[ADDRESS_351911] is 
daprodustat versus epoe tin alfa for this challenge.
The primary  anal ysis of average SBP over [ADDRESS_351912] -dose during Acute Challenge 
2 will be an anal ysis of covariance (ANCOVA) with terms for treatment, prior 
ESA dose (low/high) , andpost-HD/pre -Acute Challenge [ADDRESS_351913] -HD/pre -Acute Challenge [ADDRESS_351914] -HD/pre -Acute Challenge 
1 SBP, and treatment b y (difference in post -HD SBP between Acute Challenge 1 
and 2) interaction.  Note that the pre -challenge SBP may  change over time 
between Acute Challenge [ADDRESS_351915] of t reatment phase on the 
covariate. Therefore, if the interaction term in this model is significant at the 0.10 
level, then the primary  model will be ANCOVA with terms for treatment , prior 
ESA dose (low/high) ,and post -HD/pre -Acute Challenge 1 SBP.  The prima ry 
model will provide a point estimate and two -sided 95% CI  for the treatment effect 
and a p -value for the superiority  assessment.  Superiority  will be established if the 
p-value is <0.05.
2015N267693_04 CONFIDENTIA L
205665
169The comparison of daprodustat versus epoetin alfa on [ADDRESS_351916] -dose in 
Acute Challenge 1 will be anal yzed using ANCOVA with terms for treatment , 
prior ESA dose (low/high) ,and post -HD/pre -Acute Challenge 1 SBP.  Similar 
analyses will be p erformed for DBP, MAP, and HR.
ANCOVA using the primary  model will be used for the analy sis of average DBP, 
MAP, and HR over [ADDRESS_351917] -dose in Acute Challenge 2 replacing the baseline 
SBP term with the analogous baseline measurement for DBP, MAP, and HR , 
respectivel y.
AUECs of SBP, DBP, MAP, and HR post Acute Challenge 2 and 1 will be 
analyzed using ANCOVA with terms for treatment and prior ESA dose 
(low/high) with 95% CI s and p -values provided for the treatment effect.
Null Hy pothesis: The difference betwe en 24 mg daprodustat versus 100 IU/kg 
epoetin alfa on 6 hr average SBP under a background of treatment (i.e., during 
Acute Challenge 2) is zero.
Alternative Hy pothesis: The difference between 24 mg daprodustat versus 100 
IU/kg epoetin alfa on 6 hr average SBP under a background of treatment (i.e. 
during Acute Challenge 2) is not zero.
An interim anal ysis will be conducted after approximately  [ADDRESS_351918] 
completed Acute Challenge 2.
If the mean change in SBP from pre -Acute Challenge 1 to the 6 -hour mean
following both Acute Challenge 1 and Acute Challenge 2 is less than 5 mmHg in 
the epoetin alfa group, then the study  will be stopped.  However, if a clinically  
meaningful difference between the two treatment groups in mean change in SBP 
from pre -Acute Cha llenge 1 to the 6 -hour mean following Acute Challenge 1 (i.e., 
>5mmHg) is observed, then the study  will be continued in order to further 
characterize the effects of daprodustat on blood pressure.
Simulations show that under assumptions of a true mean chan ge in SBP of 0 
mmHg and SD of 18 mmHg for both treatment groups at Acute Challenge 1 and 
the epoetin alfa group at Acute Challenge 2, this stoppi[INVESTIGATOR_288609] >99% of the time.  Under the assumptions of a true mean change 
in SBP of 8 mmHg and SD of 18 mmHg for both treatment groups at Acute 
Challenge 1 and the epoetin alfa group at Acute Challenge 2, this rule will result 
in stoppi[INVESTIGATOR_21356] <1% of the time.
While the above is a guideline for stoppi[INVESTIGATOR_288610], the totality  of the data 
will be considered when making the decision at the time of the interim analysis.
Section 2  INTRODUCTION
REVI SED TEXT, where text in strikethrough has been removed and bolded text has been 
added. 
Daprodustat ([COMPANY_004]1278863) is a small molecule, oral inhibiter of the HIF -PHD enzy mes 
which may  present several important advantages over other ESAs.  It is an oral 
medication and does not require cold -chain storage as do some ESAs, thus increasing 
ease of use for patients.  Moreover, data indicate that daprodustat can effectively  raise 
2015N267693_04 CONFIDENTIA L
205665
170Hgb concentrations with lower EPO levels than those observed after administration of 
ESAs [Provenzano, 2011 ].  Because of the increased CV risk associated with raising Hgb 
concentrations through large increases in EPO levels [Pfeffer, 2009], daprodustat has the 
potential to raise Hgb with less CV risk than other ESAs. 
 
.
Section 3 OBJECTIVES AND ENDPOINTS
REVI SED TEXT, where text in strikethrough has been removed and bolded text has been 
added. 
Objectives Endpoints
Primary
To compare the effect of daprodustat to epoetin 
alfa on blood pressure (BP) after Acute 
Challenge 2 (8 weeks of hemoglobin [Hgb] 
maintenance therapy)Average of systolic blood pressure (SBP) as 
measured by [CONTACT_288617] (ABPM) over [ADDRESS_351919] -dosing after 
8 weeks of H gb maintenance therapy
Secondary
To compare the initial effect of daprodustat to 
epoetin alfa on BP after Acute Challenge 1 ( 2 
weeks of erythropoiesis -stimulating agent [ESA ]
washout) Average of SBP, diastolic blood pressure 
(DBP), mean arterial blood pr essure (MAP), 
and heart rate (HR) as measured by [CONTACT_288618] 6- hr post -dosing at Day 1
 Area under the effect curve (AUEC )of SBP , 
DBP, MAP, and HR as measured by [CONTACT_288618] 24- hr post -dosing at Day 1
To compare the effect of daprodustat to epoetin 
alfa on BP after Acute Challenge 2 Average of DBP , MAP, and HR as measured 
by [CONTACT_288619] [ADDRESS_351920] -dosing at Day 57.
 AUEC of SBP , DBP, MAP, and HR as 
measured by [CONTACT_288619] [ADDRESS_351921] -dosing at 
Day 57.
To estimate the initial effect of daprodustat on 
SBP, DBP, HR andMAP after Acute Challenge 
1 Change from pre -dose in SBP, DBP, HR, and 
MAP at each timepoint at Day 1
To characterize the pharmacokinetics of 
daprodustat Plasma concentrations of daprodustat and 
metabolites and derived pharmacokinetic 
parameters including maximum observed 
concentration (Cmax ), time of occurrence of 
Cmax ( tmax ), terminal phase half -life (t½)and 
area under concentration -time curve from time 
zero to 24 hours (AUC [0-24])as appropriate
Safety
To assess the safety and tolerability of 
daprodu stat Incidence and severity of adverse events (AEs )
and serious adverse events ( SAEs )
 Reasons for discontinuation of study treatment
 Absolute values and changes from baseline 
over time in laboratory parameters, 
CCI
CCI
CCI
2015N267693_04 CONFIDENTIA L
205665
171Objectives Endpoints
electrocardiograms ( ECGs )and vital signs
Exploratory
To investigate the effect of daprodustat and 
epoetin alfa on vasoactive mediators of blood 
pressurePlasma concentrations and derived 
parameters including Cmax, tmax, t½ and 
AUC(0 -24) as appropriate (to include 
erythropoietin, endothelin -1, nitr ic oxide, 
asymmetric dimethylarginine, renin, 
angiotensin -IIand metabolites , and 
noradrenalin) 
Evaluate exposure -response relationships for 
daprodustat and: erythropoietin, endothelin -1, 
nitric oxide, asymmetric dimethylarginine, renin, 
angiotensin -II (and metabolites), and 
noradrenalin Further models (as appropriate) to describe the 
daprodustat exposure -response relationship 
with: erythropoietin, endothelin -1, nitric oxide, 
asymmetric dimethylarginine, renin, 
angiotensin -II (and metabolites), and 
norad renalin. 
To summarize the effect of daprodustat and 
epoetin alfa on SBP after Acute Challenge 1 
and Acute Challenge 2AUEC of SBP as measured by [CONTACT_288619] [ADDRESS_351922] -dosing
To compare the effect of daprodustat to epoetin 
alfa on SBP after 8 weeks of Hgb maintenance 
therapy Change from Day 1 pre -dose SBP to Day 57
pre-dose
To compare the effect of daprodustat to 
epoetin alfa on SBP at Cmax of each study 
treatment , as measured by [CONTACT_44117] Change in SBP from pre -dose on Day 1 to 
Cmax of the study treatment on Day 1
Change in SBP from pre -dose on Day 1 to 
Cmax of the study treatment on Day 57
Change in SBP from pre -dose on Day 57 to 
Cmax of the study treatment on Day 57
To compare the effect of daprodustat to 
epoetin alfa on SBP at Cmax of the 
erythropoietin le vel, as measured by [CONTACT_44117] Change in SBP from pre -dose on Day 1 to 
Cmax of erythropoietin on Day 1
Change in SBP from pre -dose on Day 1 to 
Cmax of erythropoietin on Day 57
Change in SBP from pre -dose on Day 57 to 
Cmax of erythropoietin on Day 57
Section 4 .1 Overall Design
Figure 1 Stud y Design
PREVI OUS IMAGES
2015N267693_04 CONFIDENTIA L
205665
172Week -2: ESA 
Washout
Day 1: Ran domize & 
Acute Challenge 1Day 29: Dose Adjustment  
(as n eeded)
Day 57: Acute Challenge 2Hgb Maintena nce Period 
Week 10: Follow -up
Screen ing: Between  7 and 30  
days prior to ESA Washout
REVI SED I MAGE
REVI SED TEXT, where text in strikethrough has been removed:
Following the 2-week ESA washout, subjects will be randomized 1:[ADDRESS_351923] rage weekl y (for epoetins or darbepoetin) or monthly  
(for methoxy  polyethylene gl ycol (PEG) -epoetin beta) dosing during the 12 weeks prior
to ESA washout as follows:
Low ESA dose: <100 IU/kg/week epoetin alfa OR <0.5 µg/kg/week darbepoetin 
OR <0.6 µg/kg/we ek methoxy  PEG -epoetin beta
High ESA dose: ≥100 IU/kg/week epoetin alfa OR ≥0.5 µg/kg/week darbepoetin 
OR 0.6 µg/kg/week methoxy  PEG -epoetin beta
On Day  1, subjects will be randomized and undergo Acute Challenge 1, a single dose 
challenge to compare the a cute effects on BP of the highest planned once -daily  
maintenance dose of daprodustat (24 mg) to the highest starting dose of epoetin alfa 
(100 IU/kg).  Subjects will have BP monitored for [ADDRESS_351924] 
serial blood sampling to assess the pharmacokinetics of daprodustat and the time -course Week -2: ESA 
Washout
Day 1: Randomize 
& Acute Challenge 
1Day 15, 29 & 43: Dose 
Adjustment (as 
needed)
Day 57: Acute Challenge 2Hgb Maintenance 
Period 
Week 10: Follow -up
Screening: Between 7 and 
30 days prior to ESA 
Washout

2015N267693_04 CONFIDENTIA L
205665
173of various biomarkers.  Acute Challenge 1 will be started promptl yfollowing completion 
of a mid -week dial ysis session.
Section 4.4 Design Justification
REVI SED TEXT, where text in strikethrough has been removed and bolded text has been 
added :
This will be an open -label study  since the primary  endpoint (SBP by  [CONTACT_44117]) is an 
objective measure and unlikely  to be influenced b y knowledge of the treatment 
received.  Additionally , an open label design will facili tate the conduct of the 
interim analy sis.  Lastl y,Additionally , blinding of an injectable comparator and 
oral study  drug is impractical in this case.
Section 4.6 Benefit: Risk Assessment
REVI SED TEXT, where text in strikethrough has been removed and bolde d text has been 
added :
Summaries of findings from both clinical and non -clinical studies conducted with 
daprodustat can be found in the Daprodustat Investigator’s Brochure (IB) and IB 
Supplements , if applicable .[GlaxoSmithKline Document Number RM2008/0026 7/07; 
GlaxoSmithKline Document Number 2015N266524_00 ; GlaxoSmithKline Document 
Number 2015N266524_01].
Section 5 SELECTION OF STUDY POPULATION AND WITHDRAWAL 
CRITERIA
REVI SED TEXT, where text in strikethrough has been removed and bolded text has been 
adde d:
Specific information regarding warnings, precautions, contraindications, adverse events, 
and other pertinent information on daprodustat that may  impact subject eligibility  is 
provided in the Daprodustat I nvestigator’s Brochure [ GlaxoSmithKline Document 
Number RM2008/[ZIP_CODE]/07 ]and IB Supplements , if applicable .[GlaxoSmithKline 
Document Number 2015N266524_00 ; GlaxoSmithKline Document Number 
2015N266524_01 ].
Deviations from inclusion and exclusion criteria are not allowed because they can 
potentially  jeopa rdize subject safet y, the scientific integrit y of the stud y, or regulatory 
acceptability .  Adherence to the criteria as specified in the protocol is essential.
Section 5.2 Inclusion Criteria
REVI SED TEXT, where text in strikethrough has been removed and bo lded text has been 
added:
2015N267693_04 CONFIDENTIA L
[ADDRESS_351925] will be eligible for inclusion in this study onl y if all of the following criteria 
apply :
AGE
1.≥[ADDRESS_351926] AND DIAGNOSIS INCLUDING DISEASE SEVERITY
2.Hemoglobin: Stable Hgb 8.5to 11.5 g/dL inclusive (See Section 5.1).
3.Dialysis frequency: On hemodialy sis (HD, hemofiltration or hemodi afiltration) 
three -to five -times weekly  for at least 4 weeks prior to screening.
4.Dialysis adequacy : A single pool Kt/V urea 1.2 based on a historical value obtained 
within the 3 months prior to screening in order to ensure the adequacy  of dialy sis.  If 
Kt/Vurea is not available, then an average of the last 2 values of urea reduction ratio 
(URR) is at least 65%.  NOTE : Only  needs confirming at screening.
5.ESA treatment :Treated with anESA (epoetins or their biosimilars, darbepoetin, or 
methoxy  PEG -epoetin be ta) for at least 4 weeks prior to screening.
6.Iron replacement therapy : Subjects may  be on stable (<50% change in overall 
dose and compliance of 80% of prescribed doses in the 4 weeks prior to and 
including the screening period) maintenance oral or IV ( ≤100 mg/week) iron 
supplementation.  If subjects are on oral or IV iron, then doses must be stable for the 
4 weeks prior to Washout .
7.Estimated Dry Weight (EDW) :  Mid-week average weight gain change between 
dialy sis treatments <5% as assessed pre-andpost-dialysis from at the sScreening to
andWashout visits .
8.Antihypertensive Medication: Meets the following criteria:
On at least 1antihy pertensive medication [excluding diuretics]
AND
On that same medication and the same dose for at least [ADDRESS_351927] 25 hours on two separate 
sessions.
Section 5.3 Exclusion Criteria
REVI SED TEXT, where text in strikethrough has been removed and bolded text has been 
added:
A subject will not be eligible for inclusion in this study  if an y of the following criteria 
apply:
2015N267693_04 CONFIDENTIA L
205665
175CKD -RELATED CRITERIA
1.Dialysis modality : Planned change from HD to peritoneal dialy sis within the study  
time period, or on home dialy sis.
2.Renal transplant : Planned kidney  transplant within the 16weeks following the 
Screening visit.
3.High ESA dose : An ep oetin alfa dose of ≥360 IU/kg/week IV or ≥250 IU/kg/week 
subcutaneous (SC), or darbepoetin dose of ≥1.8 µg/kg/week IV or SC, or methoxy  
PEG -epoetin beta dose of 2.2 µg/kg/week within the 8 weeks prior to screening 
through Week -4.
4.Mircera : Planned or rec orded a dministration of Mircera ( methoxy  PEG -epoetin beta ) 
within the 4 weeks prior to theWashout visit .
CARDIOVASCULAR DISEA SE-RELATED CRITERIA
5.Myocardial infarction or acute coronary syndrome: Within the 3 months prior to 
Washout .
6.Stroke or transient ischemic attack: Within the 3 months prior to Washout .
7.Heart failure: Chronic Class I V heart failure ( HF), as defined b y the [LOCATION_001] 
Heart Association (NYHA) functional classification sy stem diagnosed prior to 
Washout .
8.QT interval corrected for heart rate using Bazett’s formula (QTcB ):QTcB >500 
msec, or QTcB >530 msec in subjects with Bundle Branch Block.  There is no QTc 
exclusion for subjects with a predominantly  paced rhy thm.
9.Current uncontrolled hypertension: Resting post dialysis systolic blood press ure 
>160 mmHg; or diastolic blood pressure >100 m mHg at screening or uncontrolled 
hypertension as determined by [CONTACT_093] .
10.Atrial Fibrillation: Presence of atrial fibrillation.
OTHER DISEASE -RELATE D CRITERIA
11.Inflammatory disease: Active chronic in flammatory  disease that could impact 
erythropoiesis (e.g., scleroderma, s ystemic lupus ery thematos us, rheumatoid arthritis, 
celiac disease) diagnosed prior to Washout .
12.Aplasias: History  of bone marrow aplasia or pure red cell aplasia.
13.Other causes of anemi a:Pernicious anemia, thalassemia major, sickle cell disease or 
myelodysplastic s yndrome.
14.Liver disease (any one of the following):
Alanine transaminase (ALT) >2x upper limit of normal (ULN) (screening only )
Bilirubin >1.5xUL N (screening only )
NOTE: Isolated bilirubin >1.5xUL N is acceptable to keep in the study if 
bilirubin is fractionated and direct bilirubin <35%.
Current unstable liver or biliary  disease per investigator assessment, generally  
defined b y the presence of ascites, encephalopathy, coagulopat hy, 
hypoalbuminaemia, esophageal or gastric varices, persistent jaundice, or cirrhosis.
NOTE: Stable chronic liver disease (including asymptomatic gallstones, chronic 
2015N267693_04 CONFIDENTIA L
205665
176hepatitis B or C, or Gilbert’s sy ndrome) are acceptable if subject otherwise meets 
entry  criteria.
15.Major surgery: Major surgery  (excluding vascular access surgery ) within the 3 
months prior to Washout ,or planned during the study .
16.Transfusion: Blood transfusion within the 8 weeks prior to Washout , or an 
anticipated need for blood transfusion d uring the study .
17.Gastrointestinal (GI) bleeding: Evidence of actively  bleeding gastric, duodenal, or 
esophageal ulcer disease ORclinically  significant GI bleeding within the 8weeks
prior to Washout .
18.Acute Infection: Clinical evidence of acute infection o r history  of infection requiring 
intravenous (IV) antibiotic therap y within the 8weeks prior to Washout .
NOTE: IV antibiotics as prophy laxis are allowed.
19.Malignancy: History  of malignancy  within the two y ears prior to screening through 
Day [ADDRESS_351928] (e.g., Bosniak Category  IIF, III or IV) 3 cm.
NOTE: ONL Y exception is localized squamous cell or basal cell carcinoma of the 
skin that has been definitively  treated more than 4 weeks prior to screening.
20.Blood Pressure Measurement: Subjects with an upper arm diameter which cannot 
be measured b y oscillometer/ sph ygmomanometer cuff ORfor whom blood pressure 
cannot be measured in the opposite arm of current vascular access.
2015N267693_04 CONFIDENTIA L
205665
177CONCOMITANT MEDICA TIONS
21.Severe allergic reactions: History  of severe allergic or anaphy lactic reactions or 
hypersensitivity  to excipi[INVESTIGATOR_38852] (see Daprodustat IB for 
list of excipi[INVESTIGATOR_840] [GlaxoSmithKline Document Number RM2008/[ZIP_CODE]/07 ]).
22.Drugs and supplements: Use of an y prescription or non -prescription drugs or 
dietary  supplements that are prohibited (See Section 6.11.3 ), from screening until 
Washout .
23.Prior investigational product exposure : The subject has participated in a clinical 
trial and has received an experimental investigational product within the [ADDRESS_351929] prior to screening, 
whichever is longer .
GENERAL HEALTH RELATED CRITERIA
24.Other conditions: Any other condition, clini cal or laboratory  abnormality , or 
examination finding that the investigator considers would put the subject at 
unacceptable risk, which may  affect study  compliance or prevent understanding of the 
aims or investigational procedures or possible consequences of the study .
25.Females ONLY: Subject is pregnant [as confirmed by  a positive serum human 
chorionic gonadotrophin (hCG) test for females of reproductive potential (FRP) 
only], subject is breastfeeding, or subject is of reproductive potential and does not 
agree to follow one of the contraceptive options listed in the L ist of Highl y Effective 
Methods for Avoiding Pregnancy  in Section 12.4.7 .
DIAGNOSTIC ASSESSMENTS AND OTHER CRITERIA
26.Vitamin B 12:At or below the lower limit of the reference range (may  rescreen in a 
minimum of 8 weeks , following treatment ).
27.Folate: <2.0 ng/mL (4.5 nmol/L) (may  rescreen in a minimum of 4 weeks , following 
treatment ).
28.Ferritin: <100 ng/mL
29.Transferrin saturation (TSAT): <20%.
Section 5.5.1 Criteria for Permanent Discontinuation fr om Study Treatment and 
Early Withdrawal
REVI SED TEXT, where text in strikethrough has been removed and bolded text has been 
added:
Subjects must permanently discontinue study treatment and be withdrawn from the 
study  for the following reasons:
Meets Hgb st oppi[INVESTIGATOR_3418] (See Section [IP_ADDRESS] )
Receives a blood transfusion
Receives a kidney  transplant
Becomes pregnant or intends to become pregnant during the stud y
Active GI bleeding
2015N267693_04 CONFIDENTIA L
205665
178Diagnosis of cancer, with the exception of squamous cell or basal cell carcin oma
Liver chemistry  abnormalities exceeding the threshold criteria (See Section 5.5.3 )
Misses 2 consecutive dialy sis sessions
Need for chronic (more than 14 day s) use Useof prohibited medication (See 
Section 6.11.3 )
Myocardial infarction or acute coronary syndrome
Stroke or transient ischemic attack
New diagnosis of Class IV heart failure, as defined by  [CONTACT_247555] (NYHA) functional classification s ystem
Active chronic inflammatory  disease that could impact ery thropoiesis
Any new diagnos is of hematological disease including those affecting platelets, 
white or red blood cells, coagulation disorders, or any other cause of anemia of
chronic disease other than renal disease
Section [IP_ADDRESS] Hemoglobin Stoppi[INVESTIGATOR_288611] 2 Hgb Stoppi[INVESTIGATOR_288612], where text in strikethrough has been removed:
Day 1 (Prior to Acute Challenge 1)
Hgb at Visit Action
<7.5Repeat HemoCue assessment on the same sample at same study visit to confirm; take average of [ADDRESS_351930] from the study.
7.5-<11.5decrease of 2.0 in Hgb 
over 2 weeksRepeat HemoCue assessment on the same sample at same study visit 
to confirm; take average of [ADDRESS_351931] from the study.
increase of 1.3 in Hgb 
over 2 weeksRepeat HemoCue assessment on the same sample at same study visit 
to confirm; take average of [ADDRESS_351932] 
from the study.
11.5Repeat HemoCue assessment on the same sample at same study visit to confirm; take average of 2 
values.  If confirmed, avoid dosing and continue washout for one additional week.  Progress with 
Acute Challenge 1 one week later if Hgb has decreased below 11.5; if not then withdraw subject from 
study.
2015N267693_04 CONFIDENTIA L
205665
179Days 15, 29, & 43
Hgb at Visit Actio n
<7.5Repeat HemoCue assessment on the same sample at same study visit to confirm; take average of [ADDRESS_351933] from the study.
7.5-<12.0decrease of 2.0 in Hgb 
over 2 weeksRepe at HemoCue assessment on the same sample at same study visit 
to confirm; take average of [ADDRESS_351934] from the study.
increase of 1.3 in Hgb 
over 2 weeksRepeat HemoCue assessment on the same sample at same study visit 
to confirm; take average of [ADDRESS_351935] from the study.
Day 57 (Prior to Acute Challenge 2)
Hgb at Visit Action
<7.5Repeat HemoCue assessme nt on the same sample at same study visit to confirm; take average of [ADDRESS_351936] from the study.
7.5-<11.5decrease of 2.0 in Hgb 
over 2 weeksRepeat HemoCue assessment on the sa me sample at same study visit 
to confirm; take average of [ADDRESS_351937] from the study.
increase of 1.3 in Hgb 
over 2 weeksRepeat HemoCue assessment on the same sample at same stud y visit 
to confirm; take average of [ADDRESS_351938] from the study.
11.5Repeat HemoCue assessment on the same sample at same study visit to confirm; take average of [ADDRESS_351939] from the study.
Section 5.5.3 Liver Chemistry Stoppi[INVESTIGATOR_288608], where text in strikethrough has been removed and bolded text has been 
added:
Liver chemistry stoppi[INVESTIGATOR_288613] y and evaluate liver event etiology (in alignment with the Food and 
Drug Administration [FDA ]premarketin g clinical liver safet y guidance). 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guid
ances/UCM174090.pdf
Discontinuation of study intervention for abnormal liver tests is required when:
a participant meets one of the conditions outlined in the algorithm below .
when in the presence of abnormal liver chemistries not meeting protocol -
specified stoppi[INVESTIGATOR_004], the investigator believes study intervention 
discontinuation is in the best interest of the participant . 
Section 6.2 Treat ment Assignment
2015N267693_04 CONFIDENTIA L
205665
180REVI SED TEXT, where text in strikethrough has been removed and bolded text has been 
added:
Subjects will be stratified by [CONTACT_278823] (as outlined in Section 4.1) and randomized 
1:[ADDRESS_351940] potential 
selection bias due to the open -label design.  Once a randomization number has been 
assigned b y thean Interactive Voice/Web Response System (IVWRS ) at time of 
Randomization , it must not be re -assigned.
Subjects will be assigned to study  medication in accordance with the randomization 
schedule generated b y Clinical Statistics , prior to the start of the stud y, using validated 
internal software.
Section 6.3 Blinding
REVI SED TEXT, where text in strikethrough has been removed:
This will be an open -label study .  However, there are no plans to generate any  aggregated 
unblinded summaries during the conduct of the study  except the summaries necessary  for 
the planned interim anal ysis as defined in Section 9.3.2 .
Section 6.4.1 Subjects Randomized to Daprodustat
REVI SED TEXT, where text in strikethrough has been removed and bolded text has been 
added:
Subjects randomized to daprodustat will have doses adjusted , as required, to target Hgb 
within the range of 10.0 -11.0 g/dL.  Dose adjustments will be assigned automatically via 
the IVWRS based on the subject’s Hgb value via onsite HemoCue assessment according 
to the following algorithms:
Day 1 (HemoCue Prior to Ac ute Challenge 1)
Hgb (g/dL) Action or Dose
<7.5Repeat HemoCue assessment on the same sample at same study visit to confirm; take 
average of [ADDRESS_351941] from the study.
7.5and <10.0 6 mg daprodustat
10.0 and <11.5 4 mg d aprodustat
11.5Repeat HemoCue assessment on the same sample at same study visit to confirm; take 
average of [ADDRESS_351942] from study.
The 8 week Hgb maintenance dosing will begin on Day  2, following Acute Challenge 1. 
Acute Challenge dosing is the same for all subjects on the daprodustat arm: 24 mg.
Days 15, 29, &43, &57
2015N267693_04 CONFIDENTIA L
205665
181The available dose steps for daprodustat are outlined below (hi ghlighted boxes indicate 
starting doses).  Dose adjustments will result in the daprodustat dose being increased or 
decreased b y one dose step .
Hgb (g/dL)Hgb change since
previous study visitDose Adjustment
<7.5 Any changeRepeat HemoCue assessment on the same sample at same study 
visit to confirm; take average of [ADDRESS_351943] from the study.
7.5 to <9.5 Decreasing or No change 1Increase to the next higher dose step
7.5 to <9.5 Increasing 2Maintain dose
9.5 to ≤11.5 Any change Maintain dose
>11.5 to <12.0Increasing or No change Decrease to the next lower dose step
Decreasing Maintain dose
≥12.0 Any changeRepeat HemoCue assessment on the same sample at same study 
visit to conf irm; take average of 2 values.  If confirmed, HOLD dosing 
for 2 weeks until next study visit. 3
7.5 to <12.0increase of 1.3 in Hgb 
over 2 weeks 4Repeat HemoCue assessment on the same sample at same 
study visit to confirm; take average of 2 values. If co nfirmed, 
decrease to next lower dose step,
7.5 to <12.0Increase of > 2.0 in Hgb 
over previous 4 weeks 
(Days 29, 43, 57 4only)Repeat HemoCue assessment on the same sample at same 
study visit to confirm; take average of 2 values. If confirmed, 
decrease t o next lower dose step,
1No change is defined as an increase < 0.5 g/dL
2Increase is defined as an increase ≥ 0.5 g/dL
3If Hgb remains ≥12.[ADDRESS_351944] dose.
4 Only applies at Day 57 if a repeat AC2 is necessary.  The dose should be decreased for the 1 week between AC2 
and Additional AC2.
Section 6.11.1 Estimated Dry Weight and Antihypertensive Medication Changes
REVI SED T EXT, where text in strikethrough has been removed and bolded text has been 
added (including the section title):
It is preferred that changes to EDW subject weight and antihy pertensive medication(s) 
are not made while the subject is part of this study , howe ver, subjects should remain in 
the study  regardless of any  changes.   All medication and dose changes should be 
recorded in the eCRF.
Section 6.11.3 Prohibited Medications and Non -Drug Therapi[INVESTIGATOR_014]
2015N267693_04 CONFIDENTIA L
205665
182REVI SED TEXT, where text in strikethrough has been removed and bolded text has been 
added:
Use of an y of the following prescription drugs from sScreening until [ADDRESS_351945] 
dose of randomized treatment is prohibited and will constitute a protocol violation.
Strong inhibitor sof CYP2C8 (e.g., gemfibrozil , high dose clopi[INVESTIGATOR_7745] [300 mg])
Strong inducer sof CYP2C8 (e.g., rifampin/rifampi[INVESTIGATOR_2513] )
Section 6.11.5 Iron Protocol
REVI SED TEXT, where bolded text has been added:
Subjects must remain iron replete throughout the study .  If ferritin and TSAT are 
collected per local clinical practice while enrolled, the following is recommended.
Iron therap y will be administered if ferritin is ≤100 ng/mL and/or TSAT is ≤20%.  The 
investigator should choose the route of administration and dose of iron based on subject’s 
iron status and local clinical practice.  
All iron (excluding multivitamins) must be stopped and cannot be administered if:
Ferritin >800 ng/mL AND TSAT >20% OR
TSAT >40%
Section 7.1 Time and Events Table
Table 4 Study  Procedures and Assessments on Acute Challenge Day s (Treatment Period 
Day 1 and Day  57)
No changes made to the table itself.
Revised text in the footnotes only ; text in bold has been added:
1 Procedures to be repeated if Acute Challenge 2 fails quality control criteria (For more detail refer to Section 7.5.1)
2 Applies to Acute Challenge 1 only
3Timing of ABPM measurements does not correlate with specified time points in Table 4 .
4 PK to be drawn from daprodustat subjects only.
Section [IP_ADDRESS] Time Period and Frequency for Collecting AE and SAE Information
REVI SED TEXT, where bolded text has been added:
Any SAEs assessed as related to study  participation (e.g., proto col-mandated 
procedures, invasive tests, or change in existing therap y) or related to a [COMPANY_004] 
product will be recorded from the time a subject consents to participate in the 
study  up to and including any  follow -up contact.
2015N267693_04 CONFIDENTIA L
205665
183AEs will be collected from the start of washout until the follow -up contact (see 
Section [IP_ADDRESS] ), at the timepoints specified in the Time and Events Table (Section 
7.1).
Medical occurrences that begin prior to the start of washout but after obtaining 
informed consent may  be recorded on the Medical History /Current Medical 
Conditions section of the CRF.
All SAEs will be recorded and reported to [COMPANY_004] within 24 hours, as indicated in 
Section 12.4.The investigator will submit any updated SAE data to the 
sponsor within 24 hours of it being availa ble.  
Investigators are not obligated to activel y seek AEs or SAEs in former study 
subjects.  However, if the investigator learns of any  SAE, including a death, at any  
time after a subject has been discharged from the study , and he/she considers the 
event reasonabl y related to the study  treatment or study  participation, the 
investigator must promptly  notify  [COMPANY_004].
NOTE: The method of recording, evaluating and assessing causalit y of AEs and SAEs 
plus procedures for completing and transmitting SAE reports to G SK are provided in 
Section 12.4.
Section [IP_ADDRESS] Adverse Events of Special Interest
REVI SED TEXT, where bolded text has been added:
The investigator or site staff will be responsible for detecting, documenting and reporting 
any AEs of special interest or a ny event that may  potentially  be one of the categories 
listed below (using preferred terms):
Death, myocardial infarction ( MI), stroke , heart failure, thromboembolic events,
thrombosis of vascular access
Thrombosis and/or tissue ischemia secondary  to exces sive ery thropoiesis
Cardiomy opath y
Pulmonary  artery  hypertension (see also Section [IP_ADDRESS] )
Cancer -related mortality  and tumor progression and recurrence
Esophageal and gastric erosions
Proliferative retinopathy , macular edema, choroidal neovascularization
Exacerbation of rheumatoid arthritis
Worsening of hypertension
The results of an y investigation should be recorded in the relevant sections of the 
subject’s eCRF.
Section 7.3.2 Pregnancy
2015N267693_04 CONFIDENTIA L
205665
184REVI SED TEXT, where text in strikethrough has been removed and bolde d text has been 
added:
Details of all pregnancies in female subjects and the outcome for the neonate, if 
applicable , will be collected after the start of dosing and until 147days post -last dose.   
If a pregnancy  is reported ,then the investigator should i nform [COMPANY_004] within 2 weeks of 
learning of the pregnancy  and should follow the procedures outlined in Section 12.4.8 .
Section 7.3.6 Clinical Safety Laboratory Assessments
Table 5 Protocol Required Safety  Laboratory  Assessments
REVI SED TEXT, where text in stri kethrough has been removed and bolded text has been 
added:
All protocol required laboratory  assessments, as defined in Table 5must be conducted in 
accordance with the Laboratory  Manual, and Protocol Time and Events Schedule.  
Laboratory  requisition forms must be completed and samples must be clearly  labelled 
with the subject number, protocol number, site/center number, and visit date.  Details for 
the preparation and shipment of samples will be provided b y the laboratory and are 
detailed in the SRM.  Refer ence ranges for all safety  parameters will be provided to the 
site by  [CONTACT_90633].
If additional non -protocol specified laboratory  assessments are performed at the 
institution’s local laboratory  and result in a change in subject management or are 
considered clinically  significant by  [CONTACT_093] (e.g., SAE or AE or dose 
modification) the results must be recorded in the eCRF.
Refer to the SRM for appropriate processing and handling of samples to avoid duplicate 
and/or a dditional blood draws.
All study -required laboratory  assessments will be performed b y a central laboratory , apart 
from HemoCue Hgb . The results of each HemoCue test must be entered into the eCRF.
NOTE:  Local laboratory results are onl y required in the eve nt that the central laboratory  
results are not available in time for either a treatment and/or response evaluation to be 
performed.  If a local sample is required ,it is important that the sample for central 
analysis is obtained at the same time. Addition ally if the local laboratory  results are used 
to make either a treatment or response evaluation, the results must be entered into the 
eCRF.
2015N267693_04 CONFIDENTIA L
205665
185Hematology , clinical chemistry , and additional parameters to be tested are listed in Table 
5.
Laboratory 
AssessmentsParameters
HematologyPlatelet Count RBC Indices: WBC Count with 
Differential:
RBC Count MCV Neutrophils
Hemoglobin MCH Lymphocytes
Hematocrit MCHC Monocytes
WBC Count (absolute) RDW Eosinophils
Reticulocyte Count CHr Basophils
Clinical 
Chemis tryPotassium AST (SGOT) Total and direct/indirect 
bilirubin
Sodium ALT (SGPT) Total Protein
Glucose Calcium (Albumin adjusted) Alkaline Phosphatase
Albumin Phosphate
Other Screening 
TestsSerum hCG pregnancy test Serum ferritin Folate
Estradiol 1Serum iron Vitamin B12
FSH1Serum transferrin UIBC
TSAT
NOTE: Details of Liver Chemistry Stoppi[INVESTIGATOR_131963] -Up Assessments after liver 
stoppi[INVESTIGATOR_31777] 12.2.
1As needed in women of no n-child bearing potential only.
Abbreviations: ALT= Alanine transaminase; AST= Aspartate transaminase; CHr=Reticulocyte h aemoglobin content; 
FSH=follicle stimulating hormone; MCH= Mean corpuscular h aemoglobin; MCHC= Mean corpuscular hemoglobin 
concentratio n; MCV= Mean corpuscular volume; RBC= Red blood cell; RDW= Red blood cell distribution width; 
SGOT=Serum glutamic oxaloacetic transaminase; SGPT=Serum glutamic -pyruvic transaminase; TSAT = transferrin 
saturation; UIBC= unsaturated iron binding capacity; WBC=White blood cells;
Section 9.2.1 Sample Size Assumptions
REVI SED TEXT, where bolded text has been added:
It is expected that 31 subjects will be randomized into each treatment arm.  Assuming a 
20% withdrawal rate during the Hgb Maintenance Period, ther e will be 25 subjects per 
treatment arm that will undertake Acute Challenge 2.  The study  will continue to recruit 
subjects until it is projected that 25 subjects per treatment arm complete and pass QC for
Acute Challenge 2.
Assuming a 5% significance leve l and a true standard deviation (SD) of 16 mmHg for 
average SBP over 6 hours, a sample size of 25 subjects per treatment group will provide 
greater than 90% power to detect a -15 mmHg difference between treatment groups.  
Under these assumptions, statistic al significance will be obtained if there is more than a 
9.1 mmHg mean difference observed in favor of daprodustat.
Section 9.3.2 Interim Analysis
REVI SED TEXT, where text in strikethrough has been removed and bolded text has been 
added:
2015N267693_04 CONFIDENTIA L
[ADDRESS_351946] completed 
Acute Challenge 2.
If the mean change in SBP from pre -Acute Challenge 1 to the 6 -hour mean following 
both Acute Challenge 1 and Acu te Challenge 2 is less than 5 mmHg in the epoetin alfa 
group, then the study  will be stopped.  However, if a clinicall y meaningful difference 
between the two treatment groups in mean change in SBP from pre -Acute Challenge 1 to 
the 6 -hour mean following Acu te Challenge 1 (i.e., >5 mmHg) is observed, then the 
study  will be continued in order to further characterize the effects of daprodustat on blood 
pressure.
Simulations show that under assumptions of a true mean change in SBP of 0 mmHg and 
SD of 18 mmHg for both treatment groups at Acute Challenge 1 and the epoetin alfa 
group at Acute Challenge 2, this stoppi[INVESTIGATOR_288604] >99% 
of the time.  Under the assumptions of a true mean change in SBP of 8 mmHg and SD of 
18 mmHg for bot h treatment groups at Acute Challenge 1 and the epoetin alfa group at 
Acute Challenge 2, this rule will result in stoppi[INVESTIGATOR_21356] <1% of the time.
While the above is a guideline for stoppi[INVESTIGATOR_288605] , the totality  of the data 
will be co nsidered when making the decision at the time of the interim analy sis.
Section 9.4.1 Primary Analyses
REVI SED TEXT, where bolded text has been added:
The primary  anal ysis of average SBP over [ADDRESS_351947] -dose during Acute Challenge 2 will 
be an analy sis of co variance (ANCOVA) with terms for treatment, prior ESA dose 
(low/high), and post -HD/pre -Acute Challenge [ADDRESS_351948] -HD/pre -
Acute Challenge [ADDRESS_351949] -HD/pre -Acute Challenge 1 SBP, and treatment by  
(difference in post -HD SBP between Ac ute Challenge 1 and 2) interaction.  Note that the 
pre-challenge SBP may  change over time between Acute Challenge [ADDRESS_351950] of treatment phase 
on the covariate. Therefore, if the interaction term in this model is significant at the 0.10 
level, then the primary  model will be ANCOVA with terms for treatment , prior ESA 
dose (low/high), and post -HD/pre -Acute Challenge 1 SBP.  The primary  model will 
provide a point estimate and two -sided 95% CI for the treatment effect and a p -value for 
the superiority  assessment.  Sup eriority  will be established if the p -value is <0.05.
Section 9.4.2 Secondary Analyses
REVI SED TEXT, where bolded text has been added:
Average SBP over [ADDRESS_351951] -dose in Acute Challenge 1 will be anal yzed using ANCOVA 
with terms for treatment , prior ESA do se (low/high), and post -HD/pre -Acute Challenge 
[ADDRESS_351952] Acute Challenge 2 and 1 will be anal yzed 
using ANCOVA with terms for treatment and prior ESA dose (low/high) with 95% CI s 
and p -values provided for the treatment effect.
Section 11 References 
REVI SED TEXT, where bolded text has been added:
Campochiaro PA and the first ARVO/[COMPANY_007] Institute Working Group et al. Ocular 
versus extraocular neovascularization: Mirror images or vague r esemblances. Invest 
Ophthalmol & Vis Sci. 2006; 47:[ADDRESS_351953] growth in advanced stages of autosomal 
dominant polycystic kidney disease ; Kidney International (2018) 94, 849 –851.
Kraus, A., et al, HIF -1α promotes cyst pr ogression in a mouse model of autosomal 
dominant polycystic kidney disease; Kidney International, 2018.
Navaneethan SD, for CRIC investigators: Prevalence, Predictors, and Outcomes of 
Pulmonary Hypertension in CKD. J Am Soc Nephrol 2016, 27:877 –886.
Section 12.1 Appendix 1 –Abbreviations and Trademarks
REVI SED TEXT, where bolded text has been added:
ABPM Ambulatory  blood pressure monitoring
ADMA Asymmetric dimethy arginine
AE Adverse event
ALT Alanine transaminase
AMD Age-Related Macular Degeneration
ANCOVA Analy sis of Covariance
AST Aspartate transaminase
AUEC Area under the effect curve
AUC (0 -24) Area under concentration -time curve from time zero to 24 hours
BP Blood pressure
CHr Reticulocy te hemoglobin content
CI Confidence interval
CKD Chronic kidney  disease
Cmax Maximum observed concentration
CPK Creatine phosphokinase
CV Cardiovascular
DBP Diastolic blood pressure
dL Deci liter
2015N267693_04 CONFIDENTIA L
205665
188DNA Deox yribonucleic acid
ECG Electrocardiogram
ECHO Echocardiogram
eCRF Electronic Case Report Form
EDW Estimated Dry  Weight
EPO Erythropoietin
ESA Erythropoiesis -stimulating agent
ET-1 Endothelin -1
FDA Food and Drug Administration
FRP Females of Reproductive Potential
FSH Follicle Stimulating Hormone
GCP Good Clinical Practice
G Gram
GI Gastroint estinal
[COMPANY_004] GlaxoSmithKline
hCG Human chorionic gonadotrophin
HD Hemodialy sis dependent
HDPE High Density  Polyethylene
HF Heart Failure
Hgb Hemoglobin
HIF Hypoxia -inducible factor
HR Hour/heart rate
IB Investigator’s Brochure
ICH International Co nference on Harmonization
IEC Independent Ethics Committee
INR International Normalized Ratio
IRB Institutional Review Board
ITT Intent -to-treat
IU International Unit
IV Intravenous
IVWRS Interactive Voice/Web Response Sy stem
KDIGO Kidney  Disease I mproving Global Outcomes
KG Kilogram
LDH Lactate deh ydrogenase 
MAP Mean Arterial Blood Pressure
MCH Mean corpuscular hemoglobin
MCHC Mean corpuscular hemoglobin concentration
MCV Mean corpuscular volume
MedDRA Medical Dictionary  for Regulatory  Acti vities
MG Milligram
MI Myocardial infarction
ML Milliliter 
mmHG Millimeter of mercury
MSDS Material Safet y Data Sheet
ND Non-dialysis dependent
NO Nitric Oxide
2015N267693_04 CONFIDENTIA L
[ADDRESS_351954] Level
NYHA [LOCATION_001] Heart Association
PAS P Pulmonary Artery Systolic Pressure
PCI Percutaneous Coronary Intervention
PD Pharmacod ynamic
PEG Polyethylene gl ycol
PGI2 Prostaglandin I 2
PHD Prolyl hydroxylase domain
PHI Proly l hydroxylase inhibitor
PK Pharmacokinetic
proADM Proadrenomedullin
PRS Projec t Requirement Specification
PRVP Peak Right Ventricular Pressure
PSRAE Possible suicidality  related adverse event
QC Quality  Control
QTc QT interval corrected for heart rate
QTcB QT interval corrected for heart rate using Bazett’s formula
RAP Reporti ng and Anal ysis Plan
RBC Red blood cell
RDW Red blood cell distribution width
rhEPO Recombinant human ery thropoietin 
RNA Ribonucleic acid
SAE Serious adverse event
SBP Systolic blood pressure
SC Subcutaneous
SD Standard deviation
SGOT Serum gluta mic oxaloacetic transaminase
SGPT Serum glutamic -pyruvic transaminase
sPAP Systolic Pulmonary  Artery Pressure
SRM Study  Reference Manual
T1/[ADDRESS_351955] Upper limit of normal
URR Urea reduction ratio
WBC White blood cells
2015N267693_04 CONFIDENTIA L
205665
190Section 12.3 Appendix 3: Daprodustat Risk Assessment
REVI SED TEXT, where text in strikethrough has been removed and bolded text has been added:
Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
Excessive erythropoiesis (polycythemia) 
leading to thrombosis and/or tissue ischemiaIn animal studies, excessive erythropoies is (Hgb/Hct > upper limit normal)
attributed to daprodustat was associated with vascular 
congestion /inflammation , microthrombi, and tissue ischemia in a number of 
organs.
In the phase 2 proof of concept study, a high incidence of 
discontinuation due to he moglobin stoppi[INVESTIGATOR_3418] (Hgb > 13.5 g/dL or 
Hgb increased > 1 g/dL over any 2 -week period) was observed.  In non -
dialysis subjects administered 10 mg, 25 mg, 50 mg or 100 mg of 
daprodustat daily, a total of 21 of 61 subjects (34%) met these criteria.  I n 
hemodialysis -dependent subjects administered either 10 mg or 25 mg of 
daprodustat daily, a total of 8 of 31 subjects (26%) met these criteria.
Following review of clinical data received to date, this has not been identified 
as a safety concern for dapro dustat.
Phase 2 dose -ranging studies, and associated statistical and exposure 
response modelling has informed Phase 3 dose rationale, starting doses, 
dose levels, and dose adjustment scheme to optimize Hgb management.
Integrated AE data [including 2 global phase 2b studies (24 -week 
treatment duration) and 2 Japanese phase 3 studies (52 -week treatment 
duration)]: Few subjects experienced a possible thrombosis related 
adverse event in the setting of excessive erythropoiesis [3/688 (0.5%) 
subjects on daprodust at vs. 0/404 on rhEPO].
Following review of clinical data received to date, this has not been 
identified as a safety concern for daprodustat when dose is managed Specific eligibility criteria related to requirements 
for entry Hgb are detailed in Section 5
Hgb will be closely monitored throughout the 
dosing period as outlined in the Time and Events 
Table (Section 7.1)
Specif ic guidance for dose adjustment, dose 
interruption, or discontinuation of daprodustat 
based on achieved Hgb (including rate of 
change) is provided in Section [IP_ADDRESS]
Instream m Monitoring of emerging safety data 
by [CONTACT_288652]
2015N267693_04 CONFIDENTIA L
205665
191Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
appropriately according to target Hgb. However, experience with 
daprodustat is currently insu fficient to fully characterize this risk .
Worsening hypertension In a dog cardiovascular study, single oral doses of daprodustat (up to 90 
mg/kg) did not produce effects on blood pressure.
Marketed rhEPO and its analogues have been associated with risks 
related to uncontrolled hypertension, including the need for initiation of 
or increases in antihypertensive therapy when used in patients with 
anemia of CKD (i.e. 25% Epogen, 27% Mircera, and 40% Aranesp treated 
patients with renal anemia required initiation or increase in their anti -
hypertensive medic ations; hypertensive encephalopathy and seizures 
have been reported. The contribution of rhEPO -associated hypertension 
to the unfavourable effects on cardiovascular outcomes remains 
uncertain).
Integrated AE data from clinical trials with daprodustat [incl uding 2 
global phase 2b studies (24 -week treatment duration) and 2 Japanese 
phase 3 studies (52 -week treatment duration)]: 
oThe majority (>90%) of subjects had baseline history of 
hypertension.
oNo meaningful difference was seen between treatment groups in 
AEs (preferred term) of “hypertension” [29/688 (4%) daprodustat vs. 
19/404 (4%) rhEPO; 0.91 relative risk (RR) (95% confidence interval: 
0.5, 1.67)] or “blood pressure increased” [16 (2%) daprodustat vs. 7 
(2%) rhEPO; RR 1.22 (0.48,3.11)]. Results were not substantively 
different between non -dialysis and haemodialysis subjects.
oAlthough no clinically meaningful changes in blood pressure were 
observed, subjects in both treatment groups required increases in 
anti-HTN medications: Specific eligibility criteria related to blo od 
pressure, including exclusion of subjects 
with uncontrolled hypertension, are 
detailed in Section 6.2
Blood pressure will be closely monitored 
throughout the dosing period as outlined in 
the Time and Events Table Section 7.1.
Monitoring of emerging safe ty data by [CONTACT_288631].
2015N267693_04 CONFIDENTIA L
205665
192Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
oIn the 24 -week global phase 2 b studies, 25/170 (15%) of ND 
subjects receiving daprodustat vs. 18/80 (14%) control and 
22/177 (12%) of HD subjects receiving daprodustat vs. 2/39 
(5%) control.
oIn the 52 -week Japan phase 3 studies, 57/149 (38%) of ND 
subjects receiving daprodustat vs. 68 /150 (45%)  rhEPO 
and 51/136 (38%) of HD subjects receiving daprodustat vs. 
66/135 (49%) for rhEPO.
The data received to date from completed clinical trials with daprodustat 
are insufficient to refute this risk.
Death, MI, stroke, heart failure, 
thromboembolic events, thrombosis of 
vascular access at Hgb levels which are within 
the normal range (i.e. not polycythemic 
conditions)Marketed rhEPO /ESAs and its analogs have been associated with an 
increased risk for death and serious cardiovascular events when used in 
patients with anemia of CKD.   Clinical studies with marketed 
rhEPO/analogs have suggested “higher” target hemoglobin, rate of 
hemoglobin rise of greater than 1 g/dL in any 2 -week period, and/or 
higher doses may contribute to these risks.
In non -clinical studies conducted to date, not observed at tolerated 
doses when hemoglobin/hematocrit within normal range for species.
Integrated AE data from clinical trials with daprodustat [including 2 
global phase 2b studies (24 -week treatment duration) and 2 Japanese 
phase 3 studies (52 -week treatment duration)]: No meaningful difference 
was seen between treatment groups in the overall incidence of this 
AESI: [39/688 (5.5% ) daprodustat vs. 25/404 (6%) rhEPO; 0.92 relative 
risk (95% confidence interval: 0.55, 1.53)]. Within this composite AESI, 
the most frequent event types were heart failure (at least [ADDRESS_351956] 13 events rhEPO) and thrombosis (at le ast [ADDRESS_351957] 8 event rhEPO); and a numerical 
imbalance was noted in events of myocardial ischemia (at least [ADDRESS_351958] 1 event rhEPO). The small number of events Specific eligi bility criteria related to CV risk are 
outlined in Section 5.3
Hgb will be closely monitored throughout the 
dosing period as outlined in the Time and Events 
Table Section 7.1
Instream m Monitoring of emerging safety data 
by [CONTACT_288652]
2015N267693_04 CONFIDENTIA L
205665
193Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
makes it difficult to draw any firm conclusio ns.
Not observed at tolerated doses when hemoglobin/hematocrit within normal 
range for species.
The clinical data received to date from completed clinical trials with 
daprodustat are insufficient to conclude substantiate or refute this risk.
Esophageal and gastric erosionsIn animal studies, undesirable GI effects including emesis, abnormal feces 
and/or decreased food consumption/body weight loss and stomach erosions/ 
ulcers with hemorrhage were observed with daprodustat.
In ratsrodents ,stomach erosions were observed with intravenous and oral 
administration of daprodustat.
Stomach erosions/ulcers also reported in rats with marketed rhEPOs/ESAs.
Gender -averaged systemic exposure (AUC) at the no observed adverse 
effect levels (NOAEL) are 3.3 -fold (monkeys) and 737 -fold (rats) above 
human exposure (25 mg daprodustat).
In clinical trials to date with daprodustat, mild -moderate GI signs and 
symptoms represent the most frequently reported adverse event, however 
causal association has not bee n established.
Integrated AE data from clinical trials with daprodustat [including 2 
global phase 2b studies (24 -week treatment duration) and 2 Japanese 
phase 3 studies (52 -week treatment duration)] : No meaningful difference 
was seen between treatment grou ps in reports of this AESI [17 (2.7%) 
daprodustat vs. 10 (2.3%) rhEPO; 1.16 relative risk (95% confidence 
interval: 0.52, 2.58)].
Following review of clinical data received to date, GI erosions have not been 
identified as a safety concern for daprodustat.Suspected GI bleeding or significant symptoms 
consistent with erosion should be investigated 
diagnostically (i.e. endoscopic examination) as 
clinically warranted
Instream m Monitoring of emerging safety data 
by [CONTACT_288653] -related mortality and tumor 
progression and recurrenceMarketed r heEPO and its analogs have been associated with increased risk 
of cancer related morbidity and mortality when used in patients with cancer.
Administration of 60mg/kg daprodustat t o mice caused minimal increases in Specific eligibility criteria related to personal 
history of malignancy or subjects with complex 
kidney cyst a re outlined in Section 5.3.
2015N267693_04 CONFIDENTIA L
205665
194Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
circulating VEGF while significant EPO increases were observed.
In clinical studies with daprodustat up to 4 weeks duration, a dose -
ordered increase in VEGF plasma concentrations, an angiogenic factor 
that has been implic ated in tumor growth, was observed at doses 
ranging from 10 to 150 mg.  In clinical studies up to 24 weeks duration at 
doses up to 25 mg, changes in VEGF plasma concentrations were 
variable but similar relative to control.
Integrated AE data [including 2 g lobal phase 2b studies (24 -week 
treatment duration) and 2 Japanese phase 3 studies (52 -week treatment 
duration)]: No meaningful difference was seen between treatment 
groups in the occurrence of this AESI: [8/688 (1.1%) daprodustat vs. 
4/404 (0.9%) rhEPO; 1 .14 relative risk (95% confidence interval: 0.31, 
4.28)].
Clinical experience to date is not yet sufficient to substantiate or refute 
this as a safety concern for daprodustat.
There were no daprodustat -related neoplastic findings in a 2 -year rat oral 
carci nogenicity study (lifetime study).
In clinical studies conducted to date, administration of daprodustat has been 
associated with:
Once daily administration:
In studies up to 4 weeks duration, a dose -ordered increase in VEGF 
plasma concentrations at doses r anging from 10 to 150 mg.
In studies up to 24 weeks duration at doses up to 25 mg, changes in 
VEGF plasma concentration were variable but similar relative to control.
Systemic EPO concentrations within the physiologic range.Stoppi[INVESTIGATOR_288614] 
5.5.1.
Instream m Monitoring of emerging safety data 
by [CONTACT_288654]
2015N267693_04 CONFIDENTIA L
205665
195Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
Three times weekly administrati on:
In studies up to 4 weeks duration at doses of 10 to 30 mg:
oDose dependent increases in plasma VEGF and EPO 
concentrations were observed.
oPre-dose concentrations of EPO and VEGF were near or 
below baseline indicating no accumulation of EPO or 
VEGF after three times weekly dosing.
Following review of clinical data received to date, this has not been identified 
as a safety concern for daprodustat.
Pulmonary artery hypertension (PA H)A role for HIF -regulated pathways in the pathophysiology of PAH has been 
suggested based on well established effects of acute and chronic hypoxia in 
man on the pulmonary vasculature (vasoconstriction), and by [CONTACT_288655] g mutations that result in decreased HIF 
degradation [ Smith , 2006; Formenti , 2011].
There have been no histopathologic findings suggestive of PAH in pre -clinical 
safety studies (up to 13 -weeks duration in mice and dogs, up to 26-weeks 2 
years in rat s and m ice, and up to 39 -weeks in monkeys.
Acute hypoxic challenge (rats): Daprodustat produced increases in peak right 
ventricular pressure (PRVP) during acute hypoxia that were slightly higher 
than the vehicle control group.  These hypoxia -induced PRVP changes fall 
within the range of PRVP differences noted among non -treated rats.
Results from a clinical study of acute hypoxic challenge in healthy 
volunteers demonstrated that short -term (5 days) therapy with daprodustat 
5mg or 100mg ha dsno clinically significan t effect on transthoracic
echocardiographically (ECHO) estimate sdofsystolic pulmonary artery 
systolic pressure (sPA SP) under either normoxic or hypoxic conditions.
ECHO assessments performed in Phase 2b studies (24 weeks treatment Instream m Monitoring of emerging safety data 
by [CONTACT_288654]
2015N267693_04 CONFIDENTIA L
205665
196Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
duration) did not ident ify any clinically meaningful changes in sPAP PASP
in subjects participants not on dialysis for daprodustat . In hemodialysis 
subjects participants , mean absolute change from baseline in sPAP PASP
was similar for both treatment groups; however, there was a numeric 
imbalance (Daprodustat Total : 8 [7%]; Control 0) in subjects participants
reaching the sPAP PASP PCI (>20 mmHg increase from baseline). 
Regarding this imbalance, there were a number of confounding factors in 
the study, most notably a 4.5:1 randomization scheme and inconsistency in 
timing of ECHOs relative to dialysis day.  Additionally, 2 of 3 subjects
participants with resolution of sPAP PASP on safety follow -up ECHOs had 
confounding conditions that could contribute to resolution other than 
discontinuation of study treatment drug ; and there was no dose relationship 
forsubjects participants meeting the sPAP PASP percutaneous 
coronary intervention (PCI)criterion. Ov erall, there is insufficient evidence 
to conclude a relationship to treatment with daprodustat .A post -hoc 
analysis was performed using a definition of PAH commonly cited in 
the literature [Navaneethan, 2016]. Subjects with sPAP >35 mmHg 
and/or tricuspid regurgitation maximum jet velocity (TRV) >2.5 m/s 
were considered as having PAH.   Regardless of baseline status of 
PAH, there was no clinically meaningful difference in the proportion of 
subjects with on -treatment PAH between the two treatment groups:
oSubj ects with PAH at baseline: 35/113 (31%) vs. 21/54 
(39%) (ND) and 37/115 (32%) vs. 7/21 (33%) (HD), 
daprodustat vs. control, respectively.
oSubjects without PAH at baseline: 25/113 (22%) vs. 12/54 
(22%) (ND) and 22/115 (19%) vs. 6/21 (29%) (HD), 
daprodustat vs. control, respectively.
Integrated AE data [including 2 global phase 2b studies (24 -week 
treatment duration) and 2 Japanese phase 3 studies (52 -week treatment 
duration)] : Four (0.5%) non -serious AEs in the daprodustat group vs 0 in 
rhEPO. 
Review of su bject level information did not suggest adverse 
treatment effect: 2 subjects from phase2b that met protocol 
2015N267693_04 CONFIDENTIA L
205665
197Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
specified stoppi[INVESTIGATOR_288615] -serious 
AEs of ‘pulmonary arterial pressure increased’ and 2 subjects from 
Japan Phase 3 had n on-serious AE ‘pulmonary hypertension’ in 
setting of concurrent serious AEs of acute pulmonary embolus and 
mitral regurgitation identified during hospi[INVESTIGATOR_288616].
Following review of clinical data received to date, this has not bee n identified 
as a safety concern for daprodustat.
Cardiomyopathy Published data suggest that cardiac effects of HIF stabilization are likely a 
function of the mechanism, extent, and duration of the effects, and can range 
from protective to detrimental depending upon the specific model and 
experimental conditions utilized.
Small increases in cardiac troponin in 6 month rat study with 
daprodustat were consistent with the background finding of 
spontaneous rodent cardiomyopathy.  There were no elevations 
observed in cardiac troponin in 9 month monkey study with 
daprodustat .
With lifetime exposure to daprodustat in a 2 -year rat oral carcinogenicity 
study, an exacerba tion of rat spontaneous, progressive cardiomyopathy 
(PCM)(focal myofiber degeneration/necrosis with inflammatory infiltrates) was 
observed at doses of 0.8 mg/kg/day and above, although total incidence and 
severity distribution within any daprodustat -group were within historical control 
ranges.  This is consistent with an equivocal threshold for exacerbation of 
spontaneous, progressive cardiomyopathy at 0.8 mg/kg/day which is also the 
threshold dose for observing increased Hct values in individual rats.
Card iomyopathy has not been associated with naturally occurring mutation in 
man which results in increased HIF stabilization.
ECHO assessments performed in phase 2b studies (24 weeks treatment 
duration) did not identify any clinically meaningful changes in LVE F for Instr eam m Monitoring of emerging safety data 
by [CONTACT_288656]
2015N267693_04 CONFIDENTIA L
205665
198Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
daprodustat.
Integrated AE data from clinical trials with daprodustat [including 2 
global phase 2b studies (24 -week treatment duration) and 2 Japanese 
phase 3 studies (52 -week treatment duration)]: No meaningful difference 
was seen between treatment groups in reports of this AESI [1 (0.1%) 
daprodustat vs. 1 (0.2%) rhEPO; 0.64 relative risk (95% confidence 
interval: 0.02, 18.07)].
Following review of clinical data received to date, this has not been identified 
as a safety concern for daprodustat.
Proliferative retinopathy, macular edema, 
choroidal neovascularizationIncreases in local (ocular) VEGF production with retinal neovascularization 
and macular edema observed in diabetic retinopathy and to choroidal 
leakage, edema and neovascularization seen in age -related macular 
degeneration [Campochiaro, 2006]
Administration of 60 mg/kg daprodustat to mice caused minimal increases in 
circulating VEGF while significant EPO in creases were observed.
Aside from congestion of retinal vessels and optic disc hyperemia secondary 
to markedly increased red cell mass, there were no ocular abnormalities 
observed in non -clinical studies.
No ocular abnormalities with daprodustat were seen in non -clinical 
studies of up to 13 weeks duration in mice and dogs, 26 weeks in rats, 
and 39 weeks in monkeys.
In clinical studies up to 4 weeks duration, a dose -ordered increase in VEGF 
plasma concentrations was observed at doses ranging from 10 to 150 m g 
administered once daily and from 10 to 30 mg administered three times 
weekly. In studies up to 24 weeks duration at doses up to 25 mg, changes in 
VEGF plasma concentrations were variable but similar relative to control.
Ophthalmologic assessments perform ed in phase 2b studies (24 weeks 
treatment duration) did not identify any clinically meaningful changes in Instream m Monitoring of emerging safety data 
by [CONTACT_288656]
2015N267693_04 CONFIDENTIA L
205665
199Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
proliferative retinopathy, macular edema, or choroidal neovascularization with 
daprodustat.
Integrated AE data [including 2 global phase 2b studies ( 24-week 
treatment duration) and 2 Japanese phase 3 studies (52 -week treatment 
duration)] : No meaningful difference was seen between treatment 
groups in reports of this AESI [9 (2.9%) daprodustat vs. 6 (2.5%) rhEPO; 
1.19 relative risk; (95% confidence inter val: 0.42, 3.43)].
Following review of clinical data received to date, this has not been identified 
as a safety concern for daprodustat.
Exacerbation of rheumatoid arthr itis In inflamed rheumatic joints, activation of HIF -related genes secondary to 
decreased oxygen and pro -inflammatory cytokines has been postulated to 
contribute to the neo -angiogenesis, proliferation and infiltration of rheumatoid 
synovial fibroblasts [Westra , 2010; Muz, 2009].
No abnormalities seen in non -clinical studies conducted to date for 
daprodustat.
Integrated AE data [including 2 global phase 2b studies (24 -week 
treatment duration) and 2 Japanese phase 3 studies (52 -week treatment 
duration)]: No meaningful difference was seen between treatment 
groups in reports of this AESI [2 (0.3%) daprodustat vs. 1 (0.2%) rhEPO; 
1.20 relative risk; (95% confidence interval: 0.07, 20.87) and the 
incidence of musculoskeletal AEs was generally lower in the 
daprodu stat treatment group].
Following review of clinical data received to date, this has not been identified 
as a safety concern for daprodustat.Instream m Monitoring of emerging safety data 
by [CONTACT_288657] -drug interactions Dapr odustat is a substrate of CYP2C8 :Co-administration of daprodustat 
with a strong CYP2C8 inhibitor increased the maximum plasma 
concentration (Cmax )and area under curve (AUC )of daprodustat, 4 -and 
19-fold, respectively, while co -administration of a weak i nhibitor (i.e., Co-administration of daprodustat with strong 
CYP2C8 inhibitors (e.g., gemfibrozil) and 
inducers (e.g., rifa mpin/rifampi[INVESTIGATOR_2513]) is not 
2015N267693_04 CONFIDENTIA L
205665
200Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
trimethoprim) increased the Cmax and AUC of daprodustat by 1.3 -and 1.5 -
fold, respectively. Population PK analysis from completed Phase 2 
studies suggests that co -administration of daprodustat with a moderate 
CYP2C8 inhibitor (i.e., clopi[INVESTIGATOR_278458]) leads to a ~ 2 -fold increase in AUC, 
with no clinically -significant increase in the measured Hb response.
Although CYP2C8 induction studies were not performed, co -administration of 
daprodustat with an inducer of CYP2C8 (e.g., rifampin/rifampi[INVESTIGATOR_2513]) may
decrease the exposure of daprodustat.
Although co -administration of daprodustat with strong inhibitors and inducers 
of CYP2C8 is prohibited, inadvertent co -administration may occur. Due to the 
known time delay in enhancing erythropoiesis by [CONTACT_288649], c o-
administration with strong CYP2C8 inhibitors for up to 14 days is not 
anticipated to lead to immediate marked increases in hemoglobin levels. 
Therefore, there is adequate time to change to alternate therapy that does not 
inhibit CYP2C8.
Additionally, as the time for maximum induction of CYP2C8 occurs 
approximately 10 -14 days of dosing with rifampin ( Brodie , 2013; Ohnhaus , 
1989), daprodustat systemic exposure will decrease over time which will result 
in a lag period before an effect on Hgb is recognized an d is of clinical concern.
Daprodustat is an inhibitor of CYP2C8 : A clinical drug interaction study 
between 25mg and 100mg daprodustat with a CYP2C8 substrate (i.e., 
pi[INVESTIGATOR_051]) showed that there is no PK interaction at these doses of 
daprodustat.  
Dapro dustat is a substrate of Breast cancer resistance protein (BCRP) :  
Population PK analysis from Phase 2 studies suggested that while
BCRP inhibitors were a covariate for daprodustat apparent total body 
clearance (CL/F) (8.6% lower clearance) the predicted c hange in 
exposure was not considered to be of clinical relevance.
Daprodustat is an inhibitor of organic anion transporter polypedtides
(OATP)1B1/1B3 :  A clinical drug interaction study between 25mg and permitted as outlined in Section 6.11.3.
Co-administration of daprodustat with moderate 
CYP2C8 inhibitors (i.e., clopi[INVESTIGATOR_7745], 
teriflunomide, deferasirox) should be performed 
with caution. If one of these medications is 
started, stop ped or the dose is changed, Hgb 
should be monitored every 4 weeks. Specific 
guidance on the management of potential drug -
drug interactions and concomitant medications is 
provided in Section 6.11.
Hgb will be closely monitored throughout the 
dosing period a s outlined in the Time and Events 
Table (Section 7.1)
Specific guidance for dose adjustment, dose 
interruption, or discontinuation of daprodustat 
based on achieved Hgb is provided in Section 
[IP_ADDRESS].
Instream m Monitoring of emerging safety data 
by [CONTACT_288658]
2015N267693_04 CONFIDENTIA L
205665
201Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
100mg daprodustat with an OATP1B1/1B3 substrate (i.e. , rosuvastatin) 
showed no PK interaction at these doses of daprodustat.
Population PK analysis from completed Phase 2 studies suggests that co -
administration of daprodustat with a moderate CYP2C8 inhibitor, leads to a ~ 
2-fold increase in AUC, with no clin ically -significant increase in the measured 
Hgb response.
Daprodustat is an inhibitor of CYP2C8 in vitro, with an IC 50value of 21 µM.
Population PK analysis from completed Phase 2 studies suggests that co -
administration of daprodustat with clopi[INVESTIGATOR_7745] (a moderate CYP2C8 inhibitor) 
leads to a ~ 2 -fold increase in AUC, with no clinically -significant increase in 
the measured Hgb response
Co-administration of daprodustat with potent BCRP inhibitors has the potential 
to increase exposure of daprodustat.  Use of BCRP inhibitors (mostly weak) 
was found to result in a small change in metabolite exposure (20% increase in 
AUC).
Daprodustat is an inhibitor of OATP1B1/1B3 in vitro, with IC 50values of 6 µM 
and 11 µM, respectively. A clinical drug interaction study betw een 25 mg 
daprodustat with either a CYP2C8 substrate or an OATP1B1/1B3 substrate 
showed that there is no PK interaction at this dose of daprodustat.
Cyst progression in patients with 
autosomal dominant polycystic kidney 
disease (ADPKD)Published data provide in vivo evidence for a potential role of HIF -1a in 
the growth of polycystic kidneys; Hif -1a deletion was sufficient to 
significantly mitigate a progressive polycystic phenotype in an ADPKD 
mouse model, while conversely pharmacologic HIF -1a stabilization was 
sufficient to convert a mild polycystic disease into a severely 
aggravated phenotype with marked loss of renal fu nction. However, the 
dose of FG -2216 (a PHI) used resulted in a sig nificant erythropoietic 
response as reflected by ≥10% relative increases in hematocrit over the 
course of the study (Kraus, 2018; Hofherr, 2018). (Kraus, 2018; Hofherr,  Kidney function  will be monitored 
throughout the dosing period as outlined in 
the Time and Events Table (Section 7.1).
Monitoring of emerging safety data by [CONTACT_288631].
2015N267693_04 CONFIDENTIA L
205665
202Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
2018).
A review of the non -clinical data from toxicity studies conducted with 
daprodust at does not indicate an exacerbation in incidence or severity 
of kidney cysts in daprodustat -treated animals in comparison to 
controls.  However, the wild type animals used in these toxicity studies 
have a very low background incidence of renal cysts and a re not 
comparable to the mice used in the Kraus article (Kraus, 2018) which are 
an inducible kidney epi[INVESTIGATOR_2130] -specific Pkd1 -deletion model.
There is limited experience with daprodustat in subjects with ADPKD in 
completed clinical trials. In the Japan phas e 3 study in non -dialysis 
subjects, there were 5 subjects with ADPKD (all CKD stage 5) in each 
treatment group.  Mean baseline eGFR was 10 mL/min/1.73m2 in the 
daprodustat subjects vs. 16 mL/min/1.73m2 in the rhEPO subjects.  The 
mean (SD) percent change f rom baseline at Week 52 in eGFR was: -18% 
(8) vs. -21% (14) in daprodustat vs. rhEPO, respectively.
Following review of clinical data received to date, this has not been 
identified as a safety concern for daprodustat.
Other
rhEPO risks (Control) See risks outlined in table for daprodustat for excessive erythropoie sis 
(polycythemia) leading to thrombosis and/or tissue ischemia, death, MI, 
stroke, heart failure, thromboembolic events, thrombosis of vascular access, 
and for cancer -related mortality and tumor progression.
Uncontrolled hypertension
Pure red cell aplasi aSee mitigation strategies outlined in table for 
daprodustat for excessive erythropoiesis 
(polycythemia) leading to thrombosis and/or 
tissue ischemia; risk of death, MI, stroke, heart 
failure, thromboembolic events, thrombosis of 
vascular access; and for increased cancer -
related mortality and tumor progression.
Specific eligibility criteria related to blood 
pressure management are outlined in Section 5 .
Specific eligibility criteria related to personal 
2015N267693_04 CONFIDENTIA L
205665
203Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
history of pure red cell aplasia are outlined in 
Section 5.3